ciprofloxacin has been researched along with Bacterial Disease in 747 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "For the treatment of spontaneous bacterial peritonitis (SBP), cefotaxime, ceftriaxone, and ciprofloxacin were used as first-line agents." | 9.69 | Response-Guided Therapy With Cefotaxime, Ceftriaxone, or Ciprofloxacin for Spontaneous Bacterial Peritonitis: A Randomized Trial: A Validation Study of 2021 AASLD Practice Guidance for SBP. ( Baik, SK; Han, KH; Heo, J; Heo, NY; Jung, YK; Kang, SH; Kim, BI; Kim, HS; Kim, MY; Kim, TH; Kim, YS; Park, JY; Park, SY; Seo, YS; Sohn, JH; Suh, SJ; Um, SH; Yim, HJ; Yim, SY, 2023) |
| "Once weekly ciprofloxacin was as effective as daily norfloxacin for the prevention of SBP in cirrhotic patients with ascites." | 9.27 | Daily Norfloxacin vs. Weekly Ciprofloxacin to Prevent Spontaneous Bacterial Peritonitis: A Randomized Controlled Trial. ( Jang, JY; Jung, YK; Kim, BI; Kim, HS; Kim, YS; Lee, YR; Park, SY; Seo, YS; Suh, SJ; Um, SH; Yim, HJ; Yim, SY, 2018) |
| "Rifaximin was compared with placebo and ciprofloxacin for treatment of travelers' diarrhea in a randomized, double-blind clinical trial." | 9.12 | A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea. ( Bourgeois, AL; Dupont, HL; Ericsson, CD; Haake, R; Halpern, J; Jiang, ZD; Steffen, R; Taylor, DN, 2006) |
| "The suitability of the 18F-labelled fluoroquinolone antibiotic ciprofloxacin ([18F]ciprofloxacin) for imaging of bacterial infections with positron emission tomography (PET) was assessed in vitro and in vivo." | 9.11 | In vitro and in vivo evaluation of [18F]ciprofloxacin for the imaging of bacterial infections with PET. ( Brunner, M; Dobrozemsky, G; Dudczak, R; Joukhadar, C; Kletter, K; Lackner, E; Langer, O; Minar, E; Mitterhauser, M; Müller, M; Müller, U; Wadsak, W; Zeitlinger, M; Ziegler, S, 2005) |
| "We compared baseline and post-therapy prostate specific antigen (PSA) in patients with chronic bacterial prostatitis who were treated with levofloxacin or ciprofloxacin." | 9.11 | Treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers serum prostate specific antigen. ( Kahn, JB; Schaeffer, AJ; Tennenberg, AM; Wu, SC, 2005) |
| "The aim of this study was to compare the efficacy of single-dose intravenous cefazolin prophylaxis with single-dose oral ciprofloxacin prophylaxis in patients undergoing tension-free inguinal hernia repair with polypropylene mesh." | 9.11 | Single-dose oral ciprofloxacin compared with single-dose intravenous cefazolin for prophylaxis in inguinal hernia repair: a controlled randomized clinical study. ( Ergör, G; Füzün, M; Hoşgörler, F; Kiliç, D; Terzi, C; Unek, T, 2005) |
| "To investigate the value of Tc-99m ciprofloxacin imaging in the differential diagnosis of chronic bacterial prostatitis." | 9.10 | Tc-99m ciprofloxacin imaging in diagnosis of chronic bacterial prostatitis. ( Choe, W; Kim, S; Lee, SM; Moon, Y; Pai, SH; Ryu, JK; Seong, DW; Suh, JK, 2003) |
| "To compare the safety and efficacy of levofloxacin with that of ciprofloxacin for the treatment of chronic bacterial prostatitis." | 9.10 | Levofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis: a randomized double-blind multicenter study. ( Bundrick, W; Heron, SP; Kahn, JB; Ray, P; Schiff, WM; Tennenberg, AM; Wiesinger, BA; Wright, PA; Wu, SC; Zadeikis, N, 2003) |
| "The efficacy and safety of ciprofloxacin 500 mg bd for 28 days were assessed in 65 adult males with symptomatic bacterial prostatitis, from eight centres in Germany." | 9.09 | Ciprofloxacin in the treatment of chronic bacterial prostatitis: a prospective, non-comparative multicentre clinical trial with long-term follow-up. The German Prostatitis Study Group. ( Busch, W; Focht, J; Naber, KG, 2000) |
| "To assess topical ciprofloxacin in patients with moderate severity of suspected bacterial corneal ulcers." | 9.09 | Topical ciprofloxacin for bacterial corneal ulcer. ( Buranapongs, W; Kosrirukvongs, P, 2000) |
| "The aim of this prospective double-blind study was to evaluate the value of long-term antibiotic prophylaxis using ciprofloxacin for the prevention of spontaneous bacterial peritonitis (SBP) in 60 cirrhotic patients with low ascitic fluid protein levels (< 15 g/L)." | 9.08 | Ciprofloxacin and long-term prevention of spontaneous bacterial peritonitis: results of a prospective controlled trial. ( Bacq, Y; Bohn, B; Cordier, L; Franza, A; Fratte, S; Kitmacher, P; Nousbaum, JB; Paris, JC; Rolachon, A; Stahl, JP, 1995) |
| "Fifty-three granulocytopenic patients were studied in a randomized trial comparing trimethoprim-sulfamethoxaxole (ST) alone with ST + ciprofloxacin (CPFX) for prevention of bacterial infections." | 9.08 | [Chemoprophylaxis of bacterial infections in granulocytopenic patients with new quinolone: a comparison of trimethoprim-sulfamethoxazole (ST) alone with ST plus ciprofloxacin]. ( Murase, T, 1995) |
| "To compare the efficacy and safety of ciprofloxacin (CIP) and trimethoprim/sulfamethoxazole (TMS) for the prevention of bacterial infections in patients who received bone marrow transplantation (BMT) for the treatment of solid and hematopoietic neoplasms." | 9.08 | Ciprofloxacin versus trimethoprim/sulfamethoxazole for prophylaxis of bacterial infections in bone marrow transplant recipients: a randomized, controlled trial. ( Antman, KH; Finberg, R; Kalish, LA; Kehoe, K; Lew, MA; Nadler, L; Ritz, J, 1995) |
| "A study was conducted to determine the safety and efficacy of topically applied ciprofloxacin ophthalmic solution in a pediatric population experiencing acute bacterial conjunctivitis." | 9.08 | A comparison of ciprofloxacin and tobramycin in bacterial conjunctivitis in children. ( Gross, RD; Hoffman, RO; Lindsay, RN, 1997) |
| "A total of 251 adults with chronic sinusitis were enrolled into this prospective multicentre, double-blind, double-placebo comparison of ciprofloxacin (500 mg twice daily) with amoxycillin/clavulanic acid (500 mg three times daily)." | 9.07 | A double-blind comparison of ciprofloxacin and amoxycillin/clavulanic acid in the treatment of chronic sinusitis. ( Beauvillain, C; Berche, P; Bordure, P; Legent, F, 1994) |
| "Efficacy and safety of oral ciprofloxacin were studied in a prospective study at three cystic fibrosis centres, covering 24 in-patients suffering from cystic fibrosis and acute bronchopulmonary exacerbation." | 9.07 | [Oral ciprofloxacin therapy in juvenile patients with cystic fibrosis--results of a prospective pilot study]. ( Brömme, S; Handrick, W; Kharari, H; Klöditz, E; Patsch, R; Rumler, W; Schuster, R; Sollich, V; Spencker, FB, 1993) |
| "An open, randomized, comparative study of intravenous ciprofloxacin versus gentamicin and clindamycin was performed on women with postpartum endometritis." | 9.07 | Ciprofloxacin versus gentamicin/clindamycin for postpartum endometritis. ( Faro, S; Hammill, HA; Maccato, ML; Martens, MG, 1991) |
| " The use of monotherapy with intravenous ciprofloxacin (200 to 300 mg every 12 h) was evaluated against combined therapy with piperacillin plus amikacin in febrile granulocytopenic patients with solid tumor or lymphoma." | 9.07 | Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors. The European Organization for Research on Treatment of Cancer ( Calandra, T; Gaya, H; Glauser, M; Klastersky, J; Meunier, F; Viscoli, C; Zinner, SH, 1991) |
| "In this study, fleroxacin (FLRX), a new quinolone derivative, was orally given at 300 mg once daily for 14 days to 102 patients with non-catheterized complicated urinary tract infections in order to determine the optimal treatment duration." | 9.07 | [A study on the treatment duration of an antibacterial agent in complicated urinary tract infections. Utility and recurrence after 14-day treatment by fleroxacin]. ( Arakawa, S; Hamami, G; Hazama, M; Kamidono, S; Matsumoto, O; Okamoto, Y; Sengoku, A; Takagi, S; Tanaka, H; Yamazaki, H, 1991) |
| "A multicenter, prospective clinical study of 148 culture-proven cases of bacterial keratitis, treated with ciprofloxacin 0." | 9.07 | Clinical evaluation of ciprofloxacin 0.3% ophthalmic solution for treatment of bacterial keratitis. ( Leibowitz, HM, 1991) |
| "We compared the combination of teicoplanin plus ciprofloxacin with gentamicin plus piperacillin for the empirical treatment of fever in 80 neutropenic patients." | 9.06 | A randomized study of teicoplanin plus ciprofloxacin versus gentamicin plus piperacillin for the empirical treatment of fever in neutropenic patients. ( Collins, PW; Delord, C; Kelsey, SM; Newland, AC; Weinhard, B, 1990) |
| "We examined the efficacy of ciprofloxacin as an empirical treatment for fever in 97 neutropenic patients in a randomized study of ciprofloxacin and benzylpenicillin versus netilmicin and piperacillin." | 9.06 | A comparative study of intravenous ciprofloxacin and benzylpenicillin versus netilmicin and piperacillin for the empirical treatment of fever in neutropenic patients. ( Jenkins, GC; Kelsey, SM; Newland, AC; Shaw, E; Wood, ME, 1990) |
| "To assess the efficacy of ciprofloxacin in neutropenic patients, we conducted a randomized prospective trial comparing the combination of ciprofloxacin and netilmicin against piperacillin plus netilmicin as an empiric treatment of fever in cancer patients with neutropenia." | 9.06 | Randomized trial comparing ciprofloxacin plus netilmicin versus piperacillin plus netilmicin for empiric treatment of fever in neutropenic patients. ( Anderson, H; Chan, CC; Oppenheim, BA; Scarffe, JH; Swindell, R, 1989) |
| "Forty-eight patients with peripheral vascular disease (46 with diabetes mellitus) who presented to the hospital for treatment of lower extremity infections were randomized in a blinded fashion to receive oral ciprofloxacin at a dosage of either 750 mg or 1,000 mg twice daily." | 9.06 | Therapy of lower extremity infections with ciprofloxacin in patients with diabetes mellitus, peripheral vascular disease, or both. ( Canter, K; Clabots, C; Fasching, CE; Gerding, DN; Lissack, LM; Peterson, LR, 1989) |
| "The efficacy and safety of sequential intravenous/oral ciprofloxacin in moderate to severe respiratory tract infections (RTI) were compared with those of ceftazidime in a prospective clinical trial." | 9.06 | Sequential intravenous-oral administration of ciprofloxacin vs ceftazidime in serious bacterial respiratory tract infections. ( Basir, R; Khan, FA, 1989) |
| "This study developed further clinical experience in using a single agent ("monotherapy") as empirical treatment for neutropenic patients with fever, and compared the safety and toxicity of two candidate agents, ceftazidime and ciprofloxacin." | 9.06 | A prospective, randomized comparison of ceftazidime and ciprofloxacin as initial empiric therapy in neutropenic patients with fever. ( Bayston, KF; Cohen, J; Want, S, 1989) |
| "Urinary tract infections in 32 patients were treated with 250 mg of ciprofloxacin twice daily for seven to eight days." | 9.06 | Treatment of urinary tract infections with ciprofloxacin. ( Bonamini, A; Curotto, A; Giberti, C; Martorana, G; Oneto, F; Pizzorno, R; Soro, O, 1988) |
| "Oral ciprofloxacin was used at doses ranging from 500 mg to 1500 mg twice daily for 15 to 476 (mean 139) days for treatment of acute or chronic osteomyelitis in 38 patients, and acute arthritis in two." | 9.06 | Therapy of acute and chronic gram-negative osteomyelitis with ciprofloxacin. Report from a Swedish Study Group. ( , 1988) |
| "80 adult outpatients suffering from otitis media, sinusitis (maxillaris or frontalis) or peritonsillitis were treated with 500 mg ciprofloxacin b." | 9.06 | Antibacterial treatment of otitis and sinusitis with ciprofloxacin and penicillin V--a comparison. ( Falser, N; Mittermayer, H; Weuta, H, 1988) |
| "Bacterial infections of the skin or soft tissue responded to ciprofloxacin 500 mg tablets b." | 9.06 | Bacterial infections of the skin treated with ciprofloxacin. ( Bielunska, S; Gawkonska, M; Gorkiewicz-Petkow, A; Jablonska, S; Petkow, L; Weuta, H, 1988) |
| "Ciprofloxacin, a new quinolone derivative, was given prophylactically (500 mg twice daily) to 15 patients with acute leukemia during remission induction treatment." | 9.06 | Ciprofloxacin for infection prevention in patients with acute leukemia. ( Dekker, AW; Rozenberg-Arska, M, 1987) |
| "Thirty two patients with proven chronic bacterial prostatitis were treated with ciprofloxacin 500 mg twice daily orally for four weeks." | 9.06 | Treatment of chronic bacterial prostatitis with ciprofloxacin. ( de Leur, EJ; Ferwerda, WH; Hoogkamp-Korstanje, JA; Langemeyer, TN; Schipper, JJ; van der Wal, T; van Oort, H, 1987) |
| "8 years) with chronic postsurgical osteomyelitis were treated with ciprofloxacin." | 9.06 | Treatment of chronic postsurgical osteomyelitis with ciprofloxacin. ( Hoogkamp-Korstanje, JA, 1987) |
| "Fifty-six patients receiving remission induction treatment for acute leukemia were studied in a randomized trial comparing ciprofloxacin with trimethoprim-sulfamethoxazole plus colistin for prevention of infections." | 9.06 | Infection prophylaxis in acute leukemia: a comparison of ciprofloxacin with trimethoprim-sulfamethoxazole and colistin. ( Dekker, AW; Rozenberg-Arska, M; Verhoef, J, 1987) |
| "Twenty adult patients with cystic fibrosis who were experiencing acute pulmonary exacerbations were enrolled in a randomized, controlled trial comparing oral ciprofloxacin with intravenous tobramycin plus azlocillin." | 9.06 | Ciprofloxacin versus tobramycin plus azlocillin in pulmonary exacerbations in adult patients with cystic fibrosis. ( Black, PG; Bosso, JA; Matsen, JM, 1987) |
| "Twenty patients with lower respiratory tract infections presumably caused by ciprofloxacin-susceptible bacteria were admitted to a non-comparative, prospective clinical study." | 9.06 | Efficacy and safety of oral ciprofloxacin in the treatment of respiratory tract infections associated with chronic hepatitis. ( Bianchi, W; Esposito, S; Gagliardi, R; Galante, D, 1987) |
| "Twenty adult patients with chronic contiguous osteomyelitis caused by aerobic gram-negative bacilli were enrolled in an open, prospective cooperative study to determine the effect of oral ciprofloxacin therapy in a dosage of 750 mg every 12 hours." | 9.06 | Oral ciprofloxacin therapy for chronic contiguous osteomyelitis caused by aerobic gram-negative bacilli. ( Craven, PC; Gilbert, DN; Marsh, PK; Preheim, LC; Tice, AD, 1987) |
| "The efficacy and toxicity of ciprofloxacin, an orally administered fluoroquinolone, were evaluated in 24 infections in 23 patients with osteomyelitis caused by aerobic gram-negative bacilli." | 9.06 | Clinical efficacy of ciprofloxacin therapy for gram-negative bacillary osteomyelitis. ( Boscia, J; Bush, LM; Hessen, MT; Ingerman, MJ; Kaufman, DH; Kaye, D; Korzeniowski, OM; Santoro, J; Topiel, M; Weiner, P, 1987) |
| "In a one-year follow-up study, short-term therapy with ciprofloxacin proved to be beneficial in the treatment of chronic bacterial prostatitis, particularly in cases of Escherichia coli prostatitis." | 9.06 | Treatment of chronic bacterial prostatitis with ciprofloxacin. Results of a one-year follow-up study. ( Dalhoff, A; Schiefer, HG; Weidner, W, 1987) |
| "In a prospective, randomized, double-blind trial, ciprofloxacin (250 mg orally, twice daily) was compared with cinoxacin (500 mg orally, twice daily) in 60 patients with urinary tract infections." | 9.06 | Ciprofloxacin versus cinoxacin in therapy of urinary tract infections. A randomized, double-blind trial. ( Alpert, ML; Citron, DM; Ginsberg, BP; Goldstein, EJ; Greenway, FL; Kahn, RM, 1987) |
| "Ciprofloxacin treatment of urinary tract infections in 23 patients (16 with and seven without urorenal abnormalities) was compared with beta-lactam antibiotic therapy given orally to 10 comparable patients." | 9.06 | Comparison of ciprofloxacin and beta-lactam antibiotics in the treatment of urinary tract infections and alteration of fecal flora. ( Daikos, GL; Jackson, GG; Kathpalia, SB; Lolans, VT; Sharifi, R, 1987) |
| "The effectiveness and safety of ciprofloxacin, a new quinolone antibiotic, were prospectively evaluated in the treatment of patients with complicated urinary tract infections caused by gram-negative organisms resistant to trimethoprim/sulfamethoxazole." | 9.06 | Oral ciprofloxacin in the treatment of elderly patients with complicated urinary tract infections due to trimethoprim/sulfamethoxazole-resistant bacteria. ( Bittner, MJ; Cuevas, TA; Mellencamp, MA; Preheim, LC; Roccaforte, JS, 1987) |
| "2 years), with urinary tract infections caused by Pseudomonas species or other organisms resistant to trimethoprim-sulfamethoxazole were treated with 500 mg of orally administered ciprofloxacin every 12 hours." | 9.06 | Oral ciprofloxacin in resistant urinary tract infections. ( Andriole, VT; Berenson, CS; Greco, TP; Mangi, RJ; Ryan, JL; Sims, M; Thornton, GF, 1987) |
| "In a double-blind, randomized trial, 85 adult patients with acute diarrhea (more than three watery stools per day) received either 500 mg of ciprofloxacin twice daily or placebo for five days." | 9.06 | Clinical efficacy of ciprofloxacin compared with placebo in bacterial diarrhea. ( Diridl, G; Pichler, HE; Stickler, K; Wolf, D, 1987) |
| " In an ongoing study, 11 patients with nosocomial lower respiratory tract infections were given 200 mg of intravenous ciprofloxacin every 12 hours." | 9.06 | Dual individualization of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. ( Cumbo, TJ; Fracasso, JE; Nix, DE; Peloquin, CA; Sands, MF; Schentag, JJ; Vance, JW; Vari, AJ, 1987) |
| "The clinical and bacteriological efficacy and safety of ciprofloxacin given as oral doses of 500 to 1,500 mg (normally 750 mg) twice daily for treatment of Gram-negative bacillary osteomyelitis are reviewed." | 8.77 | Ciprofloxacin in the treatment of acute and chronic osteomyelitis: a review. ( Norrby, SR, 1989) |
| "To evaluate the impact of cessation of ciprofloxacin prophylaxis during stem cell transplantation for multiple myeloma." | 7.91 | Ciprofloxacin prophylaxis during autologous stem cell transplantation for multiple myeloma in patients with a high rate of fluoroquinolone-resistant gram-negative bacteria colonization. ( Gabalec, F; Paterova, P; Radocha, J; Zak, P; Zavrelova, A, 2019) |
| "The addition of doxycycline to standard prophylaxis with ciprofloxacin seems to reduce the number of NF episodes and documented bacterial infections in patients with MM undergoing ASCT, without increasing rate of serious complications." | 7.88 | Addition of doxycycline to ciprofloxacin for infection prophylaxis during autologous stem cell transplants for multiple myeloma. ( Davidson, J; Drabick, JJ; Hale, CM; Sivik, JM; Talamo, G, 2018) |
| "The aim of the study was to describe the incidence and type of bacterial infections associated with the use of ciprofloxacin prophylaxis as single agent in pediatric patients with acute myeloid leukemia (AML)." | 7.85 | Bacterial Infections in Children With Acute Myeloid Leukemia Receiving Ciprofloxacin Prophylaxis. ( Al Omar, S; Al Qasem, W; Anabtawi, N; Rihani, R, 2017) |
| "The objectives of this study were to investigate risk factors and the incidence of ciprofloxacin resistance and extended-spectrum beta-lactamases (ESBL) in patients with acute bacterial prostatitis (ABP)." | 7.83 | Risk Factor Analysis of Ciprofloxacin-Resistant and Extended Spectrum Beta-Lactamases Pathogen-Induced Acute Bacterial Prostatitis in Korea. ( Lee, DG; Lee, SH; Lee, Y; Yoo, KH, 2016) |
| "The objective of this study was to determine if specific species of microorganisms are associated with severe infection and amputation in patients with a diabetic foot infection and to evaluate the effectiveness of clindamycin and ciprofloxacin in this population." | 7.80 | Are clindamycin and ciprofloxacin appropriate for the empirical treatment of diabetic foot infections? ( de Vries, MG; Ekkelenkamp, MB; Peters, EJ, 2014) |
| "Ciprofloxacin is considered to be a safe and effective treatment for acute infectious colitis." | 7.80 | Acute pancreatitis secondary to ciprofloxacin therapy in patients with infectious colitis. ( Cheung, DY; Cho, HJ; Cho, SH; Kim, JI; Kim, JK; Kim, SS; Lee, HJ; Sung, HY, 2014) |
| "99mTc-ciprofloxacin is a radiopharmaceutical preparation sintetized to improve diagnostic accuracy of bacterial infections in human tissues." | 7.75 | Estimation of 99mTc-ciprofloxacin accumulation indexes in bone and joint bacterial infections. ( Dugonjić, S; Janković, Z; Popović, Z; Pucar, D, 2009) |
| "The objective of this investigation was to assess retrospectively the safety and the efficacy of oral ciprofloxacin plus cefuroxime axetil compared to the combination of oral ciprofloxacin plus amoxicillin/clavulanate, as initial outpatient treatment, in low-risk cancer patients with fever and neutropenia." | 7.74 | Comparison of two oral regimens for the outpatient treatment of low-risk cancer patients with chemotherapy-induced neutropenia and fever: ciprofloxacin plus cefuroxime axetil versus ciprofloxacin plus amoxicillin/clavulanate. ( Karabelis, A; Kordossis, T; Kosmas, C; Sipsas, NV; Skopelitis, E; Tsavaris, N; Vadiaka, M; Ziakas, PD, 2007) |
| "Twice daily ciprofloxacin @ 500 mg for 28 days proved to be the most cost effective treatment for chronic bacterial prostatitis." | 7.71 | Cost effectiveness model comparing trimethoprim sulfamethoxazole and ciprofloxacin for the treatment of chronic bacterial prostatitis. ( Kaplan, S; Kurzer, E, 2002) |
| "Retrospective evaluation of Tc-99m ciprofloxacin (infection) scintigraphy consecutively performed in a series of patients clinically suspected for peripheral osteomyelitis (OM), spondylodiscitis (SD) and fever of unknown origin (FUO)." | 7.71 | [Tc-99m ciprofloxacin in clinically selected patients for peripheral osteomyelitis, spondylodiscitis and fever of unknown origin--preliminary results]. ( Gallowitsch, HJ; Gomez, I; Heinisch, M; Kresnik, E; Kumnig, G; Lind, P; Mikosch, P, 2002) |
| "To assess the value of prophylactic ciprofloxacin in reducing the incidence of neutropenic fever in men receiving intensive chemotherapy for germ cell tumours, we reviewed the case notes of 88 consecutive patients treated between January 1986 and December 1992." | 7.69 | Chemotherapy for germ cell tumours: prophylactic ciprofloxacin reduces the incidence of neutropenic fever. ( Counsell, R; Pratt, J; Williams, MV, 1994) |
| "Fifty consecutive episodes of neutropenia were studied in patients with AML who received prophylaxis with ciprofloxacin and these were compared with a historic control group of another 50 consecutive episodes of neutropenia in AML patients who did not receive antibiotic prophylaxis." | 7.69 | [Prophylaxis with ciprofloxacin in postchemotherapy neutropenia in acute myeloid leukemia]. ( Bueno, J; Juliá, A; López, A; Novo, A; Soler, JA, 1994) |
| "We present the results of a protocol of empiric monotherapy of continuous ambulatory peritoneal dialysis (CAPD)-related peritonitis with ciprofloxacin (CPX), with a special emphasis on the evolution of our results after seven years of continued use of this drug." | 7.69 | Treatment of CAPD-related peritonitis with ciprofloxacin: results after seven years. ( Bouza, P; García Falcón, T; López Vázquez, M; Pérez Fontán, M; Rodríguez-Carmona, A; Tresancos, C; Valdés, F, 1996) |
| "As urinary tract infections in immunosuppressed renal transplant patients present a major therapeutic problem for clinicians in charge of renal units, the efficacy of the antibiotic ciprofloxacin in such cases was tested in this study." | 7.68 | Treatment of urinary tract infections with ciprofloxacin after renal transplantation. ( Alivanis, P; Dioudis, C; Grekas, D; Thanos, V; Tourkantonis, A, 1993) |
| "Seventeen adult patients with chronic osteomyelitis were treated with oral ciprofloxacin, 750 mg twice daily." | 7.68 | Oral ciprofloxacin for treatment of chronic osteomyelitis. ( Bortoletto, ML; Brasil Filho, R; Carvalho, MC; Levi, GC; Lobo, IM; Mendonça, JS; Silva, ML; Trevisanello, C; Yamaguti, A, 1993) |
| "In a retrospective study, the clinical and microbiological efficacy of amoxycillin-clavulanic acid and ciprofloxacin were evaluated in outpatients observed within the previous year who were affected by acute purulent exacerbations of chronic bronchitis." | 7.68 | Comparative clinical and microbiological study of amoxycillin-clavulanic acid and ciprofloxacin in acute purulent exacerbations of chronic bronchitis. ( Beghi, G; Caratozzolo, O; Legnani, D; Lombardo, VM; Negretto, GG, 1992) |
| "We studied the entry of ciprofloxacin into the cerebrospinal fluid (CSF) in 37 patients with various types of meningitis (bacterial meningitis 10 patients, viral 12 patients, tuberculous 7 patients)." | 7.68 | Entry of ciprofloxacin into cerebrospinal fluid during bacterial, viral and tuberculous meningitis. ( Barsić, B; Beus, I; Himbele, J; Lisić, M; Marton, E; Schönwald, S, 1991) |
| "From October 1983 to October 1986, 39 patients with chronic osteomyelitis (of at least two month's duration) were treated with either pefloxacin (n = 15), ofloxacin (n = 17), or ciprofloxacin (n = 7)." | 7.67 | Evaluation of pefloxacin, ofloxacin and ciprofloxacin in the treatment of thirty-nine cases of chronic osteomyelitis. ( Bernard, E; Dellamonica, P; Drugeon, HB; Etesse, H; Garraffo, R, 1989) |
| "42 patients with bacterial infections caused by resistant to other available in this country antibiotics, immunocompromised patients and patients in severe life-threatening conditions were treated with ciprofloxacin (Ciprobay--Bayer) in tablets." | 7.67 | [Ciprofloxacin in bacterial infections]. ( Belovezhdov, N; Monova, D, 1989) |
| "Twenty-five acutely ill patients, 21 men and 4 women aged 20-90 years (mean, 54 years) with acute community-acquired bacterial pneumonia, were treated with ciprofloxacin orally." | 7.67 | Use of oral ciprofloxacin in community-acquired pneumonia. ( Bassaris, HP; Chrysanthopoulos, CJ, 1989) |
| "Eighty hospital patients with acute purulent exacerbations of chronic bronchitis associated with Haemophilus influenzae, Streptococcus pneumoniae, Branhamella catarrhalis or Pseudomonas aeruginosa were treated with ciprofloxacin." | 7.67 | Ciprofloxacin in the treatment of acute exacerbations of chronic bronchitis. ( Baur, C; Davies, BI; Maesen, FP, 1986) |
| "Ciprofloxacin, a new quinolone derivative, was given prophylactically (500 mg twice a day) to 15 patients with acute leukemia during remission induction treatment for a mean duration of 42 days." | 7.67 | Ciprofloxacin for selective decontamination of the alimentary tract in patients with acute leukemia during remission induction treatment: the effect on fecal flora. ( Dekker, AW; Rozenberg-Arska, M; Verhoef, J, 1985) |
| "The use of ciprofloxacin for the treatment of pulmonary infection in cystic fibrosis patients was investigated." | 7.67 | The use of ciprofloxacin in the treatment of patients with cystic fibrosis. ( Bakker, W; Mattie, H; van den Broek, PJ; van Gulpen, C, 1987) |
| "Thirty four patients with acute purulent exacerbations of chronic bronchitis were treated with 500 mg ciprofloxacin twice daily, orally, for ten days." | 7.67 | Treatment of acute exacerbations of chronic bronchitis with ciprofloxacin. ( Hoogkamp-Korstanje, JA; Klein, SJ, 1987) |
| " The aim was to investigate the efficacy of long-term administration of ciprofloxacin to prevent SBP." | 6.73 | Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: a randomized, placebo-controlled study. ( Abecasis, R; Cartier, M; Dominguez, N; Fassio, E; Guevara, M; Landeira, C; Levi, D; Longo, C; Lucero, R; Miguez, C; Muñoz, A; Romero, G; Terg, R, 2008) |
| "The efficacy and safety of two oral dosing regimens of gatifloxacin were compared to ciprofloxacin in the treatment of complicated urinary tract infection in a randomised, double-blind multi-centre trial." | 6.71 | Gatifloxacin 200 mg or 400 mg once daily is as effective as ciprofloxacin 500 mg twice daily for the treatment of patients with acute pyelonephritis or complicated urinary tract infections. ( Ankel-Fuchs, D; Bartnicki, A; Bischoff, W; Hanus, M; Milutinovic, S; Naber, KG; Schönwald, S; van Belle, F; Weitz, P, 2004) |
| "The efficacy and safety of two oral dosing regimens of gatifloxacin compared with ciprofloxacin for the treatment of acute uncomplicated lower urinary tract infection was investigated in a double-blind, randomised study, in adult female patients who received either gatifloxacin (400 mg as a single shot or 3 days of 200 mg once daily) or ciprofloxacin (250 mg given twice daily for 3 days)." | 6.71 | Gatifloxacin 400 mg as a single shot or 200 mg once daily for 3 days is as effective as ciprofloxacin 250 mg twice daily for the treatment of patients with uncomplicated urinary tract infections. ( Allin, DM; Ankel-Fuchs, D; Clarysse, L; Haworth, DA; Hopkins, G; James, IG; Naber, KG; Raini, C; Schneider, H; Wall, A; Weitz, P, 2004) |
| " Patients were randomly divided into three groups of 30; the first group was dosed with pefloxacin 800 mg i." | 6.68 | Comparative activities of pefloxacin and ciprofloxacin in the treatment of chronic respiratory tract infections. ( Arcidiacono, MM; Cogo, R; Fraschini, F; Monzani, GP; Scaglione, F; Scamazzo, F, 1995) |
| "Ciprofloxacin was compared to ciprofloxacin plus amoxicillin as antibacterial prophylaxis in 53 evaluable patients with neutropenic episodes, because an oral penicillin may help to decrease the incidence of gram-positive infections." | 6.67 | Chemoprophylaxis of bacterial infections in granulocytopenic patients with ciprofloxacin vs ciprofloxacin plus amoxicillin. ( Bosi, A; Ciolli, S; Donnini, E; Fanci, R; Guidi, S; Leoni, F; Longo, G; Rossi Ferrini, P, 1993) |
| " The bioavailability of ciprofloxacin appeared comparable to that found in previously published studies of normal volunteers and patients not receiving chemotherapy." | 6.67 | Prophylaxis of bacterial infections with ciprofloxacin in patients undergoing bone marrow transplantation. ( Antman, KH; Finberg, R; Kalish, L; Kehoe, K; Lew, MA; Mayer, R; Nadler, L; Ritz, J; Takvorian, T, 1991) |
| "Ciprofloxacin was clinically more effective than the standard therapy in reducing the size of the ulcer (p less than 0." | 6.66 | A comparative study of ciprofloxacin and conventional therapy in the treatment of patients with chronic lower leg ulcers infected with Pseudomonas aeruginosa or other gram-negative rods. ( Kariniemi, AL; Karppinen, L; Valtonen, V, 1989) |
| "Ciprofloxacin treatment was successful in all nine patients with chlamydial or gonococcal PID and in six of seven with nonchlamydial nongonococcal PID." | 6.66 | A comparison of ciprofloxacin with doxycycline plus metronidazole in the treatment of acute pelvic inflammatory disease. ( Aine, R; Grönroos, P; Heinonen, PK; Miettinen, A; Punnonen, R; Teisala, K, 1989) |
| "Ciprofloxacin was given orally at different dose regimens: 500 mg b." | 6.66 | Efficacy and safety of ciprofloxacin in the treatment of UTIs and RTIs in patients affected by liver diseases. ( Barba, D; Bianchi, W; Esposito, S; Gagliardi, R; Galante, D; Giusti, R, 1988) |
| "Ciprofloxacin has proved to be superior to cefalexin in the treatment of lower UTI." | 6.66 | Bacterial infections of the lower urinary tract treated with ciprofloxacin or cefalexin--a comparative study. ( Jórasz, J; Ktos, K; Polubiec, A; Stepka, K; Strazynska, R; Weuta, H, 1988) |
| "Ciprofloxacin was as effective as ampicillin and produced a 98 percent clinical cure rate." | 6.66 | Controlled, comparative study of ciprofloxacin versus ampicillin in treatment of bacterial respiratory tract infections. ( Afzal, Q; Guarneri, JJ; Khan, FA; LaBombardi, V; Raoof, S; Wollschlager, CM, 1987) |
| "Ciprofloxacin displays excellent in vitro activity against gram-negative bacilli and offers the potential for outpatient therapy." | 6.66 | Oral ciprofloxacin therapy for gram-negative bacillary osteomyelitis. ( Francis, JB; Freer, C; Lesse, AJ; Salata, RA; Scheld, WM, 1987) |
| " The use of antibiotics with favourable pharmacokinetic/pharmacodynamic profiles and convenient dosing schedules, which effectively increase bacterial eradication and patient compliance, can help to curb the current epidemic of resistance and reduce the rate of clinical failure associated with resistance." | 6.42 | Extended-release ciprofloxacin (Cipro XR) for treatment of urinary tract infections. ( Elkharrat, D; Naber, KG; Palou, J; Talan, DA, 2004) |
| "Ciprofloxacin is a potent fluoroquinolone antibiotic with in vitro activity against many significant gram-positive and gram-negative ocular pathogens." | 6.38 | Insights from experimental data on ciprofloxacin in the treatment of bacterial keratitis and ocular infections. ( Cokingtin, CD; Hyndiuk, RA, 1991) |
| "The incidence and of bacterial infections, and resulting mortality, among cancer patients is growing dramatically, worldwide." | 5.72 | Dual acting acid-cleavable self-assembling prodrug from hyaluronic acid and ciprofloxacin: A potential system for simultaneously targeting bacterial infections and cancer. ( Devnarain, N; Gafar, MA; Govender, T; Ibrahim, UH; Khan, R; Mocktar, C; Mohammed, M; Oh, JK; Omolo, CA; Pant, A; Salih, M; Shunmugam, L, 2022) |
| "For the treatment of spontaneous bacterial peritonitis (SBP), cefotaxime, ceftriaxone, and ciprofloxacin were used as first-line agents." | 5.69 | Response-Guided Therapy With Cefotaxime, Ceftriaxone, or Ciprofloxacin for Spontaneous Bacterial Peritonitis: A Randomized Trial: A Validation Study of 2021 AASLD Practice Guidance for SBP. ( Baik, SK; Han, KH; Heo, J; Heo, NY; Jung, YK; Kang, SH; Kim, BI; Kim, HS; Kim, MY; Kim, TH; Kim, YS; Park, JY; Park, SY; Seo, YS; Sohn, JH; Suh, SJ; Um, SH; Yim, HJ; Yim, SY, 2023) |
| "Osteomyelitis is a major problem worldwide and is devastating due to the potential for limb-threatening sequelae and mortality." | 5.46 | Design, Synthesis, and Antimicrobial Evaluation of a Novel Bone-Targeting Bisphosphonate-Ciprofloxacin Conjugate for the Treatment of Osteomyelitis Biofilms. ( Bakhshalian, N; Bartoszewicz, M; Ebetino, FH; Junka, AF; Lundy, MW; Mahabady, S; McKenna, CE; Neighbors, JD; Oleksy, M; Richard, E; Russell, RG; Sadrerafi, K; Sedghizadeh, PP; Sun, S; Szymczyk, P; Tjokro, N, 2017) |
| " Ciprofloxacin pharmacokinetics in critically ill patients do not change over time, and intra-abdominal sepsis does not alter ciprofloxacin pharmacokinetic parameters to a greater degree than sepsis from other causes in critically ill patients." | 5.33 | Fluid shifts have no influence on ciprofloxacin pharmacokinetics in intensive care patients with intra-abdominal sepsis. ( Gous, A; Hon, H; Lipman, J; Mathivha, R; Pinder, M; Scribante, J; Stass, H; Tshukutsoane, S; Verhoef, L, 2005) |
| "We studied the tolerance and pharmacokinetic parameters of ciprofloxacin in (2 mg/kg, i." | 5.30 | Tolerance and pharmacokinetics of ciprofloxacin in the chick. Preliminary experience in subjects of pediatric age with urinary tract infections (UTI). ( Barberi, I; De Sarro, A; Masaracchio, A; Naccari, F; Salpietro, DC, 1998) |
| "Serum sickness is a systemic hypersensitivity reaction initially reported in children receiving horse serum." | 5.28 | Serum sickness-like illness associated with ciprofloxacin. ( Slama, TG, 1990) |
| "Ciprofloxacin is a new fluoroquinolone that is easily administered by parenteral and oral route." | 5.28 | [Evaluation of ciprofloxacin for the treatment of severe bacterial infections]. ( Bouza, E; García de la Torre, M; López, JC; offcenado, E; Rodríguez-Créixems, M; Romero, J, 1989) |
| "The optimal approach to reduce bacterial infections in granulocytopenic patients is still controversial." | 5.28 | [Prevention of bacterial infections using ciprofloxacin in granulocytopenic patients with cancer]. ( Gerain, J; Leleux, A; Libert, J; Meunier, F; Snoeck, R, 1989) |
| "Ciprofloxacin was well tolerated." | 5.28 | Efficacy of ciprofloxacin in the treatment of various bacterial infections. ( Hutchison, J; Nolen, TM; Phillips, HL, 1989) |
| "Once weekly ciprofloxacin was as effective as daily norfloxacin for the prevention of SBP in cirrhotic patients with ascites." | 5.27 | Daily Norfloxacin vs. Weekly Ciprofloxacin to Prevent Spontaneous Bacterial Peritonitis: A Randomized Controlled Trial. ( Jang, JY; Jung, YK; Kim, BI; Kim, HS; Kim, YS; Lee, YR; Park, SY; Seo, YS; Suh, SJ; Um, SH; Yim, HJ; Yim, SY, 2018) |
| "The osteomyelitis was secondary to trauma in 12 patients, joint replacement in six, previous acute hematogenous infection in two and osteotomy in one." | 5.27 | Treatment of chronic osteomyelitis with ciprofloxacin. ( Mulier, JC; Stuyck, J; Verbist, L, 1987) |
| "Ciprofloxacin is a fluorinated carboxyquinolone that inhibits Enterobacteriaceae, staphylococci, and Pseudomonas at low concentrations." | 5.27 | Effect of ciprofloxacin on fecal flora of patients with cystic fibrosis and other patients treated with oral ciprofloxacin. ( Chin, NX; Jules, K; Neu, HC; Scully, BE, 1987) |
| "Seventy-seven patients [25 with clinical suspicion of diabetic foot osteomyelitis (DFOM), 25 with orthopedic device-related infection (ODRI) and 27 with tubercular bone infection] underwent three-phase Tc-methylenediphosphonate bone scintigraphy followed by static Tc-ciprofloxacin imaging at 1, 4 and 24 h." | 5.13 | Efficacy of indigenously developed single vial kit preparation of 99mTc-ciprofloxacin in the detection of bacterial infection: an Indian experience. ( Aggarwal, S; Bhatnagar, A; Bhattacharya, A; Gill, SS; Goni, VG; Kashyap, R; Mittal, BR; Prasad, V; Rai, R; Sharma, S; Singh, AK; Singh, B; Sunil, HV; Taneja, A, 2008) |
| "Rifaximin was compared with placebo and ciprofloxacin for treatment of travelers' diarrhea in a randomized, double-blind clinical trial." | 5.12 | A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea. ( Bourgeois, AL; Dupont, HL; Ericsson, CD; Haake, R; Halpern, J; Jiang, ZD; Steffen, R; Taylor, DN, 2006) |
| "The suitability of the 18F-labelled fluoroquinolone antibiotic ciprofloxacin ([18F]ciprofloxacin) for imaging of bacterial infections with positron emission tomography (PET) was assessed in vitro and in vivo." | 5.11 | In vitro and in vivo evaluation of [18F]ciprofloxacin for the imaging of bacterial infections with PET. ( Brunner, M; Dobrozemsky, G; Dudczak, R; Joukhadar, C; Kletter, K; Lackner, E; Langer, O; Minar, E; Mitterhauser, M; Müller, M; Müller, U; Wadsak, W; Zeitlinger, M; Ziegler, S, 2005) |
| "We compared baseline and post-therapy prostate specific antigen (PSA) in patients with chronic bacterial prostatitis who were treated with levofloxacin or ciprofloxacin." | 5.11 | Treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers serum prostate specific antigen. ( Kahn, JB; Schaeffer, AJ; Tennenberg, AM; Wu, SC, 2005) |
| "The aim of this study was to compare the efficacy of single-dose intravenous cefazolin prophylaxis with single-dose oral ciprofloxacin prophylaxis in patients undergoing tension-free inguinal hernia repair with polypropylene mesh." | 5.11 | Single-dose oral ciprofloxacin compared with single-dose intravenous cefazolin for prophylaxis in inguinal hernia repair: a controlled randomized clinical study. ( Ergör, G; Füzün, M; Hoşgörler, F; Kiliç, D; Terzi, C; Unek, T, 2005) |
| "In this study we aimed to determine the microorganisms found in perianal fistulas in Crohn's disease and whether treatment with ciprofloxacin affects these microorganisms." | 5.11 | Perianal fistulas in Crohn's disease are predominantly colonized by skin flora: implications for antibiotic treatment? ( Boelens, HA; Endtz, HP; Hansen, BE; Kuipers, EJ; Kusters, JG; Ouwedijk, M; Van der Woude, CJ; West, RL, 2005) |
| "In cirrhotic patients with variceal bleeding and with Child-Pugh class B or C, the use of intravenous ciprofloxacin for 3 days after EVL was not only effective in the prevention of bacterial infections but also cost-effective." | 5.10 | [Prospective randomized trial of intravenous ciprofloxacin for prevention of bacterial infection in cirrhotic patients with esophageal variceal bleeding]. ( Choi, KW; Choi, MS; Hong, SN; Kim, BJ; Kim, JJ; Koh, KC; Lee, CY; Lee, JH; Lee, SY; Paik, SW; Rhee, JC; Rhee, PL; Ryu, MK, 2002) |
| "Evaluation of benzylpenicillin (penicillin G) effect for infection prophylaxis at the oncological patients with severe postcytostatic neutropenia was performed." | 5.10 | [Benzylpenicillin efficacy for neutropenic infection prophylaxis in patients with cancer and postcytostatic neutropenia]. ( Chimishkian, KL; Dmitrieva, NV; Larionova, VB; Minenko, SV; Ptushkin, VV; Sokolova, EN; Zhukov, NV, 2002) |
| "To investigate the value of Tc-99m ciprofloxacin imaging in the differential diagnosis of chronic bacterial prostatitis." | 5.10 | Tc-99m ciprofloxacin imaging in diagnosis of chronic bacterial prostatitis. ( Choe, W; Kim, S; Lee, SM; Moon, Y; Pai, SH; Ryu, JK; Seong, DW; Suh, JK, 2003) |
| "To compare the safety and efficacy of levofloxacin with that of ciprofloxacin for the treatment of chronic bacterial prostatitis." | 5.10 | Levofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis: a randomized double-blind multicenter study. ( Bundrick, W; Heron, SP; Kahn, JB; Ray, P; Schiff, WM; Tennenberg, AM; Wiesinger, BA; Wright, PA; Wu, SC; Zadeikis, N, 2003) |
| "In hospitalized low-risk patients who have fever and neutropenia during cancer chemotherapy, empirical therapy with oral ciprofloxacin and amoxicillin-clavulanate is safe and effective." | 5.09 | A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. ( Chanock, S; Freifeld, A; Gill, V; Hicks, JE; Hiemenz, J; Hiemenz, S; Lewis, L; Marchigiani, D; Pizzo, PA; Steinberg, SM; Walsh, T, 1999) |
| "The efficacy and safety of ciprofloxacin 500 mg bd for 28 days were assessed in 65 adult males with symptomatic bacterial prostatitis, from eight centres in Germany." | 5.09 | Ciprofloxacin in the treatment of chronic bacterial prostatitis: a prospective, non-comparative multicentre clinical trial with long-term follow-up. The German Prostatitis Study Group. ( Busch, W; Focht, J; Naber, KG, 2000) |
| "To assess topical ciprofloxacin in patients with moderate severity of suspected bacterial corneal ulcers." | 5.09 | Topical ciprofloxacin for bacterial corneal ulcer. ( Buranapongs, W; Kosrirukvongs, P, 2000) |
| "The objective of this study was to characterize the prevalence and clinical significance of ciprofloxacin-resistant Escherichia coli in perianal swabs of patients with hematologic malignancies in a German university hospital." | 5.09 | Prevalence of ciprofloxacin-resistant Escherichia coli in hematologic-oncologic patients. ( Baum, HV; Franz, U; Geiss, HK, 2000) |
| "The aim of this prospective double-blind study was to evaluate the value of long-term antibiotic prophylaxis using ciprofloxacin for the prevention of spontaneous bacterial peritonitis (SBP) in 60 cirrhotic patients with low ascitic fluid protein levels (< 15 g/L)." | 5.08 | Ciprofloxacin and long-term prevention of spontaneous bacterial peritonitis: results of a prospective controlled trial. ( Bacq, Y; Bohn, B; Cordier, L; Franza, A; Fratte, S; Kitmacher, P; Nousbaum, JB; Paris, JC; Rolachon, A; Stahl, JP, 1995) |
| "Fifty-three granulocytopenic patients were studied in a randomized trial comparing trimethoprim-sulfamethoxaxole (ST) alone with ST + ciprofloxacin (CPFX) for prevention of bacterial infections." | 5.08 | [Chemoprophylaxis of bacterial infections in granulocytopenic patients with new quinolone: a comparison of trimethoprim-sulfamethoxazole (ST) alone with ST plus ciprofloxacin]. ( Murase, T, 1995) |
| "To compare the efficacy and safety of ciprofloxacin (CIP) and trimethoprim/sulfamethoxazole (TMS) for the prevention of bacterial infections in patients who received bone marrow transplantation (BMT) for the treatment of solid and hematopoietic neoplasms." | 5.08 | Ciprofloxacin versus trimethoprim/sulfamethoxazole for prophylaxis of bacterial infections in bone marrow transplant recipients: a randomized, controlled trial. ( Antman, KH; Finberg, R; Kalish, LA; Kehoe, K; Lew, MA; Nadler, L; Ritz, J, 1995) |
| "The objective of this study was to evaluate the efficacy of oral ciprofloxacin in preventing febrile morbidity superimposed on the neutropenia induced from a paclitaxel regimen in ovarian cancer patients." | 5.08 | Chemoprophylaxis with ciprofloxacin in ovarian cancer patients receiving paclitaxel: a randomized trial. ( Carlson, JW; Carson, LF; Copeland, LJ; Fowler, JM; Mayer, AR; Mitchell, SK, 1997) |
| "A study was conducted to determine the safety and efficacy of topically applied ciprofloxacin ophthalmic solution in a pediatric population experiencing acute bacterial conjunctivitis." | 5.08 | A comparison of ciprofloxacin and tobramycin in bacterial conjunctivitis in children. ( Gross, RD; Hoffman, RO; Lindsay, RN, 1997) |
| " The aim of this study was to investigate the efficacy of prophylactic intestinal decontamination with oral ciprofloxacin for the prevention of bacterial infections in cirrhotic patients with upper gastrointestinal bleeding." | 5.08 | The effect of ciprofloxacin in the prevention of bacterial infection in patients with cirrhosis after upper gastrointestinal bleeding. ( Chang, FY; Hou, MC; Hsieh, WJ; Hwang, SJ; Lee, FY; Lee, SD; Lin, HC, 1998) |
| "To determine the sensitivity and specificity of 99mTc-Infecton (Infecton), a novel ciprofloxacin based imaging agent, in detecting sites of infection." | 5.08 | Evaluation of the efficacy of 99mTc-Infecton, a novel agent for detecting sites of infection. ( Britton, KE; Das, SS; Hall, AV; Solanki, KK; Vinjamuri, S, 1998) |
| "The purpose of this study was to test the comparative efficacy and toxicity of empiric gentamicin and ciprofloxacin, in combination with piperacillin, in febrile patients with treatment-induced neutropenia." | 5.08 | Ciprofloxacin plus piperacillin is an equally effective regimen for empiric therapy in febrile neutropenic patients compared with standard therapy. ( Betts, RF; Blair, EA; Flesher, WR; Griggs, JJ; Norton, JR; Rowe, JM, 1998) |
| "A total of 251 adults with chronic sinusitis were enrolled into this prospective multicentre, double-blind, double-placebo comparison of ciprofloxacin (500 mg twice daily) with amoxycillin/clavulanic acid (500 mg three times daily)." | 5.07 | A double-blind comparison of ciprofloxacin and amoxycillin/clavulanic acid in the treatment of chronic sinusitis. ( Beauvillain, C; Berche, P; Bordure, P; Legent, F, 1994) |
| "We studied the effectiveness of prophylactic oral ciprofloxacin and rifampin on fever prevention in patients undergoing autologous bone marrow transplantation (ABMT) for breast cancer." | 5.07 | Sequential prophylactic oral and empiric once-daily parenteral antibiotics for neutropenia and fever after high-dose chemotherapy and autologous bone marrow support. ( Gilbert, C; Hussein, A; Meisenberg, B; Perfect, J; Peters, WP; Ross, M; Vredenburgh, J, 1994) |
| "To study whether oral ciprofloxacin would be as effective in preventing bacterial infections in severely myelosuppressed patients as selective antibiotic modulation of the gut flora with neomycin/polymyxin B sulfate/nalidixic acid (NPN)." | 5.07 | Infection prevention in severely myelosuppressed patients: a comparison between ciprofloxacin and a regimen of selective antibiotic modulation of the intestinal flora. ( Akard, L; Allen, SD; Black, JR; Cromer, M; Jansen, J; Wheat, LJ, 1994) |
| "Efficacy and safety of oral ciprofloxacin were studied in a prospective study at three cystic fibrosis centres, covering 24 in-patients suffering from cystic fibrosis and acute bronchopulmonary exacerbation." | 5.07 | [Oral ciprofloxacin therapy in juvenile patients with cystic fibrosis--results of a prospective pilot study]. ( Brömme, S; Handrick, W; Kharari, H; Klöditz, E; Patsch, R; Rumler, W; Schuster, R; Sollich, V; Spencker, FB, 1993) |
| "Teicoplanin plus ciprofloxacin was compared with gentamicin plus piperacillin for the empirical treatment of fever in 80 neutropenic patients." | 5.07 | Teicoplanin plus ciprofloxacin versus gentamicin plus piperacillin in the treatment of febrile neutropenic patients. ( Collins, PW; Kelsey, SM; Newland, AC; Weinhardt, B, 1992) |
| " A randomized, double-blind, multicenter study was conducted in 492 patients to compare the safety and efficacy of temafloxacin 600 mg with ciprofloxacin 750 mg for the treatment of bacterial infections of the skin or skin structure." | 5.07 | Systemic antimicrobial therapy in skin and skin structure infections: comparison of temafloxacin and ciprofloxacin. ( Jungkind, DL; Parish, LC, 1991) |
| "An open, randomized, comparative study of intravenous ciprofloxacin versus gentamicin and clindamycin was performed on women with postpartum endometritis." | 5.07 | Ciprofloxacin versus gentamicin/clindamycin for postpartum endometritis. ( Faro, S; Hammill, HA; Maccato, ML; Martens, MG, 1991) |
| " The use of monotherapy with intravenous ciprofloxacin (200 to 300 mg every 12 h) was evaluated against combined therapy with piperacillin plus amikacin in febrile granulocytopenic patients with solid tumor or lymphoma." | 5.07 | Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors. The European Organization for Research on Treatment of Cancer ( Calandra, T; Gaya, H; Glauser, M; Klastersky, J; Meunier, F; Viscoli, C; Zinner, SH, 1991) |
| "In this study, fleroxacin (FLRX), a new quinolone derivative, was orally given at 300 mg once daily for 14 days to 102 patients with non-catheterized complicated urinary tract infections in order to determine the optimal treatment duration." | 5.07 | [A study on the treatment duration of an antibacterial agent in complicated urinary tract infections. Utility and recurrence after 14-day treatment by fleroxacin]. ( Arakawa, S; Hamami, G; Hazama, M; Kamidono, S; Matsumoto, O; Okamoto, Y; Sengoku, A; Takagi, S; Tanaka, H; Yamazaki, H, 1991) |
| "A multicenter, prospective clinical study of 148 culture-proven cases of bacterial keratitis, treated with ciprofloxacin 0." | 5.07 | Clinical evaluation of ciprofloxacin 0.3% ophthalmic solution for treatment of bacterial keratitis. ( Leibowitz, HM, 1991) |
| "More patients receiving ciprofloxacin did not develop fever during neutropenia and did not receive antibiotics (34%) compared with those receiving norfloxacin (25%) (P = 0." | 5.07 | Prevention of bacterial infection in neutropenic patients with hematologic malignancies. A randomized, multicenter trial comparing norfloxacin with ciprofloxacin. The GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. ( , 1991) |
| "We compared the combination of teicoplanin plus ciprofloxacin with gentamicin plus piperacillin for the empirical treatment of fever in 80 neutropenic patients." | 5.06 | A randomized study of teicoplanin plus ciprofloxacin versus gentamicin plus piperacillin for the empirical treatment of fever in neutropenic patients. ( Collins, PW; Delord, C; Kelsey, SM; Newland, AC; Weinhard, B, 1990) |
| "From June 1985 to September 1987, 202 adults were enrolled in a randomized, double-blinded study comparing ciprofloxacin (500 mg) with sulfamethoxazole and trimethoprim (160 mg/800 mg) or placebo for adults with acute diarrhea." | 5.06 | Empiric antimicrobial therapy of domestically acquired acute diarrhea in urban adults. ( Goodman, LJ; Hines, D; Kaplan, RL; Landau, W; Mayer, KW; Nelson, JA; Parkhurst, GW; Petrak, R; Segreti, J; Trenholme, GM, 1990) |
| "We examined the efficacy of ciprofloxacin as an empirical treatment for fever in 97 neutropenic patients in a randomized study of ciprofloxacin and benzylpenicillin versus netilmicin and piperacillin." | 5.06 | A comparative study of intravenous ciprofloxacin and benzylpenicillin versus netilmicin and piperacillin for the empirical treatment of fever in neutropenic patients. ( Jenkins, GC; Kelsey, SM; Newland, AC; Shaw, E; Wood, ME, 1990) |
| "To assess the efficacy of ciprofloxacin in neutropenic patients, we conducted a randomized prospective trial comparing the combination of ciprofloxacin and netilmicin against piperacillin plus netilmicin as an empiric treatment of fever in cancer patients with neutropenia." | 5.06 | Randomized trial comparing ciprofloxacin plus netilmicin versus piperacillin plus netilmicin for empiric treatment of fever in neutropenic patients. ( Anderson, H; Chan, CC; Oppenheim, BA; Scarffe, JH; Swindell, R, 1989) |
| "Forty-eight patients with peripheral vascular disease (46 with diabetes mellitus) who presented to the hospital for treatment of lower extremity infections were randomized in a blinded fashion to receive oral ciprofloxacin at a dosage of either 750 mg or 1,000 mg twice daily." | 5.06 | Therapy of lower extremity infections with ciprofloxacin in patients with diabetes mellitus, peripheral vascular disease, or both. ( Canter, K; Clabots, C; Fasching, CE; Gerding, DN; Lissack, LM; Peterson, LR, 1989) |
| "The efficacy and safety of sequential intravenous/oral ciprofloxacin in moderate to severe respiratory tract infections (RTI) were compared with those of ceftazidime in a prospective clinical trial." | 5.06 | Sequential intravenous-oral administration of ciprofloxacin vs ceftazidime in serious bacterial respiratory tract infections. ( Basir, R; Khan, FA, 1989) |
| "This study developed further clinical experience in using a single agent ("monotherapy") as empirical treatment for neutropenic patients with fever, and compared the safety and toxicity of two candidate agents, ceftazidime and ciprofloxacin." | 5.06 | A prospective, randomized comparison of ceftazidime and ciprofloxacin as initial empiric therapy in neutropenic patients with fever. ( Bayston, KF; Cohen, J; Want, S, 1989) |
| "In a multicenter, randomized clinical trial, the efficacy of ciprofloxacin plus azlocillin was compared with that of a standard regimen of ceftazidime plus amikacin for the initial empiric treatment of fever in neutropenic cancer patients." | 5.06 | Multicenter, randomized trial of ciprofloxacin plus azlocillin versus ceftazidime plus amikacin for empiric treatment of febrile neutropenic patients. ( Arnow, P; Edlin, B; Flaherty, JP; George, D; O'Keefe, P; Waitley, D; Weinstein, RA, 1989) |
| "Urinary tract infections in 32 patients were treated with 250 mg of ciprofloxacin twice daily for seven to eight days." | 5.06 | Treatment of urinary tract infections with ciprofloxacin. ( Bonamini, A; Curotto, A; Giberti, C; Martorana, G; Oneto, F; Pizzorno, R; Soro, O, 1988) |
| "The efficacy of oral ciprofloxacin to prevent bacterial infections during the first three months after allogeneic bone marrow transplantation (BMT) was assessed prospectively." | 5.06 | Long-term oral ciprofloxacin for infection prophylaxis in allogeneic bone marrow transplantation. ( Branolte, J; de Pauw, B; de Witte, T; Muytjens, H; Novakova, I, 1987) |
| "Oral ciprofloxacin was used at doses ranging from 500 mg to 1500 mg twice daily for 15 to 476 (mean 139) days for treatment of acute or chronic osteomyelitis in 38 patients, and acute arthritis in two." | 5.06 | Therapy of acute and chronic gram-negative osteomyelitis with ciprofloxacin. Report from a Swedish Study Group. ( , 1988) |
| "80 adult outpatients suffering from otitis media, sinusitis (maxillaris or frontalis) or peritonsillitis were treated with 500 mg ciprofloxacin b." | 5.06 | Antibacterial treatment of otitis and sinusitis with ciprofloxacin and penicillin V--a comparison. ( Falser, N; Mittermayer, H; Weuta, H, 1988) |
| "Bacterial infections of the skin or soft tissue responded to ciprofloxacin 500 mg tablets b." | 5.06 | Bacterial infections of the skin treated with ciprofloxacin. ( Bielunska, S; Gawkonska, M; Gorkiewicz-Petkow, A; Jablonska, S; Petkow, L; Weuta, H, 1988) |
| "In a randomized prospective study, 66 patients with serious bacterial infections--mainly lower respiratory tract infections--were treated with either imipenem plus cilastatin (32 patients) or ciprofloxacin (34 patients); 30 patients in each group were evaluable for efficacy." | 5.06 | Prospective randomized controlled study of ciprofloxacin versus imipenem-cilastatin in severe clinical infections. ( Borner, K; Höffken, G; Lode, H; Wagner, J; Wiley, R, 1987) |
| "Ciprofloxacin, a new quinolone derivative, was given prophylactically (500 mg twice daily) to 15 patients with acute leukemia during remission induction treatment." | 5.06 | Ciprofloxacin for infection prevention in patients with acute leukemia. ( Dekker, AW; Rozenberg-Arska, M, 1987) |
| "Multi-resistant nosocomial urinary tract infections occurring in thirty patients with neurogenic bladder dysfunction were treated with ciprofloxacin 100 mg twice daily Early bacteriological eradication was obtained in 48." | 5.06 | Treatment of multi-resistant urinary tract infections in patients with multiple sclerosis. ( Baert, L; van Poppel, H, 1987) |
| "Thirty two patients with proven chronic bacterial prostatitis were treated with ciprofloxacin 500 mg twice daily orally for four weeks." | 5.06 | Treatment of chronic bacterial prostatitis with ciprofloxacin. ( de Leur, EJ; Ferwerda, WH; Hoogkamp-Korstanje, JA; Langemeyer, TN; Schipper, JJ; van der Wal, T; van Oort, H, 1987) |
| "8 years) with chronic postsurgical osteomyelitis were treated with ciprofloxacin." | 5.06 | Treatment of chronic postsurgical osteomyelitis with ciprofloxacin. ( Hoogkamp-Korstanje, JA, 1987) |
| "Fifty-six patients receiving remission induction treatment for acute leukemia were studied in a randomized trial comparing ciprofloxacin with trimethoprim-sulfamethoxazole plus colistin for prevention of infections." | 5.06 | Infection prophylaxis in acute leukemia: a comparison of ciprofloxacin with trimethoprim-sulfamethoxazole and colistin. ( Dekker, AW; Rozenberg-Arska, M; Verhoef, J, 1987) |
| "Twenty adult patients with cystic fibrosis who were experiencing acute pulmonary exacerbations were enrolled in a randomized, controlled trial comparing oral ciprofloxacin with intravenous tobramycin plus azlocillin." | 5.06 | Ciprofloxacin versus tobramycin plus azlocillin in pulmonary exacerbations in adult patients with cystic fibrosis. ( Black, PG; Bosso, JA; Matsen, JM, 1987) |
| "Twenty patients with lower respiratory tract infections presumably caused by ciprofloxacin-susceptible bacteria were admitted to a non-comparative, prospective clinical study." | 5.06 | Efficacy and safety of oral ciprofloxacin in the treatment of respiratory tract infections associated with chronic hepatitis. ( Bianchi, W; Esposito, S; Gagliardi, R; Galante, D, 1987) |
| "Twenty adult patients with chronic contiguous osteomyelitis caused by aerobic gram-negative bacilli were enrolled in an open, prospective cooperative study to determine the effect of oral ciprofloxacin therapy in a dosage of 750 mg every 12 hours." | 5.06 | Oral ciprofloxacin therapy for chronic contiguous osteomyelitis caused by aerobic gram-negative bacilli. ( Craven, PC; Gilbert, DN; Marsh, PK; Preheim, LC; Tice, AD, 1987) |
| "The efficacy and toxicity of ciprofloxacin, an orally administered fluoroquinolone, were evaluated in 24 infections in 23 patients with osteomyelitis caused by aerobic gram-negative bacilli." | 5.06 | Clinical efficacy of ciprofloxacin therapy for gram-negative bacillary osteomyelitis. ( Boscia, J; Bush, LM; Hessen, MT; Ingerman, MJ; Kaufman, DH; Kaye, D; Korzeniowski, OM; Santoro, J; Topiel, M; Weiner, P, 1987) |
| "In a one-year follow-up study, short-term therapy with ciprofloxacin proved to be beneficial in the treatment of chronic bacterial prostatitis, particularly in cases of Escherichia coli prostatitis." | 5.06 | Treatment of chronic bacterial prostatitis with ciprofloxacin. Results of a one-year follow-up study. ( Dalhoff, A; Schiefer, HG; Weidner, W, 1987) |
| "In a prospective, randomized, double-blind trial, ciprofloxacin (250 mg orally, twice daily) was compared with cinoxacin (500 mg orally, twice daily) in 60 patients with urinary tract infections." | 5.06 | Ciprofloxacin versus cinoxacin in therapy of urinary tract infections. A randomized, double-blind trial. ( Alpert, ML; Citron, DM; Ginsberg, BP; Goldstein, EJ; Greenway, FL; Kahn, RM, 1987) |
| "Ciprofloxacin treatment of urinary tract infections in 23 patients (16 with and seven without urorenal abnormalities) was compared with beta-lactam antibiotic therapy given orally to 10 comparable patients." | 5.06 | Comparison of ciprofloxacin and beta-lactam antibiotics in the treatment of urinary tract infections and alteration of fecal flora. ( Daikos, GL; Jackson, GG; Kathpalia, SB; Lolans, VT; Sharifi, R, 1987) |
| "The effectiveness and safety of ciprofloxacin, a new quinolone antibiotic, were prospectively evaluated in the treatment of patients with complicated urinary tract infections caused by gram-negative organisms resistant to trimethoprim/sulfamethoxazole." | 5.06 | Oral ciprofloxacin in the treatment of elderly patients with complicated urinary tract infections due to trimethoprim/sulfamethoxazole-resistant bacteria. ( Bittner, MJ; Cuevas, TA; Mellencamp, MA; Preheim, LC; Roccaforte, JS, 1987) |
| "2 years), with urinary tract infections caused by Pseudomonas species or other organisms resistant to trimethoprim-sulfamethoxazole were treated with 500 mg of orally administered ciprofloxacin every 12 hours." | 5.06 | Oral ciprofloxacin in resistant urinary tract infections. ( Andriole, VT; Berenson, CS; Greco, TP; Mangi, RJ; Ryan, JL; Sims, M; Thornton, GF, 1987) |
| "In a double-blind, randomized trial, 85 adult patients with acute diarrhea (more than three watery stools per day) received either 500 mg of ciprofloxacin twice daily or placebo for five days." | 5.06 | Clinical efficacy of ciprofloxacin compared with placebo in bacterial diarrhea. ( Diridl, G; Pichler, HE; Stickler, K; Wolf, D, 1987) |
| " In an ongoing study, 11 patients with nosocomial lower respiratory tract infections were given 200 mg of intravenous ciprofloxacin every 12 hours." | 5.06 | Dual individualization of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. ( Cumbo, TJ; Fracasso, JE; Nix, DE; Peloquin, CA; Sands, MF; Schentag, JJ; Vance, JW; Vari, AJ, 1987) |
| " Bleeding is the most common complication observed after prostate biopsy, but the use of aspirin or nonsteroidal anti-inflammatory drugs is not an absolute contraindication to prostate biopsy." | 4.89 | Complications of prostate biopsy. ( Anastasiadis, A; Antoniewicz, A; Cordeiro, E; De Reijke, T; Dimitriadis, G; Zapała, L, 2013) |
| " For primary prophylaxis, short-term antibiotic treatment (oral norfloxacin or ciprofloxacin) is indicated in cirrhotic patients (with or without ascites) admitted with gastrointestinal haemorrhage (variceal or non-variceal)." | 4.84 | [Bacterial infections in liver cirrhosis]. ( Farkas, A; Papp, M; Tornai, I; Udvardy, M, 2007) |
| " Indexing terms included peritoneal dialysis, pharmacokinetics, peritonitis, vancomycin, and fluoroquinolones." | 4.78 | Continuous ambulatory peritoneal dialysis: a review of its mechanics, advantages, complications, and areas of controversy. ( Bailie, GR; Eisele, G, 1992) |
| "The clinical and bacteriological efficacy and safety of ciprofloxacin given as oral doses of 500 to 1,500 mg (normally 750 mg) twice daily for treatment of Gram-negative bacillary osteomyelitis are reviewed." | 4.77 | Ciprofloxacin in the treatment of acute and chronic osteomyelitis: a review. ( Norrby, SR, 1989) |
| " In cystic fibrosis-associated acute exacerbations of chronic pseudomonal pneumonitis, the outcome of oral ciprofloxacin therapy was very satisfactory in the six major studies reported (approximately 85% improvement rates)." | 4.77 | Clinical utility of new quinolones in treatment of osteomyelitis and lower respiratory tract infections. ( Bayer, AS, 1989) |
| "This study developed, optimized, characterized, and evaluated bioadhesive, hot-melt extruded (HME), extended-release ocular inserts containing ciprofloxacin hydrochloride (CIP-HCL) to improve the therapeutic outcomes of ocular bacterial infections." | 4.31 | Formulation development and in Vitro-Ex vivo characterization of hot-melt extruded ciprofloxacin hydrochloride inserts for ocular applications: Part I. ( Adel Ali Youssef, A; Alzahrani, A; Bandari, S; Majumdar, S; Repka, MA; Senapati, S; Tripathi, S, 2023) |
| " The study aimed to investigate the in vitro antibacterial activity of the antidepressants fluoxetine and paroxetine alone and in combination with the antibacterial ciprofloxacin against standard strains and clinical isolates to explore the repositioning of these drugs in severe bacterial infections." | 4.02 | Repositioning of antidepressant drugs and synergistic effect with ciprofloxacin against multidrug-resistant bacteria. ( Bottega, A; da Rosa, TF; de Paula, BR; Foletto, VS; Franco, LN; Hörner, R; Serafin, MB, 2021) |
| "To evaluate the impact of cessation of ciprofloxacin prophylaxis during stem cell transplantation for multiple myeloma." | 3.91 | Ciprofloxacin prophylaxis during autologous stem cell transplantation for multiple myeloma in patients with a high rate of fluoroquinolone-resistant gram-negative bacteria colonization. ( Gabalec, F; Paterova, P; Radocha, J; Zak, P; Zavrelova, A, 2019) |
| "The objective of the current retrospective study was to compare differences in rate of breakthrough infections for ciprofloxacin vs levofloxacin prophylaxis in autologous hematopoietic stem-cell transplant (HSCT) patients treated for multiple myeloma." | 3.88 | Ciprofloxacin vs levofloxacin for prophylaxis during hematopoietic stem-cell transplantation. ( Copeland, V; McLaughlin, M; Trifilio, S, 2018) |
| "The addition of doxycycline to standard prophylaxis with ciprofloxacin seems to reduce the number of NF episodes and documented bacterial infections in patients with MM undergoing ASCT, without increasing rate of serious complications." | 3.88 | Addition of doxycycline to ciprofloxacin for infection prophylaxis during autologous stem cell transplants for multiple myeloma. ( Davidson, J; Drabick, JJ; Hale, CM; Sivik, JM; Talamo, G, 2018) |
| "Ciprofloxacin generic tablets approved for human use frequently are administered to dogs for treatment of bacterial infections because they are inexpensive and readily available." | 3.85 | Ciprofloxacin Pharmacokinetics in Clinical Canine Patients. ( Papich, MG, 2017) |
| "The aim of the study was to describe the incidence and type of bacterial infections associated with the use of ciprofloxacin prophylaxis as single agent in pediatric patients with acute myeloid leukemia (AML)." | 3.85 | Bacterial Infections in Children With Acute Myeloid Leukemia Receiving Ciprofloxacin Prophylaxis. ( Al Omar, S; Al Qasem, W; Anabtawi, N; Rihani, R, 2017) |
| "The objectives of this study were to investigate risk factors and the incidence of ciprofloxacin resistance and extended-spectrum beta-lactamases (ESBL) in patients with acute bacterial prostatitis (ABP)." | 3.83 | Risk Factor Analysis of Ciprofloxacin-Resistant and Extended Spectrum Beta-Lactamases Pathogen-Induced Acute Bacterial Prostatitis in Korea. ( Lee, DG; Lee, SH; Lee, Y; Yoo, KH, 2016) |
| "The study included 50 patients with chronic prostatitis who showed hot uptake in seminal vesicles on Tc-99m ciprofloxacin imaging and eight patients who did not show hot uptake." | 3.81 | Chronic bacterial seminal vesiculitis as a potential disease entity in men with chronic prostatitis. ( Choe, WS; Choo, GY; Chung, YG; Hyun, IY; Kim, CH; Park, SH; Ryu, DS; Ryu, JK; Seong, DH; Suh, JK, 2015) |
| "The objective of this study was to determine if specific species of microorganisms are associated with severe infection and amputation in patients with a diabetic foot infection and to evaluate the effectiveness of clindamycin and ciprofloxacin in this population." | 3.80 | Are clindamycin and ciprofloxacin appropriate for the empirical treatment of diabetic foot infections? ( de Vries, MG; Ekkelenkamp, MB; Peters, EJ, 2014) |
| "Ciprofloxacin is considered to be a safe and effective treatment for acute infectious colitis." | 3.80 | Acute pancreatitis secondary to ciprofloxacin therapy in patients with infectious colitis. ( Cheung, DY; Cho, HJ; Cho, SH; Kim, JI; Kim, JK; Kim, SS; Lee, HJ; Sung, HY, 2014) |
| "We present the case of a 90-year-old woman with psoriasis vulgaris who had been treated with methotrexate for many years." | 3.79 | Methotrexate toxicity induced by ciprofloxacin leading to psoriatic plaque ulceration: a case report. ( Berger, TG; Fazel, N; Kamangar, F; Koo, JY, 2013) |
| "Ciprofloxacin was administered in a unit dose of either 200 mg (68 percent of the patients) or 300 mg (28 percent) by intravenous infusion, generally over 30 minutes every 12 hours, at a mean daily dosage of 456 mg." | 3.76 | Safety of intravenous ciprofloxacin. A review. ( Arcieri, GM; Becker, N; Esposito, B; Griffith, E; Heyd, A; Neumann, C; O'Brien, B; Schacht, P, 1989) |
| "Ciprofloxacin treatment was discontinued due to side effects in 146 patients (1." | 3.76 | Safety of oral ciprofloxacin. An update based on clinical trial results. ( Arcieri, G; Hullmann, R; Schacht, P, 1989) |
| " When given orally, ciprofloxacin exhibited 70% bioavailability and attained peak serum levels ranging between 1." | 3.76 | Ciprofloxacin: chemistry, mechanism of action, resistance, antimicrobial spectrum, pharmacokinetics, clinical trials, and adverse reactions. ( LeBel, M, 1988) |
| "Ciprofloxacin is a highly effective drug and a breakthrough in several areas of medical interest." | 3.76 | Worldwide clinical data on efficacy and safety of ciprofloxacin. ( Arcieri, G; Branolte, J; Bruck, H; Chyský, V; Griffith, E; Gruenwaldt, G; Hullmann, R; Konopka, CA; O'Brien, B; Schacht, P, 1988) |
| "99mTc-ciprofloxacin is a radiopharmaceutical preparation sintetized to improve diagnostic accuracy of bacterial infections in human tissues." | 3.75 | Estimation of 99mTc-ciprofloxacin accumulation indexes in bone and joint bacterial infections. ( Dugonjić, S; Janković, Z; Popović, Z; Pucar, D, 2009) |
| "The objective of this investigation was to assess retrospectively the safety and the efficacy of oral ciprofloxacin plus cefuroxime axetil compared to the combination of oral ciprofloxacin plus amoxicillin/clavulanate, as initial outpatient treatment, in low-risk cancer patients with fever and neutropenia." | 3.74 | Comparison of two oral regimens for the outpatient treatment of low-risk cancer patients with chemotherapy-induced neutropenia and fever: ciprofloxacin plus cefuroxime axetil versus ciprofloxacin plus amoxicillin/clavulanate. ( Karabelis, A; Kordossis, T; Kosmas, C; Sipsas, NV; Skopelitis, E; Tsavaris, N; Vadiaka, M; Ziakas, PD, 2007) |
| "The aim of this study was to compare the effectiveness of ciprofloxacin and meropenem initiated early versus later in the course of acute necrotizing pancreatitis (ANP) in rats." | 3.72 | Is late antibiotic prophylaxis effective in the prevention of secondary pancreatic infection? ( Altinatmaz, K; Ateskan, U; Baysan, A; Cinar, E; Comert, B; Mas, MR; Mas, N; Ozkomur, E; Ozyurt, M; Yasar, M; Yener, N, 2003) |
| "Twice daily ciprofloxacin @ 500 mg for 28 days proved to be the most cost effective treatment for chronic bacterial prostatitis." | 3.71 | Cost effectiveness model comparing trimethoprim sulfamethoxazole and ciprofloxacin for the treatment of chronic bacterial prostatitis. ( Kaplan, S; Kurzer, E, 2002) |
| " 99mTc-labeled ciprofloxacin does not distinguish between infections and sterile inflammatory lesions, which implies that its specificity for the detection of bacterial infections is not warranted." | 3.71 | 99mTc-labeled antimicrobial peptides for detection of bacterial and Candida albicans infections. ( Balter, HS; Lanzzeri, S; Lupetti, A; Nibbering, PH; Paulusma-Annema, A; Pauwels, EK; Rey, AM; Savio, EO; Souto, B; Welling, MM, 2001) |
| "Retrospective evaluation of Tc-99m ciprofloxacin (infection) scintigraphy consecutively performed in a series of patients clinically suspected for peripheral osteomyelitis (OM), spondylodiscitis (SD) and fever of unknown origin (FUO)." | 3.71 | [Tc-99m ciprofloxacin in clinically selected patients for peripheral osteomyelitis, spondylodiscitis and fever of unknown origin--preliminary results]. ( Gallowitsch, HJ; Gomez, I; Heinisch, M; Kresnik, E; Kumnig, G; Lind, P; Mikosch, P, 2002) |
| " We evaluated retrospectively the effect of antibiotic prophylaxis with ciprofloxacin and penicillin on the prevention of bacterial infections in 112 cases of prolonged neutropenia in adult patients treated for haematological malignancies." | 3.70 | [Evaluation of antibiotic prophylaxis in neutropenic patients with hematologic malignancies]. ( Baumgartner, JD; Cometta, A; Delarive, P; Glauser, MP, 2000) |
| "We have compared the in vitro activity of commonly used aminoglycosides--Gentamicin and Amikacin with Ciprofloxacin to determine whether the latter has any role in the empiric treatment of serious bacterial infections." | 3.69 | Choice of antibiotics for empiric treatment of serious infections. ( Bhujwala, RA; Gupta, BL; Rattan, A; Singh, S, 1994) |
| "To assess the value of prophylactic ciprofloxacin in reducing the incidence of neutropenic fever in men receiving intensive chemotherapy for germ cell tumours, we reviewed the case notes of 88 consecutive patients treated between January 1986 and December 1992." | 3.69 | Chemotherapy for germ cell tumours: prophylactic ciprofloxacin reduces the incidence of neutropenic fever. ( Counsell, R; Pratt, J; Williams, MV, 1994) |
| "Fifty consecutive episodes of neutropenia were studied in patients with AML who received prophylaxis with ciprofloxacin and these were compared with a historic control group of another 50 consecutive episodes of neutropenia in AML patients who did not receive antibiotic prophylaxis." | 3.69 | [Prophylaxis with ciprofloxacin in postchemotherapy neutropenia in acute myeloid leukemia]. ( Bueno, J; Juliá, A; López, A; Novo, A; Soler, JA, 1994) |
| "We present the results of a protocol of empiric monotherapy of continuous ambulatory peritoneal dialysis (CAPD)-related peritonitis with ciprofloxacin (CPX), with a special emphasis on the evolution of our results after seven years of continued use of this drug." | 3.69 | Treatment of CAPD-related peritonitis with ciprofloxacin: results after seven years. ( Bouza, P; García Falcón, T; López Vázquez, M; Pérez Fontán, M; Rodríguez-Carmona, A; Tresancos, C; Valdés, F, 1996) |
| "The aim of the study was to distinguish infection from inflammation in patients with suspected infection using technetium-99m Infecton." | 3.69 | Clinical evaluation of technetium-99m infecton for the localisation of bacterial infection. ( Bomanji, J; Britton, KE; Das, S; Hall, AV; Siraj, QH; Solanki, K; Vinjamuri, S, 1997) |
| "The objective of this study was to determine the efficacy and safety of the combination ciprofloxacin plus amoxicillin/clavulanic acid as an empirical treatment of infection in hematologic patients without severe neutropenia." | 3.69 | Sequential intravenous-oral ciprofloxacin plus amoxycillin/clavulanic acid shortens hospital stay in infected non severe neutropenic patients. ( Caballero, MD; Cañizo, MC; Colino, CI; Galende, J; García-Sanz, R; Gil-Hurlé, A; Hernández, JM; San Miguel, JF; Vallejo, C; Vázquez, L, 1997) |
| "As urinary tract infections in immunosuppressed renal transplant patients present a major therapeutic problem for clinicians in charge of renal units, the efficacy of the antibiotic ciprofloxacin in such cases was tested in this study." | 3.68 | Treatment of urinary tract infections with ciprofloxacin after renal transplantation. ( Alivanis, P; Dioudis, C; Grekas, D; Thanos, V; Tourkantonis, A, 1993) |
| "Seventeen adult patients with chronic osteomyelitis were treated with oral ciprofloxacin, 750 mg twice daily." | 3.68 | Oral ciprofloxacin for treatment of chronic osteomyelitis. ( Bortoletto, ML; Brasil Filho, R; Carvalho, MC; Levi, GC; Lobo, IM; Mendonça, JS; Silva, ML; Trevisanello, C; Yamaguti, A, 1993) |
| "In a retrospective study, the clinical and microbiological efficacy of amoxycillin-clavulanic acid and ciprofloxacin were evaluated in outpatients observed within the previous year who were affected by acute purulent exacerbations of chronic bronchitis." | 3.68 | Comparative clinical and microbiological study of amoxycillin-clavulanic acid and ciprofloxacin in acute purulent exacerbations of chronic bronchitis. ( Beghi, G; Caratozzolo, O; Legnani, D; Lombardo, VM; Negretto, GG, 1992) |
| "At the Eastern Section Meeting of the Triological Society January 26, 1990, Levinson et al reported outstanding success with ciprofloxacin in the treatment of malignant otitis externa." | 3.68 | The fluoroquinolones. ( Brody, T; Pensak, ML, 1991) |
| "We studied the entry of ciprofloxacin into the cerebrospinal fluid (CSF) in 37 patients with various types of meningitis (bacterial meningitis 10 patients, viral 12 patients, tuberculous 7 patients)." | 3.68 | Entry of ciprofloxacin into cerebrospinal fluid during bacterial, viral and tuberculous meningitis. ( Barsić, B; Beus, I; Himbele, J; Lisić, M; Marton, E; Schönwald, S, 1991) |
| " LJC10,627 showed stability to mouse dehydropeptidase I and was more effective in vivo than imipenem plus cilastatin against gram-negative bacterial infections and as effective against staphylococcal infections." | 3.68 | In vitro and in vivo activities of LJC10,627, a new carbapenem with stability to dehydropeptidase I. ( Jacobus, NV; Petersen, PJ; Testa, RT; Weiss, WJ, 1991) |
| "Twenty one adult patients, both males and females, with 32 bacterial infections of several localizations and moderate to severe prognosis were treated with ciprofloxacin (200 mg every 12 hours), initially intravenously and then with 500 mg every 12 hours orally during 25 +/- 11 days." | 3.67 | [Clinical experience with a new fluoroquinolone: ciprofloxacin]. ( Azanza, JR; Catalán, M; Honorato, J; Rubio, A; Suárez, J, 1989) |
| "From October 1983 to October 1986, 39 patients with chronic osteomyelitis (of at least two month's duration) were treated with either pefloxacin (n = 15), ofloxacin (n = 17), or ciprofloxacin (n = 7)." | 3.67 | Evaluation of pefloxacin, ofloxacin and ciprofloxacin in the treatment of thirty-nine cases of chronic osteomyelitis. ( Bernard, E; Dellamonica, P; Drugeon, HB; Etesse, H; Garraffo, R, 1989) |
| "42 patients with bacterial infections caused by resistant to other available in this country antibiotics, immunocompromised patients and patients in severe life-threatening conditions were treated with ciprofloxacin (Ciprobay--Bayer) in tablets." | 3.67 | [Ciprofloxacin in bacterial infections]. ( Belovezhdov, N; Monova, D, 1989) |
| "Twenty-five acutely ill patients, 21 men and 4 women aged 20-90 years (mean, 54 years) with acute community-acquired bacterial pneumonia, were treated with ciprofloxacin orally." | 3.67 | Use of oral ciprofloxacin in community-acquired pneumonia. ( Bassaris, HP; Chrysanthopoulos, CJ, 1989) |
| "Eighty hospital patients with acute purulent exacerbations of chronic bronchitis associated with Haemophilus influenzae, Streptococcus pneumoniae, Branhamella catarrhalis or Pseudomonas aeruginosa were treated with ciprofloxacin." | 3.67 | Ciprofloxacin in the treatment of acute exacerbations of chronic bronchitis. ( Baur, C; Davies, BI; Maesen, FP, 1986) |
| "Ciprofloxacin, a new quinolone derivative, was given prophylactically (500 mg twice a day) to 15 patients with acute leukemia during remission induction treatment for a mean duration of 42 days." | 3.67 | Ciprofloxacin for selective decontamination of the alimentary tract in patients with acute leukemia during remission induction treatment: the effect on fecal flora. ( Dekker, AW; Rozenberg-Arska, M; Verhoef, J, 1985) |
| "Ciprofloxacin in a low dosage of 250 mg twice a day was applied in the treatment of bacterial infections of the skin." | 3.67 | [The effectiveness of ciprofloxacin in bacterial skin infections]. ( Blenk, H; Meisel, C, 1988) |
| "The use of ciprofloxacin for the treatment of pulmonary infection in cystic fibrosis patients was investigated." | 3.67 | The use of ciprofloxacin in the treatment of patients with cystic fibrosis. ( Bakker, W; Mattie, H; van den Broek, PJ; van Gulpen, C, 1987) |
| "Twenty-four episodes of fever in neutropenic patients with haematological malignancy were treated with ciprofloxacin." | 3.67 | Preliminary evaluation of ciprofloxacin, a new 4-quinolone antibiotic, in the treatment of febrile neutropenic patients. ( Farrell, ID; Geddes, AM; Leyland, MJ; Smith, GM, 1986) |
| "Thirty four patients with acute purulent exacerbations of chronic bronchitis were treated with 500 mg ciprofloxacin twice daily, orally, for ten days." | 3.67 | Treatment of acute exacerbations of chronic bronchitis with ciprofloxacin. ( Hoogkamp-Korstanje, JA; Klein, SJ, 1987) |
| "Ciprofloxacin is active in vitro against most bacteria that cause peritonitis associated with peritoneal dialysis." | 3.67 | Effect of peritoneal dialysis fluid and pH on bactericidal activity of ciprofloxacin. ( Echols, RM; McCormick, EM, 1987) |
| "Thirty adult patients with severe skin and soft tissue infections (four with contiguous osteomyelitis) caused by a variety of bacterial pathogens were treated with oral ciprofloxacin." | 3.67 | Treatment of skin and soft tissue infections with oral ciprofloxacin. ( Fass, RJ, 1986) |
| "Twenty-one patients with cellulitis or other bacterial soft-tissue infections were treated with oral ciprofloxacin." | 3.67 | Ciprofloxacin for soft tissue infections. ( Logan, MN; Wood, MJ, 1986) |
| "Bacterial infections are common during induction therapy in children and adolescents with acute leukaemia and may cause infection-related mortality." | 3.01 | Comparative effectiveness and safety of antibiotic prophylaxis during induction chemotherapy in children with acute leukaemia: a systematic review and meta-analysis. ( Cheng, G; Diao, S; Jia, Z; Lu, X; Luo, J; Xin, L; Yang, M; Zeng, L; Zhang, L, 2023) |
| " There was no significant difference between CIP IV and MEM IV in terms of clinical efficacy, bacteriological efficacy, incidence of adverse drug reactions, duration of antimicrobial treatment, or relapse/reactivation." | 2.77 | Evaluation of the efficacy and safety of intravenous ciprofloxacin versus meropenem in the treatment of postoperative infection. ( Kato, K; Kobayashi, S; Kusachi, S; Mashita, K; Oda, S; Sumiyama, Y; Takahashi, Y; Takeyama, H, 2012) |
| " Daily assessments were made of all patients and all adverse events were recorded." | 2.73 | A prospective, controlled, randomized, non-blind, comparative study of the efficacy and safety of a once daily high dose of ceftriaxone plus ciprofloxacin versus thrice daily ceftazidime plus amikacin in empirical therapy for febrile neutropenic patients. ( Giannakakis, T; Hatzitolios, A; Kollaras, P; Kordosis, T; Metallidis, S; Nikolaidis, J; Nikolaidis, P; Seitanidis, B, 2008) |
| " The aim was to investigate the efficacy of long-term administration of ciprofloxacin to prevent SBP." | 2.73 | Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: a randomized, placebo-controlled study. ( Abecasis, R; Cartier, M; Dominguez, N; Fassio, E; Guevara, M; Landeira, C; Levi, D; Longo, C; Lucero, R; Miguez, C; Muñoz, A; Romero, G; Terg, R, 2008) |
| "Metronidazole was added to the ciprofloxacin-amoxicillin regimen where anaerobic infection was suspected." | 2.71 | Piperacillin-tazobactam versus ciprofloxacin plus amoxicillin in the treatment of infective episodes after liver transplantation. ( Burroughs, A; Fisher, N; Hastings, M; Kibbler, C; Mutimer, D; O'Grady, J; Patch, D; Philpott-Howard, J; Rolando, N; Wade, J; Wendon, J, 2003) |
| "The efficacy and safety of two oral dosing regimens of gatifloxacin were compared to ciprofloxacin in the treatment of complicated urinary tract infection in a randomised, double-blind multi-centre trial." | 2.71 | Gatifloxacin 200 mg or 400 mg once daily is as effective as ciprofloxacin 500 mg twice daily for the treatment of patients with acute pyelonephritis or complicated urinary tract infections. ( Ankel-Fuchs, D; Bartnicki, A; Bischoff, W; Hanus, M; Milutinovic, S; Naber, KG; Schönwald, S; van Belle, F; Weitz, P, 2004) |
| "The efficacy and safety of two oral dosing regimens of gatifloxacin compared with ciprofloxacin for the treatment of acute uncomplicated lower urinary tract infection was investigated in a double-blind, randomised study, in adult female patients who received either gatifloxacin (400 mg as a single shot or 3 days of 200 mg once daily) or ciprofloxacin (250 mg given twice daily for 3 days)." | 2.71 | Gatifloxacin 400 mg as a single shot or 200 mg once daily for 3 days is as effective as ciprofloxacin 250 mg twice daily for the treatment of patients with uncomplicated urinary tract infections. ( Allin, DM; Ankel-Fuchs, D; Clarysse, L; Haworth, DA; Hopkins, G; James, IG; Naber, KG; Raini, C; Schneider, H; Wall, A; Weitz, P, 2004) |
| "Only two Gram-negative bacterial infections occurred in the CIP + COL arm compared with 16 in the NEO + COL arm." | 2.70 | Oral ciprofloxacin plus colistin: prophylaxis against bacterial infection in neutropenic patients. A strategy for the prevention of emergence of antimicrobial resistance. ( Bhamra, A; Hann, IM; Kibbler, CC; Nazareth, B; Paterson, P; Prentice, HG, 2001) |
| " Patients were randomly divided into three groups of 30; the first group was dosed with pefloxacin 800 mg i." | 2.68 | Comparative activities of pefloxacin and ciprofloxacin in the treatment of chronic respiratory tract infections. ( Arcidiacono, MM; Cogo, R; Fraschini, F; Monzani, GP; Scaglione, F; Scamazzo, F, 1995) |
| "Ciprofloxacin appears to be an effective treatment of chronic otitis media, and superior to amoxycillin/clavulanic acid." | 2.67 | Controlled prospective study of oral ciprofloxacin versus amoxycillin/clavulanic acid in chronic suppurative otitis media in adults. ( Beauvillain, C; Berche, P; Bordure, P; Legent, F, 1994) |
| " Eight adverse effects were observed in five patients and treatment had to be discontinued in one case." | 2.67 | Study of the efficacy and safety of ciprofloxacin in the treatment of chronic otitis. ( Barrault, S; Dobler, S; Ebbo, D; Fombeur, JP; Koubbi, G; Laurier, JN; Lecomte, F; Sorrel, N, 1994) |
| "In a word, both drugs are effective in treating bacterial infections of digestive system, urinary system and respiratory tract." | 2.67 | [Clinical efficacy of ciprofloxacin and ofloxacin]. ( Jiang, SC; Miao, JZ; Wang, XF, 1994) |
| "Ciprofloxacin was therefore superior to the other two fluoroquinolones in preventing infections due to Gram-negative bacteria in this population of neutropenic patients." | 2.67 | Comparison of ciprofloxacin, ofloxacin and pefloxacin for the prevention of the bacterial infection in neutropenic patients with haematological malignancies. ( Accorsi, P; Betti, S; D'Antonio, D; Dell'Isola, M; Favalli, C; Fioritoni, G; Iacone, A; Parruti, G; Piccolomini, R; Quaglietta, AM, 1994) |
| " The patients were treated with Bay-o-9867 (ciprofloxacin) administered orally at a daily dosage of 500 mg (250 q 12 h) in 30 patients and of 1000 mg (500 q 12 h) in 10 patients, depending on the severity of infection." | 2.67 | [The efficacy and tolerance of Bay-o-9867 (ciprofloxacin) in the treatment of infections of the urinary tract and of the lower respiratory tract]. ( Bolognesi, S; Quartieri, F; Sconosciuto, F, 1994) |
| "Ciprofloxacin was compared to ciprofloxacin plus amoxicillin as antibacterial prophylaxis in 53 evaluable patients with neutropenic episodes, because an oral penicillin may help to decrease the incidence of gram-positive infections." | 2.67 | Chemoprophylaxis of bacterial infections in granulocytopenic patients with ciprofloxacin vs ciprofloxacin plus amoxicillin. ( Bosi, A; Ciolli, S; Donnini, E; Fanci, R; Guidi, S; Leoni, F; Longo, G; Rossi Ferrini, P, 1993) |
| " The pharmacokinetic data were fitted by iterative two-stage analysis, assuming a linear two-compartment model." | 2.67 | Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. ( Ballow, CH; Birmingham, MC; Forrest, A; Goss, TF; Nix, DE; Schentag, JJ, 1993) |
| "Ciprofloxacin was associated with an average cost savings of $293 per patient." | 2.67 | Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics. ( Backes, JM; Cumbo, TJ; Gelber, JA; Paladino, JA; Schentag, JJ; Serrianne, DJ; Sperry, HE, 1991) |
| " The bioavailability of ciprofloxacin appeared comparable to that found in previously published studies of normal volunteers and patients not receiving chemotherapy." | 2.67 | Prophylaxis of bacterial infections with ciprofloxacin in patients undergoing bone marrow transplantation. ( Antman, KH; Finberg, R; Kalish, L; Kehoe, K; Lew, MA; Mayer, R; Nadler, L; Ritz, J; Takvorian, T, 1991) |
| "Ciprofloxacin was given as an initial 100 mg twice daily as intravenous infusion, and this was switched to an oral form of 500 mg b." | 2.67 | Ciprofloxacin in severe infections. ( Aswapokee, N; Aswapokee, P; Pruksachatvuthi, S, 1990) |
| "Ciprofloxacin was associated with a low incidence of adverse events with skin rash (five cases) and nausea (one case) being reported as possibly or probably related to ciprofloxacin." | 2.67 | High dose intravenous ciprofloxacin in febrile neutropenic patients. ( Johnson, PR; Tooth, JA; Yin, JA, 1990) |
| "There were five superinfections, all in the gentamicin/azlocillin group." | 2.67 | Randomized multicentre study of ciprofloxacin and azlocillin versus gentamicin and azlocillin in the treatment of febrile neutropenic patients. ( Barker, KF; Kaczmarski, RS; Mufti, GJ; Philpott-Howard, JN; Smedley, JC; Wade, JJ, 1990) |
| "Ciprofloxacin was clinically more effective than the standard therapy in reducing the size of the ulcer (p less than 0." | 2.66 | A comparative study of ciprofloxacin and conventional therapy in the treatment of patients with chronic lower leg ulcers infected with Pseudomonas aeruginosa or other gram-negative rods. ( Kariniemi, AL; Karppinen, L; Valtonen, V, 1989) |
| " Adverse events considered possibly or probably related to the study drugs were reported in 16 of 43 patients (37." | 2.66 | Comparison of the safety and efficacy of intravenous ciprofloxacin and intravenous ceftazidime in the treatment of selected infections. ( Brennan, RO; Drew, RH; Gallis, HA; Goodwin, SD; Rumbaugh, MM; Swinney, V, 1989) |
| "For ciprofloxacin/ceftazidime treatments, respectively, the evaluated infections were: pyelonephritis (16 patients/nine patients), pneumonia (three/five), soft-tissue infections (four/zero), spontaneous peritonitis (five/two), primary bacteremia (three/eight), and other (two/two)." | 2.66 | Intravenous ciprofloxacin and ceftazidime in serious infections. A prospective, controlled clinical trial with third-party blinding. ( Amieva, RI; Macías, A; Ramos, A; Ruiz-Palacios, GM; Sifuentes-Osornio, J, 1989) |
| "Ciprofloxacin treatment was successful in all nine patients with chlamydial or gonococcal PID and in six of seven with nonchlamydial nongonococcal PID." | 2.66 | A comparison of ciprofloxacin with doxycycline plus metronidazole in the treatment of acute pelvic inflammatory disease. ( Aine, R; Grönroos, P; Heinonen, PK; Miettinen, A; Punnonen, R; Teisala, K, 1989) |
| "Ciprofloxacin was given orally at different dose regimens: 500 mg b." | 2.66 | Efficacy and safety of ciprofloxacin in the treatment of UTIs and RTIs in patients affected by liver diseases. ( Barba, D; Bianchi, W; Esposito, S; Gagliardi, R; Galante, D; Giusti, R, 1988) |
| "Ciprofloxacin has proved to be superior to cefalexin in the treatment of lower UTI." | 2.66 | Bacterial infections of the lower urinary tract treated with ciprofloxacin or cefalexin--a comparative study. ( Jórasz, J; Ktos, K; Polubiec, A; Stepka, K; Strazynska, R; Weuta, H, 1988) |
| "Ciprofloxacin was well tolerated, with the most frequent adverse reactions being rash, gastrointestinal intolerance, and increased levels of liver enzymes, each of which occurred in five patients." | 2.66 | Oral ciprofloxacin in the treatment of serious soft tissue and bone infections. Efficacy, safety, and pharmacokinetics. ( Cumbo, TJ; DeVito, JM; Kuritzky, P; Nix, DE; Schentag, JJ, 1987) |
| "Ciprofloxacin was as effective as ampicillin and produced a 98 percent clinical cure rate." | 2.66 | Controlled, comparative study of ciprofloxacin versus ampicillin in treatment of bacterial respiratory tract infections. ( Afzal, Q; Guarneri, JJ; Khan, FA; LaBombardi, V; Raoof, S; Wollschlager, CM, 1987) |
| "Fifty-two patients with serious respiratory infections were treated with orally administered ciprofloxacin; 42 patients were evaluable for the efficacy analysis and all were evaluable for determining adverse reactions." | 2.66 | Efficacy and safety of oral ciprofloxacin in the treatment of serious respiratory infections. ( Fass, RJ, 1987) |
| "Ciprofloxacin displays excellent in vitro activity against gram-negative bacilli and offers the potential for outpatient therapy." | 2.66 | Oral ciprofloxacin therapy for gram-negative bacillary osteomyelitis. ( Francis, JB; Freer, C; Lesse, AJ; Salata, RA; Scheld, WM, 1987) |
| " The drug dosage was 300 mg every 12 hours in 19 patients and 200 mg intravenously every 12 hours in nine patients." | 2.66 | Treatment of serious infections with intravenous ciprofloxacin. ( Neu, HC; Scully, BE, 1987) |
| " In general, the patients received ciprofloxacin at a dosage of 250 to 750 mg every 12 hours; the median dose was 500 mg twice daily." | 2.66 | Ciprofloxacin: an update on clinical experience. ( Arcieri, G; August, R; Becker, N; Griffith, E; Gruenwaldt, G; Heyd, A; O'Brien, B, 1987) |
| "Ciprofloxacin was as effective as amoxycillin with a successful outcome in 81% and 82% of cases respectively." | 2.66 | Efficacy and safety of ciprofloxacin in patients with respiratory infections in comparison with amoxycillin. ( Ferguson, WP; Gleadhill, IC; Lowry, RC, 1986) |
| "Hospital-acquired and community-acquired bacterial infections have already put a heavy burden on the global health system." | 2.61 | Comprehensive review on the anti-bacterial activity of 1,2,3-triazole hybrids. ( Zhang, B, 2019) |
| "Diagnosis of deep-seated bacterial infection remains a serious medical challenge." | 2.58 | Ciprofloxacin: from infection therapy to molecular imaging. ( Imran, M; Iqbal, A; Naqvi, SAR; Roohi, S; Sherazi, TA; Zahoor, AF, 2018) |
| "Ciprofloxacin has become the most prescribed drug within this class and remains as one of the top three antibacterial agents prescribed in Ethiopia." | 2.58 | Resistance profile of clinically relevant bacterial isolates against fluoroquinolone in Ethiopia: a systematic review and meta-analysis. ( Ataro, Z; Marami, D; Mitiku, H; Motbaynor, B; Sisay, M; Teklemariam, Z; Tesfa, T; Weldegebreal, F, 2018) |
| "Bacterial infections are common in cirrhotic patients with acute variceal bleeding, occurring in 20% within 48 h." | 2.50 | Role of prophylactic antibiotics in cirrhotic patients with variceal bleeding. ( Lee, YY; Mahadeva, S; Tee, HP, 2014) |
| "Ciprofloxacin was administrated in neonates as a salvage therapy for sepsis due to multidrug-resistant strains or with signs of clinical deterioration under first-line antibiotic treatment." | 2.47 | Ciprofloxacin use in neonates: a systematic review of the literature. ( Choonara, I; Jacqz-Aigrain, E; Kaguelidou, F; Turner, MA, 2011) |
| "Thus, up to date management of cancer patients, in addition to other supportive care modalities, should also incorporate diagnostic methods and therapy of infections." | 2.47 | [Treatment and prevention of infections in cancer patients with neutropenia]. ( Sinkó, J, 2011) |
| " The use of antibiotics with favourable pharmacokinetic/pharmacodynamic profiles and convenient dosing schedules, which effectively increase bacterial eradication and patient compliance, can help to curb the current epidemic of resistance and reduce the rate of clinical failure associated with resistance." | 2.42 | Extended-release ciprofloxacin (Cipro XR) for treatment of urinary tract infections. ( Elkharrat, D; Naber, KG; Palou, J; Talan, DA, 2004) |
| "Infectious diarrhea is a significant cause of morbidity and mortality and a common complaint in clinical practice." | 2.41 | The role of antibiotics in the treatment of infectious diarrhea. ( Oldfield, EC; Wallace, MR, 2001) |
| "Moxifloxacin was as effective as amoxicillin 1 g 3 times daily and clarithromycin 500 mg twice daily in CAP and as effective as clarithromycin in AECB." | 2.40 | Moxifloxacin. ( Balfour, JA; Wiseman, LR, 1999) |
| "Ciprofloxacin is an effective treatment for those infections most common in elderly patients, including infections of the urinary tract, lower respiratory tract, skin and soft-tissues, and bone and joints, and is an effective agent for prophylaxis in transurethral surgery." | 2.39 | Ciprofloxacin. A review of its pharmacological profile and therapeutic use in the elderly. ( Balfour, JA; Wiseman, LR, 1994) |
| "Ciprofloxacin has better activity against gram-negative bacilli, an advantage which may be negated by ofloxacin's longer half-life and higher serum levels." | 2.38 | Ofloxacin vs ciprofloxacin: a comparison. ( Nicolau, D; Nightingale, CH; Quintiliani, R, 1992) |
| "Ciprofloxacin is a potent fluoroquinolone antibiotic with in vitro activity against many significant gram-positive and gram-negative ocular pathogens." | 2.38 | Insights from experimental data on ciprofloxacin in the treatment of bacterial keratitis and ocular infections. ( Cokingtin, CD; Hyndiuk, RA, 1991) |
| "Ciprofloxacin is an essential enrichment of the antibacterial therapy." | 2.38 | [Effective microbiologic spectrum of gyrase inhibitors--indications and contraindications]. ( Tauchnitz, C, 1990) |
| "Ciprofloxacin is a new 4-quinolone antibacterial agent with an extended antibacterial spectrum, enhanced potency and the ability to produce therapeutic serum, tissue and urine concentrations after oral administration." | 2.37 | Overview of clinical experience with ciprofloxacin. ( Ball, AP, 1986) |
| "Ciprofloxacin is a new quinolone derivative which is particularly well adapted for the treatment of bacterial urinary tract infection." | 2.37 | Ciprofloxacin in management of urinary tract infection. ( Rubin, RH; Tolkoff-Rubin, NE, 1988) |
| "Ciprofloxacin has been most extensively studied following oral administration." | 2.37 | Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. ( Benfield, P; Campoli-Richards, DM; Monk, JP; Price, A; Todd, PA; Ward, A, 1988) |
| " They are well absorbed after oral administration, and some achieve serum and tissue levels well exceeding the minimal inhibitory concentrations for susceptible bacteria." | 2.37 | Symposium on antimicrobial agents. The quinolones. ( Walker, RC; Wright, AJ, 1987) |
| "Ciprofloxacin has been extensively investigated in various animal models of infection." | 2.37 | Animal models: the in-vivo evaluation of ciprofloxacin. ( Peterson, LR, 1986) |
| " It is difficult to generalize their clinical usefulness, since these agents exhibit different pharmacokinetic profiles, antimicrobial activity (with varied minimum inhibitory concentrations among similar organisms), and dosage regimens." | 2.37 | Review of the 4-quinolones. ( Eggleston, M; Park, SY, 1987) |
| "The incidence and of bacterial infections, and resulting mortality, among cancer patients is growing dramatically, worldwide." | 1.72 | Dual acting acid-cleavable self-assembling prodrug from hyaluronic acid and ciprofloxacin: A potential system for simultaneously targeting bacterial infections and cancer. ( Devnarain, N; Gafar, MA; Govender, T; Ibrahim, UH; Khan, R; Mocktar, C; Mohammed, M; Oh, JK; Omolo, CA; Pant, A; Salih, M; Shunmugam, L, 2022) |
| "Our report demonstrates an increase in bacterial infection burden in sites other than blood stream and subsequent increase in prevalence of antimicrobial resistance for all major isolates." | 1.62 | Prevalence, distribution and antimicrobial susceptibility pattern of bacterial isolates from a tertiary Hospital in Malawi. ( Adukwu, EC; Chisale, MRO; Kamudumuli, PS; Kumwenda, P; Ngwira, M; Tabe, ES; Ujor, VC; Wu, JTS, 2021) |
| "The objective of the present study was to develop a dosing algorithm for ciprofloxacin based on both renal function and pathogen susceptibility in critically ill patients." | 1.56 | Higher Dosage of Ciprofloxacin Necessary in Critically Ill Patients: A New Dosing Algorithm Based on Renal Function and Pathogen Susceptibility. ( Brüggemann, RJM; Burger, DM; de Lange, DW; Frenzel, T; Gieling, EM; Kolwijck, E; Pickkers, P; Schouten, JA; Ten Oever, J; Ter Heine, R; Wallenburg, E, 2020) |
| "Ciprofloxacin is a commonly prescribed antibiotic for treatment of pulmonary infections." | 1.51 | Optimization of a dry powder inhaler of ciprofloxacin-loaded polymeric nanomicelles by spray drying process. ( Farhangi, M; Kobarfard, F; Mahboubi, A; Mortazavi, SA; Vatanara, A, 2019) |
| "Diabetic foot ulcers are susceptible to infection and nonmedicated dressings are ineffective because they have no antimicrobial activity." | 1.48 | Calcium alginate-based antimicrobial film dressings for potential healing of infected foot ulcers. ( Ahmed, A; Boateng, J, 2018) |
| "The inherent bioinertness and potential bacterial infection risk are the two leading causes for Ti implant failure." | 1.48 | Preparing and immobilizing antimicrobial osteogenic growth peptide on titanium substrate surface. ( Cai, K; He, Y; Liu, J; Shen, T; Shen, X; Tao, B; Yang, W, 2018) |
| "Osteomyelitis is a major problem worldwide and is devastating due to the potential for limb-threatening sequelae and mortality." | 1.46 | Design, Synthesis, and Antimicrobial Evaluation of a Novel Bone-Targeting Bisphosphonate-Ciprofloxacin Conjugate for the Treatment of Osteomyelitis Biofilms. ( Bakhshalian, N; Bartoszewicz, M; Ebetino, FH; Junka, AF; Lundy, MW; Mahabady, S; McKenna, CE; Neighbors, JD; Oleksy, M; Richard, E; Russell, RG; Sadrerafi, K; Sedghizadeh, PP; Sun, S; Szymczyk, P; Tjokro, N, 2017) |
| "To investigate whether there is benefit with a longer acting oral fluoroquinolone, we compared the rate of infection after transrectal ultrasound-guided prostate biopsy between 2 prophylactic antibiotic regimens: ciprofloxacin vs levofloxacin, each combined with an aminoglycoside (AG)." | 1.42 | For Single Dosing, Levofloxacin Is Superior to Ciprofloxacin When Combined With an Aminoglycoside in Preventing Severe Infections After Prostate Biopsy. ( El-Shafei, A; Goldman, HB; Jones, JS; Kartha, G; Klein, EA; Unnikrishnan, R, 2015) |
| "Intensive chemotherapy for pediatric acute myeloid leukemia incurs the risk of infectious complications, but the benefits of antibiotic prophylaxis remain unclear." | 1.40 | Feasibility, efficacy, and adverse effects of outpatient antibacterial prophylaxis in children with acute myeloid leukemia. ( Avutu, V; Cao, X; Flynn, PM; Gaur, AH; Hayden, RT; Howard, SC; Inaba, H; Marszal, LN; Pounds, SB; Pui, CH; Ribeiro, RC; Rubnitz, JE, 2014) |
| "Transient fever is commonly reported as a side effect." | 1.40 | Hepatic cyst infection following aspiration sclerotherapy: a case series. ( Drenth, JP; Lantinga, MA; Wijnands, TF, 2014) |
| "Radiation combined injury (CI) is a radiation injury (RI) combined with other types of injury, which generally leads to greater mortality than RI alone." | 1.39 | Ciprofloxacin modulates cytokine/chemokine profile in serum, improves bone marrow repopulation, and limits apoptosis and autophagy in ileum after whole body ionizing irradiation combined with skin-wound trauma. ( Cary, LH; Elliott, TB; Fukumoto, R; Gorbunov, NV; Kiang, JG; Lombardini, ED, 2013) |
| "Methicillin resistance was seen in 10/46 (21." | 1.39 | Bloodstream infection among adults in Phnom Penh, Cambodia: key pathogens and resistance patterns. ( De Smet, B; Jacobs, JA; Kham, C; Koole, O; Lim, K; Lynen, L; Peetermans, WE; Phe, T; Veng, HC; Vlieghe, ER, 2013) |
| "Ciprofloxacin is an antibacterial agent used mainly in urinary tract infections and prostate inflammation." | 1.38 | Ciprofloxacin as a prophylactic agent against prostate cancer: a "two hit" hypothesis. ( Bajek, A; Drewa, T; Gurtowska, N; Kloskowski, T, 2012) |
| "Obesity is a growing problem in the United States." | 1.38 | Underdosing of common antibiotics for obese patients in the ED. ( Fuentes, JM; Mullins, ME; Roe, JL, 2012) |
| "Leprosy has many complications that include leprosy reactions, development of plantar and hand ulcerations, lagophthalomus and corneal anesthesia." | 1.38 | The pattern of bacterial isolates and drug sensitivities of infected ulcers in patients with leprosy in ALERT, Kuyera and Gambo hospitals, Ethiopia. ( Aseffa, A; Asrat, D; Baraki, A; Hunegnaw, M; Kebede, Y; Lema, T; Woldeamanuel, Y; Yamuah, L, 2012) |
| "Emphysematous gastritis is a rare form of gastritis characterized by gaseous dissection of the stomach wall usually secondary to invasion by gas forming organisms, corrosive ingestion, trauma, or gastric infarction." | 1.37 | Emphysematous gastritis associated with ulcerative esophagitis. ( Abbass, K; Akram, S; Hassan, S; Markert, R, 2011) |
| "This survey considers 8 cases of toxic epidermal necrolysis diagnosed and treated in our clinic from 2003 to 2007." | 1.36 | Basic measures and systemic medical treatment of patients with toxic epidermal necrolysis. ( Hanken, I; Sander, CA; Schimmer, M, 2010) |
| "The proven shigellosis as well as the strong suspicion have to be treated promptly with antibiotics, mainly azithromycin." | 1.35 | [Bacterial diarrheas and antibiotics: European recommendations]. ( Cohen, R; Gendrel, D, 2008) |
| "Furthermore, opportunistic secondary bacterial infection during trypanosomosis did not seem to play an important role in the changes in plasma LBP levels." | 1.35 | Lipopolysaccharide binding protein in the acute phase response of experimental murine Trypanosoma brucei brucei infection. ( Burke, J; Eckersall, PD; Jennings, FW; Mburu, JN; Mungatana, NK; Murray, M; Ngure, RM, 2009) |
| "The clinical course in acute necrotizing pancreatitis is mainly determined by bacterial infection of pancreatic and peripancreatic necrosis." | 1.34 | Effect of early and late antibiotic treatment in experimental acute pancreatitis in rats. ( Beger, HG; Gansauge, F; Isenmann, R; Kriese, D; Poch, B; Rozdzinski, E; Schwarz, M, 2007) |
| "Ciprofloxacin was taken as an example." | 1.34 | Modeling the influence of non-adherence on antibiotic efficacy: application to ciprofloxacin. ( Lansky, P; Sanda, P; Weiss, M, 2007) |
| " Ciprofloxacin pharmacokinetics in critically ill patients do not change over time, and intra-abdominal sepsis does not alter ciprofloxacin pharmacokinetic parameters to a greater degree than sepsis from other causes in critically ill patients." | 1.33 | Fluid shifts have no influence on ciprofloxacin pharmacokinetics in intensive care patients with intra-abdominal sepsis. ( Gous, A; Hon, H; Lipman, J; Mathivha, R; Pinder, M; Scribante, J; Stass, H; Tshukutsoane, S; Verhoef, L, 2005) |
| "Ciprofloxacin was administered daily via drinking water at concentrations to provide doses of 0, 0." | 1.33 | Impact of residual and therapeutic doses of ciprofloxacin in the human-flora-associated mice model. ( Bartholomew, M; Corpet, DE; Fernández, AH; Perrin-Guyomard, A; Poul, JM; Sanders, P, 2005) |
| "To define in critically ill patients receiving intravenous (iv) ciprofloxacin (200 mg or 400 mg twice daily) and undergoing routine therapeutic drug monitoring (TDM) the interindividual pharmacokinetic variability and the reliable pharmacodynamic breakpoint enabled by these fixed dosing regimens according to the PK/PD principles and to the pattern of susceptibility to this antibiotic." | 1.33 | Which reliable pharmacodynamic breakpoint should be advised for ciprofloxacin monotherapy in the hospital setting? A TDM-based retrospective perspective. ( Furlanut, M; Pavan, F; Pea, F; Poz, D; Viale, P, 2006) |
| "Clarithromycin resistance was 12% in M." | 1.33 | Antimicrobial susceptibility of common pathogens from community-acquired lower respiratory tract infections in Estonia. ( Altraja, A; Kullamaa, A; Leesik, H; Meriste, S; Naaber, P; Tamm, E, 2006) |
| "metronidazole (MTR) was compared with i." | 1.32 | Results of a prospective, randomized, double blind comparison of the efficacy and the safety of sequential ciprofloxacin (intravenous/oral)+metronidazole (intravenous/oral) with ceftriaxone (intravenous)+metronidazole (intravenous/oral) for the treatment ( Asimakopoulos, C; Bassaris, H; Harlaftis, N; Karravias, D; Kolaras, P; Nikolaidis, P; Skoutelis, A; Starakis, I, 2003) |
| "The "crown gall" hypothesis for Hodgkin's disease would explain the clinical observations of a bacterial infection the behavior as a malignant tumor." | 1.32 | Regression of lung lesions in Hodgkin's disease by antibiotics: case report and hypothesis on the etiology of Hodgkin's disease. ( Blum, S; Sauter, C, 2003) |
| "Treatment with rifampin, tobramycin, and ciprofloxacin was started 7 days after subcutaneous implantation of catheters precolonized with 10(4) CFU of S." | 1.32 | Rapid direct method for monitoring antibiotics in a mouse model of bacterial biofilm infection. ( Contag, PR; Francis, KP; Kadurugamuwa, JL; Kimura, R; Purchio, T; Sin, LV; Yu, J, 2003) |
| "The diagnosis of deep seated bacterial infections, such as intra-abdominal abscesses, endocarditis, and osteomyelitis, can be difficult and delayed, thereby compromising effective treatment." | 1.31 | Imaging bacterial infection with (99m)Tc-ciprofloxacin (Infecton). ( Amaral, H; Bhatnagar, A; Britton, KE; Das, SS; Katamihardja, AH; Malamitsi, J; Moustafa, HM; Padhy, AK; Solanki, KK; Soroa, VE; Sundram, FX; Wareham, DW, 2002) |
| "Moxifloxacin was more potent than ofloxacin and ciprofloxacin against Gram-positive rods and anaerobic cocci." | 1.31 | Antianaerobic activity of moxifloxacin compared with that of ofloxacin, ciprofloxacin, clindamycin, metronidazole and beta-lactams. ( Behra-Miellet, J; Dubreuil, L; Jumas-Bilak, E, 2002) |
| "gif" BORDER="0"> and AUIC(ss) were calculated for each clinical case included in the study, from simulated plasma level curves corresponding to the dosage regimen administered." | 1.31 | A retrospective analysis of pharmacokinetic/pharmacodynamic indices as indicators of the clinical efficacy of ciprofloxacin. ( Colino, CI; Sánchez-Navarro, A; Sánchez-Recio, MM, 2000) |
| "Ciprofloxacin appears to be a good therapeutic choice for the treatment of severe nosocomial infections in NICU." | 1.31 | [Nosocomial infections in neonatal and pediatric intensive care. The appeal of ciprofloxacin]. ( Benomar, S; Lahbabi, MS; Nejjari, N, 2000) |
| "Bacterial infections were seen in 37% of patients with acute pancreatitis." | 1.31 | Incidence, spectrum and antibiotic sensitivity pattern of bacterial infections among patients with acute pancreatitis. ( Bohidar, NP; Garg, PK; Kapil, A; Khanna, S; Tandon, RK, 2001) |
| "Ciprofloxacin has been shown to be safe and efficacious in children in developing countries." | 1.30 | Use of ciprofloxacin in developing countries. ( Green, S; Tillotson, G, 1997) |
| "Schematic dosage adjustments for aminoglycosides, vancomycin, and ciprofloxacin were derived from published data on the prolongation of elimination half-lives in patients with renal impairment." | 1.30 | Dosage adjustment of antiinfective therapy in patients with renal impairment. ( Borner, K; Eckhardt, A; Keller, F; Zellner, D, 1997) |
| "Levofloxacin was generally one to two dilutions more active than ofloxacin, while ciprofloxacin was active against aerobes (MIC < or = 1 mg/L) but less active against anaerobic strains (MIC90 < or = 16 mg/L)." | 1.30 | Trovafloxacin compared with levofloxacin, ofloxacin, ciprofloxacin, azithromycin and clarithromycin against unusual aerobic and anaerobic human and animal bite-wound pathogens. ( Citron, DM; Goldstein, EJ; Hudspeth, M; Hunt Gerardo, S; Merriam, CV, 1998) |
| "catarrhalis produced beta-lactamase." | 1.30 | Antimicrobial susceptibility of community-acquired lower respiratory tract bacterial pathogens isolated in the UK during the 1995-1996 cold season. ( Felmingham, D; Grüneberg, RN; Harding, I; Robbins, MJ; Shrimpton, S; Tesfaslasie, Y, 1998) |
| "We studied the tolerance and pharmacokinetic parameters of ciprofloxacin in (2 mg/kg, i." | 1.30 | Tolerance and pharmacokinetics of ciprofloxacin in the chick. Preliminary experience in subjects of pediatric age with urinary tract infections (UTI). ( Barberi, I; De Sarro, A; Masaracchio, A; Naccari, F; Salpietro, DC, 1998) |
| "Ciprofloxacin was given orally at the starting dose of 250 mg every 12 hours for 7 days followed by a single dose of 250 mg/day from day 7 to day 14 and 125 mg/day for the next 3 weeks." | 1.30 | Efficacy of oral ciprofloxacin as selective intestinal decontaminant in cirrhosis. ( Borzio, M; Fragiacomo, L; Galvagno, D; Piantoni, L; Salerno, F; Saudelli, M, 1997) |
| "Clinafloxacin activity was notably high against Staphylococcus aureus and, against ciprofloxacin-resistant strains, this high activity was maintained in vitro and measurable activity was demonstrated in vivo." | 1.30 | Bacterial eradication by clinafloxacin, CI-990, and ciprofloxacin employing MBC test, in-vitro time-kill and in-vivo time-kill studies. ( Cohen, MA; Gage, JW; Huband, MD; Roland, GE; Yoder, SL, 1998) |
| "Ciprofloxacin was released over seven days with an average release rate of 1." | 1.30 | A liposomal hydrogel for the prevention of bacterial adhesion to catheters. ( Bruce, AW; DiCosmo, F; DiTizio, V; Ferguson, GW; Khoury, AE; Mittelman, MW, 1998) |
| " Three pharmacodynamic parameters, T > MIC, C(max)/MIC and AUC/MIC (T = time, C(max) = peak serum concentration, AUC = area under the curve), were compared with area under the bacterial-kill curve (AUBKC) (after transformation of the AUBKC) using a simple E(max) or sigmoidal E(max) model." | 1.30 | Comparison of in-vitro pharmacodynamics of once and twice daily ciprofloxacin. ( Bowker, KE; Holt, HA; Lewis, R; MacGowan, AP; Rogers, CA; Wootton, M, 1999) |
| "To identify the rate of postoperative bacterial infection following full-face carbon dioxide (CO2) laser resurfacing with and without antibiotic prophylaxis." | 1.30 | Cutaneous CO2 laser resurfacing infection rate with and without prophylactic antibiotics. ( Alster, TS; Walia, S, 1999) |
| "Ciprofloxacin is a new orally administrable fluoroquinolones, with considerable efficacy against multiresistant organisms." | 1.29 | Ciprofloxacin in multi-resistant infections in childhood: an audit. ( Bhutta, ZA; Khan, DM, 1995) |
| "Renal scarring could not be prevented in the group in which prednisolone was administered in the period during which the urethra was regularly being clamped." | 1.29 | Effect of prednisolone on ascending renal infection due to biofilm disease and lower urinary tract obstruction in rats. ( Haraoka, M; Kubo, S; Kumazawa, J; Matsumoto, T; Takahashi, K; Tanaka, M, 1995) |
| "The 2-pyridones are a new class of broad-spectrum orally bioavailable antibacterial agents." | 1.29 | Efficacies of ABT-719 and related 2-pyridones, members of a new class of antibacterial agents, against experimental bacterial infections. ( Alder, J; Clement, J; Flamm, B; Hutch, T; Jarvis, K; Meulbroek, J; Mitten, M; Oleksijew, A; Paige, L; Shipkowitz, N, 1995) |
| "Sparfloxacin was fourfold more active against Staphylococcus aureus and Streptococcus pneumoniae." | 1.29 | In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens. ( Ahlén, S; Malmborg, AS, 1993) |
| "Ciprofloxacin appears to be an effective single agent in the treatment of ulcerative keratitis." | 1.29 | Comparison of topical ciprofloxacin to conventional antibiotic therapy in the treatment of ulcerative keratitis. ( Abrams, DA; Katz, HR; Parks, DJ; Sarfarazi, FA, 1993) |
| "Ciprofloxacin was the quinolone of choice in 24/32 (75%) of assessable cases." | 1.29 | An audit of ciprofloxacin use in a district general hospital. ( Fenelon, LE; MacGowan, AP; Reeves, DS; Smyth, EG; Speirs, GE; Speller, DC; Wilcox, MH, 1995) |
| "We used this agent to image bacterial infection in 56 patients (one twice) with known or suspected sites of infection." | 1.29 | Comparison of 99mTc infecton imaging with radiolabelled white-cell imaging in the evaluation of bacterial infection. ( Bomanji, J; Britton, KE; Das, SS; Hall, AV; O'Shaughnessy, E; Siraj, Q; Solanki, KK; Vinjamuri, S, 1996) |
| "Ciprofloxacin is an effective drug for initial treatment of SBP/CNNA." | 1.29 | Frequency, microbial spectrum and outcome of spontaneous bacterial peritonitis in north India. ( Ayyagari, A; Ghoshal, UC; Naik, SR; Puri, AS; Puri, J; Saraswat, VA; Sharma, BC, 1996) |
| "Sparfloxacin is a new oral fluoroquinolone agent with putative activity against common pediatric pathogens." | 1.28 | In vitro activity of sparfloxacin (AT-4140), a new quinolone agent, against invasive isolates from pediatric patients. ( Akaniro, JC; Arguedas, AG; Stutman, HR; Vargas, OM, 1992) |
| "In comparative study of patients with laryngeal cancer, perioperative prophylaxis with ciprofloxacin was estimated." | 1.28 | [Perioperative preventive use of ciprofloxacin in patients with cancer of the larynx]. ( Chylak, J; Kulczyński, B; Kwiatek, G; Michalska, W; Pietkiewicz, K; Szmeja, Z, 1991) |
| "Intravenous ciprofloxacin at a daily dosage of 400 mg divided in two doses was administered to 19 patients with severe infections caused by ciprofloxacin-susceptible bacteria." | 1.28 | Intravenous ciprofloxacin for the treatment of severe infections. ( Baiocchi, P; Brandimarte, C; Gelfusa, V; Santini, C; Serra, P; Tarasi, A; Venditti, M, 1991) |
| "Ciprofloxacin was used as both initial and replacement for parenteral therapy in a variety of infections." | 1.28 | Pharmacoepidemiology of ciprofloxacin: analysis of use patterns and cost impact. ( Barnes, J; Dudley, MN; Graham, KK; Marchbanks, CR, 1991) |
| " The pharmacokinetic profile of the drug was then superimposed on the bacterial MIC, and we then derived the patients individual peak to MIC ratio, area above MIC, and time above MIC." | 1.28 | Correlation of pharmacokinetic parameters to efficacy of antibiotics: relationships between serum concentrations, MIC values, and bacterial eradication in patients with gram-negative pneumonia. ( Schentag, JJ, 1990) |
| "Fleroxacin was inactive against S." | 1.28 | In vivo evaluation of a dual-action antibacterial, Ro 23-9424, compared to cefotaxime and fleroxacin. ( Beskid, G; Chan, K; Cleeland, R; Keith, DD; McGarry, CM; Siebelist, J, 1990) |
| "Sparfloxacin was extremely active against Acinetobacter species, Aeromonas hydrophila, Citrobacter diversus, Enterobacter species, Escherichia coli, Klebsiella species, Proteus vulgaris, and Serratia marcescens (inhibiting greater than 90% of these isolates at a concentration of 0." | 1.28 | In vitro activity of sparfloxacin (CI-978; AT-4140) against clinical isolates from cancer patients. ( Bodey, GP; Ho, DH; LeBlanc, B; Messer, M; Nguyen, H; Rolston, KV, 1990) |
| "Ciprofloxacin has a greater than 100-fold in-vitro potency advantage over azithromycin against this organism, but azithromycin (5 mg/kg) produced a greater reduction in cfu than ciprofloxacin (100 mg/kg) at the primary site of infection (liver)." | 1.28 | Correlation of the extravascular pharmacokinetics of azithromycin with in-vivo efficacy in models of localized infection. ( Girard, AE; Girard, D; Retsema, JA, 1990) |
| "Ciprofloxacin is a fluoroquinolone antimicrobial with activity against both gram-negative and -positive bacteria including pseudomonal and staphylococcal species." | 1.28 | Ciprofloxacin drug utilization review and prospective drug use evaluation. ( Goldman, MP, 1990) |
| " Seizure activity has been reported to occur with the quinolone antibiotics and, with the increasing use of these agents, dose reductions should be kept in mind to avoid potentially serious adverse reactions." | 1.28 | Potential neurologic toxicity related to ciprofloxacin. ( Calvert, JF; Schwartz, MT, 1990) |
| "Serum sickness is a systemic hypersensitivity reaction initially reported in children receiving horse serum." | 1.28 | Serum sickness-like illness associated with ciprofloxacin. ( Slama, TG, 1990) |
| "Oral ciprofloxacin was an effective and cost-efficient alternative to traditional i." | 1.28 | Clinical and economic effect of ciprofloxacin as an alternative to injectable antimicrobial therapy. ( Bingham, DH; Powers, T, 1990) |
| "Ciprofloxacin is a new fluoroquinolone that is easily administered by parenteral and oral route." | 1.28 | [Evaluation of ciprofloxacin for the treatment of severe bacterial infections]. ( Bouza, E; García de la Torre, M; López, JC; offcenado, E; Rodríguez-Créixems, M; Romero, J, 1989) |
| "Forty six episodes of infection in 43 cancer patients were treated with oral ciprofloxacin at a dose of 750 mg every 8 h." | 1.28 | Oral ciprofloxacin therapy for infections in cancer patients. ( Bodey, GP; Cunningham, C; Haron, E; Holmes, F; Rolston, KV; Umsawasdi, T, 1989) |
| "Ciprofloxacin was the most potent antibiotic and had the broadest spectrum of activity (98% of isolates susceptible, MIC90 range: 0." | 1.28 | Nosocomial gram-negative bloodstream isolates: a comparison of in vitro antibiotic potency. ( Mori, M; Pfaller, MA; Stanley, GL; Wenzel, RP, 1989) |
| " Adverse events related to ciprofloxacin occurred in six patients and were primarily mild." | 1.28 | Safety and efficacy of intravenous ciprofloxacin in the treatment of selected infections. ( Abadie-Kemmerly, S; Pankey, GA, 1989) |
| "One hundred forty-seven cancer patients were treated with intravenously administered ciprofloxacin, 200 mg every eight hours, as initial therapy for febrile episodes." | 1.28 | Intravenous ciprofloxacin for infections in cancer patients. ( Bodey, GP; Cunningham, C; Haron, E; Rolston, KV, 1989) |
| "The optimal approach to reduce bacterial infections in granulocytopenic patients is still controversial." | 1.28 | [Prevention of bacterial infections using ciprofloxacin in granulocytopenic patients with cancer]. ( Gerain, J; Leleux, A; Libert, J; Meunier, F; Snoeck, R, 1989) |
| "Ciprofloxacin was well tolerated." | 1.28 | Efficacy of ciprofloxacin in the treatment of various bacterial infections. ( Hutchison, J; Nolen, TM; Phillips, HL, 1989) |
| "Treatment with ciprofloxacin was very well tolerated." | 1.28 | [Ciprofloxacin treatment in bacterial skin infections]. ( Küchmeister, B; Mohr, CP; Reinel, D; Ulrich, R, 1989) |
| "BMY 40062 and ofloxacin were more active than ciprofloxacin against Bacteroides fragilis and Clostridium difficile." | 1.28 | In vitro and in vivo antibacterial activities of BMY 40062, a new fluoronaphthyridone. ( Desiderio, JV; Fung-Tomc, J; Kessler, RE; Tsai, YH; Warr, G, 1989) |
| "Ciprofloxacin was 2-8 fold more active than norfloxacin and 100-fold more active than nalidixic acid." | 1.27 | The in vitro and in vivo activity of ciprofloxacin. ( Grohe, K; Zeiler, HJ, 1984) |
| "Ciprofloxacin was substantially more active than nalidixic acid or cinoxacin against all gram-negative bacteria tested." | 1.27 | In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent. ( Eliopoulos, GM; Gardella, A; Moellering, RC, 1984) |
| "Ciprofloxacin is an effective and safe therapeutic alternative in many tissue infections caused by susceptible microorganisms." | 1.27 | Open, prospective study of the clinical efficacy of ciprofloxacin. ( Bran, JL; Garcia, JF; Mejia, CR; Ramirez, CA, 1985) |
| "Ciprofloxacin activity was compared to that of cephalosporins, enoxacin, norfloxacin, ampicillin, chloramphenicol, tobramycin, ticarcillin, erythromycin and trimethoprim/sulfamethoxazole." | 1.27 | In vitro activity of ciprofloxacin against pediatric pathogens. ( Marks, MI; Scribner, RK; Weber, AH, 1985) |
| "Ciprofloxacin was the most active quinolone tested against both gentamicin-susceptible and gentamicin-resistant stains, having an MIC90 equal or less than 1 mg/l for all species studied." | 1.27 | The comparative in-vitro activity of norfloxacin, ciprofloxacin, enoxacin and nalidixic acid against 423 strains of gram-negative rods and staphylococci isolated from infected hospitalised patients. ( Guimaraes, MA; Noone, P, 1986) |
| "1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7-piperazine-1-ylquinoline-3-carboxylic acid (ciprofloxacin, Bay o-9867, Bay q-3939) was evaluated by checkerboard assay in combination with ampicillin, ticarcillin, mezlocillin, azlocillin, piperacillin, cefamandole, cefoxitin, cefotaxime, and ceftazidime." | 1.27 | Comprehensive evaluation of ciprofloxacin in combination with beta-lactam antibiotics against Enterobacteriaceae and Pseudomonas aeruginosa. ( Haller, I, 1986) |
| "Ciprofloxacin was administered orally to 48 patients with 24 Pseudomonas aeruginosa infections and 13 other infections caused by cephalothin-resistant gram-negative bacilli." | 1.27 | Ciprofloxacin therapy of infections caused by Pseudomonas aeruginosa and other resistant bacteria. ( Eron, LJ; Harvey, L; Hixon, DL; Poretz, DM, 1985) |
| "Ciprofloxacin results to be an effective antibacterial agent in a high risk population." | 1.27 | Treatment of infections in non-neutropenic patients with cancer, AIDS, or renal transplant using ciprofloxacin. ( Bianchi, W; Maggiolo, F; Ohnmeiss, H, 1988) |
| "Sch 34343 was extremely active against beta-haemolytic streptococci (Lancefield groups A, B and G) with MIC90s ranging from 0." | 1.27 | In-vitro activity of Sch 34343, a new penam, against gram-positive isolates from cancer patients. ( Alderman, HC; Alvarez, ME; Bodey, GP; Ho, DH; Hoy, JF; Rolston, KV, 1986) |
| "Ciprofloxacin is a new quinolone antimicrobial agent with activity against a broad spectrum of gram-negative and gram-positive organisms, including Pseudomonas aeruginosa and methicillin-resistant strains of staphylococci." | 1.27 | A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial. ( Arcieri, G; August, R; Becker, N; Griffith, E; Gruenwaldt, G; Heyd, A; O'Brien, B; Screen, P, 1988) |
| " Peak serum concentration (Cmax), terminal elimination half-life (t1/2 beta), apparent total body clearance (CL/f) and apparent volume of distribution (Vd/f) were 6." | 1.27 | Single and multiple dose pharmacokinetics of oral ciprofloxacin in elderly patients. ( Awni, WM; Breitenbucher, R; Guay, DR; Matzke, GR; Obaid, S; Peterson, PK; Stein, D, 1988) |
| "The osteomyelitis was secondary to trauma in 12 patients, joint replacement in six, previous acute hematogenous infection in two and osteotomy in one." | 1.27 | Treatment of chronic osteomyelitis with ciprofloxacin. ( Mulier, JC; Stuyck, J; Verbist, L, 1987) |
| "Norfloxacin was ineffective at 200 mg/kg per day against E." | 1.27 | In vivo evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones. ( Bower, RR; Chu, DT; Fernandes, PB; Jarvis, KP; Ramer, NR; Shipkowitz, N, 1986) |
| " The terminal serum elimination half-life averaged 4." | 1.27 | Pharmacokinetics and pharmacodynamics of intravenous ciprofloxacin. Studies in vivo and in an in vitro dynamic model. ( Dudley, MN; Ericson, J; Gilbert, D; Mandler, HD; Mayer, KH; Zinner, SH, 1987) |
| "Ciprofloxacin is a fluorinated carboxyquinolone that inhibits Enterobacteriaceae, staphylococci, and Pseudomonas at low concentrations." | 1.27 | Effect of ciprofloxacin on fecal flora of patients with cystic fibrosis and other patients treated with oral ciprofloxacin. ( Chin, NX; Jules, K; Neu, HC; Scully, BE, 1987) |
| "Ciprofloxacin was found to be highly effective against all gram-negative and gram-positive bacteria tested." | 1.27 | Evaluation of ciprofloxacin alone and in combination with other antibiotics in a murine model of thigh muscle infection. ( Haller, I, 1987) |
| "Ciprofloxacin was well tolerated and effective in most of the ambulatory patients with refractory Gram-negative bacillary infection." | 1.27 | Oral ciprofloxacin in refractory gram-negative bacillary infections. ( Bryant, RE; Hartstein, AI, 1987) |
| "Ciprofloxacin is a new 6-fluoro-7-piperazino-4-quinolone that is highly active against a broad array of microbial pathogens." | 1.27 | Overview of preclinical studies with ciprofloxacin. ( Goering, RV; Sanders, CC; Sanders, WE, 1987) |
| "Ciprofloxacin was effective and safe therapy of infections due to Gram-negative bacteria resistant to many of the currently available oral and parenteral agents." | 1.27 | Oral ciprofloxacin therapy of infection caused by multiply resistant bacteria other than Pseudomonas aeruginosa. ( Neu, HC; Scully, BE, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 234 (31.33) | 18.7374 |
| 1990's | 208 (27.84) | 18.2507 |
| 2000's | 132 (17.67) | 29.6817 |
| 2010's | 149 (19.95) | 24.3611 |
| 2020's | 24 (3.21) | 2.80 |
| Authors | Studies |
|---|---|
| McGuirk, PR | 1 |
| Jefson, MR | 1 |
| Mann, DD | 1 |
| Elliott, NC | 1 |
| Chang, P | 1 |
| Cisek, EP | 1 |
| Cornell, CP | 1 |
| Gootz, TD | 1 |
| Haskell, SL | 1 |
| Hindahl, MS | 1 |
| Sanchez, JP | 2 |
| Bridges, AJ | 2 |
| Bucsh, R | 1 |
| Domagala, JM | 2 |
| Gogliotti, RD | 1 |
| Hagen, SE | 2 |
| Heifetz, CL | 1 |
| Joannides, ET | 1 |
| Sesnie, JC | 1 |
| Shapiro, MA | 1 |
| Culbertson, TP | 1 |
| Gambino, L | 1 |
| Karrick, G | 1 |
| Porter, K | 1 |
| Sesnie, JA | 1 |
| Spense, FG | 1 |
| Remuzon, P | 1 |
| Bouzard, D | 2 |
| Cesare, PD | 1 |
| Essiz, M | 1 |
| Jacquet, JP | 1 |
| Kiechel, JR | 1 |
| Ledoussal, B | 1 |
| Kessler, RE | 2 |
| Fung-Tomc, J | 3 |
| Rosen, T | 1 |
| Chu, DT | 5 |
| Lico, IM | 1 |
| Fernandes, PB | 4 |
| Marsh, K | 1 |
| Shen, L | 1 |
| Cepa, VG | 1 |
| Pernet, AG | 3 |
| Maleczka, RE | 2 |
| Nordeen, CW | 2 |
| Frigola, J | 2 |
| Torrens, A | 2 |
| Castrillo, JA | 1 |
| Mas, J | 2 |
| Vañó, D | 2 |
| Berrocal, JM | 1 |
| Calvet, C | 1 |
| Salgado, L | 1 |
| Redondo, J | 1 |
| García-Granda, S | 1 |
| Parés, J | 1 |
| Corbera, J | 1 |
| Mercè, R | 1 |
| Valentí, E | 1 |
| Arhin, FF | 1 |
| Sarmiento, I | 1 |
| Belley, A | 1 |
| McKay, GA | 1 |
| Draghi, DC | 1 |
| Grover, P | 1 |
| Sahm, DF | 1 |
| Parr, TR | 1 |
| Moeck, G | 1 |
| Miller, AA | 1 |
| Bundy, GL | 1 |
| Mott, JE | 1 |
| Skepner, JE | 1 |
| Boyle, TP | 1 |
| Harris, DW | 1 |
| Hromockyj, AE | 1 |
| Marotti, KR | 1 |
| Zurenko, GE | 1 |
| Munzner, JB | 1 |
| Sweeney, MT | 1 |
| Bammert, GF | 1 |
| Hamel, JC | 1 |
| Ford, CW | 1 |
| Zhong, WZ | 1 |
| Graber, DR | 1 |
| Martin, GE | 1 |
| Han, F | 1 |
| Dolak, LA | 1 |
| Seest, EP | 1 |
| Ruble, JC | 1 |
| Kamilar, GM | 1 |
| Palmer, JR | 1 |
| Banitt, LS | 1 |
| Hurd, AR | 1 |
| Barbachyn, MR | 1 |
| Haebich, D | 1 |
| Kroll, HP | 1 |
| Lerchen, HG | 1 |
| Gadakh, AV | 1 |
| Pandit, C | 1 |
| Rindhe, SS | 1 |
| Karale, BK | 1 |
| Rajanarendar, E | 1 |
| Reddy, MN | 1 |
| Murthy, KR | 1 |
| Reddy, KG | 1 |
| Raju, S | 1 |
| Srinivas, M | 1 |
| Praveen, B | 1 |
| Rao, MS | 1 |
| Jeong, JW | 1 |
| Jung, SJ | 2 |
| Lee, HH | 1 |
| Kim, YZ | 1 |
| Park, TK | 1 |
| Cho, YL | 1 |
| Chae, SE | 1 |
| Baek, SY | 1 |
| Woo, SH | 1 |
| Lee, HS | 1 |
| Kwak, JH | 1 |
| Burchak, ON | 1 |
| Pihive, EL | 1 |
| Maigre, L | 1 |
| Guinchard, X | 1 |
| Bouhours, P | 1 |
| Jolivalt, C | 1 |
| Schneider, D | 1 |
| Maurin, M | 1 |
| Giglione, C | 1 |
| Meinnel, T | 1 |
| Paris, JM | 1 |
| Denis, JN | 1 |
| Prakash, O | 1 |
| Aneja, DK | 1 |
| Hussain, K | 1 |
| Lohan, P | 1 |
| Ranjan, P | 1 |
| Arora, S | 2 |
| Sharma, C | 1 |
| Aneja, KR | 1 |
| Azéma, J | 1 |
| Guidetti, B | 1 |
| Korolyov, A | 1 |
| Kiss, R | 1 |
| Roques, C | 1 |
| Constant, P | 1 |
| Daffé, M | 1 |
| Malet-Martino, M | 1 |
| Karuvalam, RP | 1 |
| Haridas, KR | 2 |
| Nayak, SK | 1 |
| Row, TN | 1 |
| Rajeesh, P | 1 |
| Rishikesan, R | 1 |
| Kumari, NS | 1 |
| Shelke, SN | 1 |
| Mhaske, GR | 1 |
| Bonifácio, VD | 1 |
| Gawande, MB | 1 |
| Rane, RA | 1 |
| Gutte, SD | 1 |
| Sahu, NU | 1 |
| Shelke, SH | 1 |
| Mhaske, PC | 1 |
| Nandave, M | 1 |
| Narkhade, S | 1 |
| Walhekar, NM | 1 |
| Bobade, VD | 1 |
| Hatnapure, GD | 1 |
| Keche, AP | 1 |
| Rodge, AH | 1 |
| Birajdar, SS | 1 |
| Tale, RH | 1 |
| Kamble, VM | 1 |
| Cormier, R | 1 |
| Burda, WN | 1 |
| Harrington, L | 1 |
| Edlinger, J | 1 |
| Kodigepalli, KM | 1 |
| Thomas, J | 1 |
| Kapolka, R | 1 |
| Roma, G | 1 |
| Anderson, BE | 1 |
| Turos, E | 1 |
| Shaw, LN | 1 |
| Sharma, V | 1 |
| Singh, G | 1 |
| Kaur, H | 1 |
| Saxena, AK | 1 |
| Ishar, MP | 1 |
| Srivastava, N | 1 |
| Kumar, A | 1 |
| Odžak, R | 1 |
| Skočibušić, M | 1 |
| Maravić, A | 1 |
| Ranjith, PK | 1 |
| Pakkath, R | 1 |
| Kumari, SN | 1 |
| Soni, JN | 1 |
| Soman, SS | 1 |
| Kotaiah, Y | 1 |
| Nagaraju, K | 1 |
| Harikrishna, N | 1 |
| Venkata Rao, C | 1 |
| Yamini, L | 1 |
| Vijjulatha, M | 1 |
| Ratnakar Reddy, K | 1 |
| Poornachandra, Y | 2 |
| Jitender Dev, G | 1 |
| Mallareddy, G | 1 |
| Nanubolu, JB | 1 |
| Kumar, CG | 2 |
| Narsaiah, B | 1 |
| Nagamallu, R | 1 |
| Srinivasan, B | 1 |
| Ningappa, MB | 1 |
| Kariyappa, AK | 1 |
| Venepally, V | 1 |
| Prasad, RBN | 1 |
| Jala, RCR | 1 |
| Ebrahimi, HP | 1 |
| Hadi, JS | 1 |
| Almayah, AA | 1 |
| Bolandnazar, Z | 1 |
| Swadi, AG | 1 |
| Ebrahimi, A | 1 |
| Karad, SC | 1 |
| Purohit, VB | 1 |
| Thakor, P | 1 |
| Thakkar, VR | 1 |
| Raval, DK | 1 |
| Ma, Z | 1 |
| Lynch, AS | 1 |
| Boibessot, T | 1 |
| Zschiedrich, CP | 1 |
| Lebeau, A | 1 |
| Bénimèlis, D | 1 |
| Dunyach-Rémy, C | 1 |
| Lavigne, JP | 1 |
| Szurmant, H | 1 |
| Benfodda, Z | 1 |
| Meffre, P | 1 |
| Sheppard, JG | 1 |
| Long, TE | 1 |
| Sedghizadeh, PP | 1 |
| Sun, S | 1 |
| Junka, AF | 1 |
| Richard, E | 1 |
| Sadrerafi, K | 1 |
| Mahabady, S | 1 |
| Bakhshalian, N | 1 |
| Tjokro, N | 1 |
| Bartoszewicz, M | 1 |
| Oleksy, M | 1 |
| Szymczyk, P | 1 |
| Lundy, MW | 1 |
| Neighbors, JD | 1 |
| Russell, RG | 1 |
| McKenna, CE | 1 |
| Ebetino, FH | 1 |
| Dou, X | 1 |
| Zhu, X | 2 |
| Wang, J | 1 |
| Dong, N | 1 |
| Shan, A | 1 |
| Dias, FRF | 1 |
| Novais, JS | 1 |
| Devillart, TADNS | 1 |
| da Silva, WA | 1 |
| Ferreira, MO | 1 |
| Loureiro, RS | 1 |
| Campos, VR | 1 |
| Ferreira, VF | 1 |
| de Souza, MCBV | 1 |
| Castro, HC | 1 |
| Cunha, AC | 1 |
| Szulczyk, D | 1 |
| Dobrowolski, MA | 1 |
| Roszkowski, P | 1 |
| Bielenica, A | 1 |
| Stefańska, J | 1 |
| Koliński, M | 1 |
| Kmiecik, S | 1 |
| Jóźwiak, M | 1 |
| Wrzosek, M | 1 |
| Olejarz, W | 1 |
| Struga, M | 1 |
| Zha, GF | 1 |
| Wang, SM | 1 |
| Rakesh, KP | 1 |
| Bukhari, SNA | 1 |
| Manukumar, HM | 1 |
| Vivek, HK | 1 |
| Mallesha, N | 1 |
| Qin, HL | 1 |
| Zhang, B | 1 |
| Zhang, J | 1 |
| Ba, Y | 1 |
| Wang, S | 1 |
| Yang, H | 2 |
| Hou, X | 1 |
| Xu, Z | 2 |
| Magarò, G | 1 |
| Prati, F | 1 |
| Garofalo, B | 1 |
| Corso, G | 1 |
| Furlotti, G | 1 |
| Apicella, C | 1 |
| Mangano, G | 1 |
| D'Atanasio, N | 1 |
| Robinson, D | 1 |
| Di Giorgio, FP | 1 |
| Ombrato, R | 1 |
| Kirk, R | 1 |
| Betson, M | 1 |
| Bingham, M | 1 |
| Doyle, P | 1 |
| Harvey, R | 1 |
| Huxley, A | 1 |
| Moat, J | 1 |
| Pesnot, T | 1 |
| Tait, M | 1 |
| Hallworth, S | 1 |
| Nelson, G | 1 |
| Ngoc Toan, V | 1 |
| Dinh Thanh, N | 1 |
| Minh Tri, N | 1 |
| Thi Thu Huong, N | 1 |
| Siyez, E | 1 |
| Motamedi, H | 2 |
| Fathollahi, M | 1 |
| Abiri, R | 1 |
| Kadivarian, S | 1 |
| Rostamian, M | 1 |
| Alvandi, A | 1 |
| Zheng, Y | 1 |
| Yan, Y | 1 |
| Lin, L | 1 |
| He, Q | 1 |
| Hu, H | 1 |
| Luo, R | 1 |
| Xian, D | 1 |
| Wu, J | 1 |
| Shi, Y | 1 |
| Zeng, F | 1 |
| Wu, C | 1 |
| Quan, G | 1 |
| Lu, C | 1 |
| Hardie, J | 1 |
| Makabenta, JM | 1 |
| Gupta, A | 1 |
| Huang, R | 1 |
| Cao-Milán, R | 1 |
| Goswami, R | 1 |
| Zhang, X | 2 |
| Abdulpurkar, P | 1 |
| Farkas, ME | 1 |
| Rotello, VM | 1 |
| Ibrahim, UH | 1 |
| Devnarain, N | 1 |
| Mohammed, M | 1 |
| Omolo, CA | 1 |
| Gafar, MA | 1 |
| Salih, M | 1 |
| Pant, A | 1 |
| Shunmugam, L | 1 |
| Mocktar, C | 1 |
| Khan, R | 1 |
| Oh, JK | 1 |
| Govender, T | 1 |
| Patel, H | 1 |
| Buchad, H | 1 |
| Gajjar, D | 1 |
| Mustapha, SS | 1 |
| Ibrahim, M | 1 |
| Aliyu, S | 1 |
| Abdulkadir, I | 1 |
| Song, K | 1 |
| Hao, Y | 1 |
| Liu, Y | 1 |
| Cao, R | 1 |
| He, S | 1 |
| Wen, J | 1 |
| Zheng, W | 1 |
| Wang, L | 1 |
| Zhang, Y | 1 |
| Alzahrani, A | 3 |
| Adel Ali Youssef, A | 3 |
| Senapati, S | 3 |
| Tripathi, S | 3 |
| Bandari, S | 3 |
| Majumdar, S | 3 |
| Repka, MA | 3 |
| Yim, HJ | 2 |
| Kim, TH | 1 |
| Suh, SJ | 2 |
| Yim, SY | 2 |
| Jung, YK | 2 |
| Seo, YS | 2 |
| Kang, SH | 1 |
| Kim, MY | 1 |
| Baik, SK | 1 |
| Kim, HS | 3 |
| Kim, YS | 3 |
| Park, SY | 4 |
| Kim, BI | 3 |
| Park, JY | 1 |
| Heo, J | 1 |
| Sohn, JH | 1 |
| Heo, NY | 1 |
| Han, KH | 1 |
| Um, SH | 2 |
| Yang, M | 1 |
| Lu, X | 1 |
| Xin, L | 1 |
| Luo, J | 1 |
| Diao, S | 1 |
| Jia, Z | 1 |
| Cheng, G | 1 |
| Zeng, L | 1 |
| Zhang, L | 1 |
| Shafigh Kheljan, F | 1 |
| Sheikhzadeh Hesari, F | 1 |
| Aminifazl, MS | 1 |
| Skurnik, M | 1 |
| Gholadze, S | 1 |
| Zarrini, G | 1 |
| Mekonnen, S | 1 |
| Tesfa, T | 2 |
| Shume, T | 1 |
| Tebeje, F | 1 |
| Urgesa, K | 1 |
| Weldegebreal, F | 2 |
| Huang, Y | 1 |
| Liu, D | 1 |
| Guo, R | 2 |
| Wang, B | 1 |
| Lu, Y | 1 |
| Shariati, A | 1 |
| Noei, M | 1 |
| Chegini, Z | 1 |
| Tan, EE | 1 |
| Quah, SY | 1 |
| Bergenholtz, G | 1 |
| Rosa, V | 1 |
| Hoon Yu, VS | 1 |
| Tan, KS | 1 |
| Weldrick, PJ | 1 |
| Hardman, MJ | 1 |
| Paunov, VN | 1 |
| Abd Elsalam, EA | 1 |
| Shabaiek, HF | 1 |
| Abdelaziz, MM | 1 |
| Khalil, IA | 1 |
| El-Sherbiny, IM | 1 |
| Moharana, SS | 1 |
| Panda, RK | 1 |
| Dash, M | 1 |
| Chayani, N | 1 |
| Bokade, P | 1 |
| Pati, S | 1 |
| Bhattacharya, D | 1 |
| Gieling, EM | 1 |
| Wallenburg, E | 1 |
| Frenzel, T | 1 |
| de Lange, DW | 1 |
| Schouten, JA | 1 |
| Ten Oever, J | 1 |
| Kolwijck, E | 1 |
| Burger, DM | 1 |
| Pickkers, P | 1 |
| Ter Heine, R | 1 |
| Brüggemann, RJM | 1 |
| Fang, Q | 1 |
| Yao, Z | 1 |
| Feng, L | 1 |
| Liu, T | 1 |
| Wei, S | 1 |
| Xu, P | 1 |
| Cheng, B | 1 |
| Wang, X | 1 |
| Beaussac, M | 1 |
| Luciano, L | 1 |
| Savini, H | 1 |
| Deniel, C | 1 |
| Javelle, E | 1 |
| Coton, T | 1 |
| Simon, F | 1 |
| Graif, A | 1 |
| Leung, DA | 1 |
| McKenna, G | 1 |
| Patel, KD | 1 |
| Holmes, LE | 1 |
| Grilli, CJ | 1 |
| Kumwenda, P | 1 |
| Adukwu, EC | 1 |
| Tabe, ES | 1 |
| Ujor, VC | 1 |
| Kamudumuli, PS | 1 |
| Ngwira, M | 1 |
| Wu, JTS | 1 |
| Chisale, MRO | 1 |
| Foletto, VS | 1 |
| da Rosa, TF | 1 |
| Serafin, MB | 1 |
| Bottega, A | 1 |
| Franco, LN | 1 |
| de Paula, BR | 1 |
| Hörner, R | 1 |
| Torge, A | 1 |
| Wagner, S | 1 |
| Chaves, PS | 1 |
| Oliveira, EG | 1 |
| Guterres, SS | 1 |
| Pohlmann, AR | 1 |
| Titz, A | 1 |
| Schneider, M | 1 |
| Beck, RCR | 1 |
| Papich, MG | 2 |
| Tadesse, BT | 1 |
| Ashley, EA | 1 |
| Ongarello, S | 1 |
| Havumaki, J | 1 |
| Wijegoonewardena, M | 1 |
| González, IJ | 1 |
| Dittrich, S | 1 |
| Copeland, V | 1 |
| McLaughlin, M | 1 |
| Trifilio, S | 1 |
| Mo, S | 1 |
| Bendtsen, F | 1 |
| Wiese, SS | 1 |
| Kimer, N | 1 |
| Ahmed, A | 1 |
| Boateng, J | 1 |
| Conley, ZC | 1 |
| Bodine, TJ | 1 |
| Chou, A | 1 |
| Zechiedrich, L | 1 |
| Kooti, M | 1 |
| Sedeh, AN | 1 |
| Rezatofighi, SE | 1 |
| Sivik, JM | 1 |
| Davidson, J | 1 |
| Hale, CM | 1 |
| Drabick, JJ | 1 |
| Talamo, G | 1 |
| Son, KC | 1 |
| Chung, HS | 1 |
| Jung, SI | 1 |
| Kim, MS | 1 |
| Hwang, EC | 1 |
| Kim, JW | 3 |
| Kwon, DD | 1 |
| Wells, CM | 1 |
| Beenken, KE | 1 |
| Smeltzer, MS | 1 |
| Courtney, HS | 1 |
| Jennings, JA | 1 |
| Haggard, WO | 1 |
| Lee, YR | 1 |
| Jang, JY | 1 |
| Naqvi, SAR | 1 |
| Roohi, S | 1 |
| Iqbal, A | 1 |
| Sherazi, TA | 1 |
| Zahoor, AF | 1 |
| Imran, M | 1 |
| Gao, Y | 1 |
| Na, LX | 1 |
| Zhang, S | 1 |
| Wang, AP | 1 |
| Lü, K | 1 |
| Guo, HY | 1 |
| Liu, ML | 1 |
| Wang, M | 1 |
| Fang, K | 1 |
| Hong, SMC | 1 |
| Kim, I | 1 |
| Jang, IS | 1 |
| Hong, SH | 1 |
| Mengist, A | 1 |
| Mengistu, G | 1 |
| Reta, A | 1 |
| Arruda, MEF | 1 |
| Neves, MAS | 1 |
| Diogenes, A | 1 |
| Mdala, I | 1 |
| Guilherme, BPS | 1 |
| Siqueira, JF | 1 |
| Rôças, IN | 1 |
| Zavrelova, A | 1 |
| Paterova, P | 1 |
| Gabalec, F | 1 |
| Zak, P | 1 |
| Radocha, J | 1 |
| Liu, J | 2 |
| Yang, W | 1 |
| Tao, B | 1 |
| Shen, T | 1 |
| He, Y | 1 |
| Shen, X | 1 |
| Cai, K | 1 |
| Khorshidi, S | 1 |
| Karkhaneh, A | 1 |
| Farhangi, M | 1 |
| Mahboubi, A | 1 |
| Kobarfard, F | 1 |
| Vatanara, A | 1 |
| Mortazavi, SA | 1 |
| Sisay, M | 1 |
| Ataro, Z | 1 |
| Marami, D | 1 |
| Mitiku, H | 1 |
| Motbaynor, B | 1 |
| Teklemariam, Z | 1 |
| Farag, M | 1 |
| Riddell, S | 1 |
| Daffy, J | 1 |
| Wong, LM | 1 |
| Park, KH | 1 |
| Kim, DY | 1 |
| Lee, YM | 1 |
| Lee, MS | 1 |
| Kang, KC | 1 |
| Lee, JH | 4 |
| Moon, C | 1 |
| Chong, YP | 1 |
| Kim, SH | 1 |
| Lee, SO | 1 |
| Choi, SH | 1 |
| Woo, JH | 1 |
| Ryu, BH | 1 |
| Bae, IG | 1 |
| Cho, OH | 1 |
| Smart, A | 1 |
| de Lacy Costello, B | 1 |
| White, P | 1 |
| Avison, M | 1 |
| Batty, C | 1 |
| Turner, C | 1 |
| Persad, R | 1 |
| Ratcliffe, N | 1 |
| Lundin, MS | 1 |
| Chintu, MR | 1 |
| Wang, W | 2 |
| Yang, J | 1 |
| Liu, C | 1 |
| Song, P | 1 |
| Xu, H | 1 |
| Xia, X | 1 |
| Meng, J | 1 |
| Cao, L | 1 |
| Li, Y | 1 |
| Deng, P | 1 |
| Pan, P | 1 |
| Hu, C | 1 |
| Molla, R | 1 |
| Tiruneh, M | 1 |
| Abebe, W | 1 |
| Moges, F | 1 |
| Vinnitskaia, EV | 1 |
| Drozdov, VN | 1 |
| Petyrakov, AV | 1 |
| Sil'vestrova, SIu | 1 |
| Brezgin, AG | 1 |
| Fukumoto, R | 1 |
| Cary, LH | 1 |
| Gorbunov, NV | 1 |
| Lombardini, ED | 1 |
| Elliott, TB | 1 |
| Kiang, JG | 1 |
| Vlieghe, ER | 1 |
| Phe, T | 1 |
| De Smet, B | 1 |
| Veng, HC | 1 |
| Kham, C | 1 |
| Lim, K | 1 |
| Koole, O | 1 |
| Lynen, L | 1 |
| Peetermans, WE | 1 |
| Jacobs, JA | 1 |
| Shimizu, T | 2 |
| Harada, K | 1 |
| Kataoka, Y | 1 |
| Wojciechowski, D | 1 |
| Chandran, S | 1 |
| Yang, ZT | 1 |
| Zahar, JR | 2 |
| Méchaï, F | 1 |
| Postaire, M | 1 |
| Blanot, S | 1 |
| Balfagon-Viel, S | 1 |
| Nassif, X | 1 |
| Lortholary, O | 1 |
| Liss, MA | 1 |
| Nakamura, KK | 1 |
| Meuleners, R | 1 |
| Kolla, SB | 1 |
| Dash, A | 1 |
| Peterson, EM | 1 |
| Loeb, S | 3 |
| Anastasiadis, A | 1 |
| Zapała, L | 1 |
| Cordeiro, E | 1 |
| Antoniewicz, A | 1 |
| Dimitriadis, G | 1 |
| De Reijke, T | 1 |
| Carrington, S | 1 |
| Cohall, DH | 1 |
| Gossell-Williams, M | 1 |
| Lindo, JF | 1 |
| Kamangar, F | 1 |
| Berger, TG | 1 |
| Fazel, N | 1 |
| Koo, JY | 1 |
| de Vries, MG | 1 |
| Ekkelenkamp, MB | 1 |
| Peters, EJ | 1 |
| De Rosa, FG | 1 |
| Motta, I | 1 |
| Audisio, E | 1 |
| Frairia, C | 1 |
| Busca, A | 1 |
| Di Perri, G | 1 |
| Marmont, F | 1 |
| Tai, KP | 1 |
| Kamdar, K | 1 |
| Yamaki, J | 1 |
| Le, VV | 1 |
| Tran, D | 1 |
| Tran, P | 1 |
| Selsted, ME | 1 |
| Ouellette, AJ | 1 |
| Wong-Beringer, A | 1 |
| Lee, SH | 2 |
| Teo, J | 1 |
| Heng, D | 1 |
| Zhao, Y | 1 |
| Ng, WK | 1 |
| Chan, HK | 1 |
| Tan, RB | 1 |
| Bergmann, PA | 1 |
| Mauss, KL | 1 |
| Liodaki, ME | 1 |
| Mailänder, P | 1 |
| Siemers, F | 1 |
| Stang, F | 1 |
| Lee, YY | 1 |
| Tee, HP | 1 |
| Mahadeva, S | 1 |
| Richardson, WL | 1 |
| Hammert, WC | 1 |
| Inaba, H | 1 |
| Gaur, AH | 1 |
| Cao, X | 1 |
| Flynn, PM | 1 |
| Pounds, SB | 1 |
| Avutu, V | 1 |
| Marszal, LN | 1 |
| Howard, SC | 1 |
| Pui, CH | 1 |
| Ribeiro, RC | 1 |
| Hayden, RT | 1 |
| Rubnitz, JE | 1 |
| Zordok, WA | 1 |
| Sung, HY | 1 |
| Kim, JI | 1 |
| Lee, HJ | 1 |
| Cho, HJ | 1 |
| Cheung, DY | 1 |
| Kim, SS | 1 |
| Cho, SH | 1 |
| Kim, JK | 1 |
| Ascioglu, S | 1 |
| Samore, MH | 1 |
| Lipsitch, M | 1 |
| Heidari Bateni, Z | 1 |
| Shahrokh, H | 1 |
| Salimi, H | 1 |
| Safari, H | 1 |
| Tabatabai, M | 1 |
| Saedi, D | 1 |
| Wijnands, TF | 1 |
| Lantinga, MA | 1 |
| Drenth, JP | 1 |
| Luong, B | 1 |
| Danforth, T | 1 |
| Visnjevac, O | 1 |
| Suraf, M | 1 |
| Duff, M | 1 |
| Chevli, KK | 1 |
| Unwala, DJ | 1 |
| Mayer, K | 1 |
| Hahn-Ast, C | 1 |
| Mückter, S | 1 |
| Schmitz, A | 2 |
| Krause, S | 1 |
| Felder, L | 1 |
| Bekeredjian-Ding, I | 1 |
| Molitor, E | 1 |
| Brossart, P | 1 |
| von Lilienfeld-Toal, M | 1 |
| Park, SH | 1 |
| Ryu, JK | 2 |
| Choo, GY | 1 |
| Chung, YG | 1 |
| Seong, DH | 1 |
| Kim, CH | 1 |
| Choe, WS | 1 |
| Ryu, DS | 1 |
| Hyun, IY | 1 |
| Suh, JK | 3 |
| Unnikrishnan, R | 1 |
| El-Shafei, A | 1 |
| Klein, EA | 1 |
| Jones, JS | 1 |
| Kartha, G | 1 |
| Goldman, HB | 1 |
| Bhattacharya, S | 1 |
| Goel, G | 1 |
| Mukherjee, S | 1 |
| Bhaumik, J | 1 |
| Chandy, M | 1 |
| Shotwell, MS | 1 |
| Madonia, PN | 1 |
| Connor, MJ | 1 |
| Amde, M | 1 |
| Salem, C | 1 |
| Aduroja, OA | 1 |
| Bauer, SR | 1 |
| Groszek, JJ | 1 |
| Fissell, WH | 1 |
| Baelo, A | 1 |
| Levato, R | 1 |
| Julián, E | 1 |
| Crespo, A | 1 |
| Astola, J | 1 |
| Gavaldà, J | 1 |
| Engel, E | 1 |
| Mateos-Timoneda, MA | 1 |
| Torrents, E | 1 |
| Baum, CR | 1 |
| Thornton, MD | 1 |
| Mondragón-Cardona, A | 1 |
| Jiménez-Canizales, CE | 1 |
| Alzate-Carvajal, V | 1 |
| Bastidas-Rivera, F | 1 |
| Sepúlveda-Arias, JC | 1 |
| Schröder, S | 1 |
| Abdel-Aziz, T | 1 |
| Lehmann, M | 1 |
| Ebmeyer, J | 1 |
| Sudhoff, H | 1 |
| Raman, JD | 1 |
| Lehman, KK | 1 |
| Dewan, K | 1 |
| Kirimanjeswara, G | 1 |
| Lübbert, C | 1 |
| Satpati, D | 1 |
| Arjun, C | 1 |
| Krishnamohan, R | 1 |
| Samuel, G | 1 |
| Banerjee, S | 1 |
| Li, M | 1 |
| Neoh, KG | 1 |
| Xu, L | 1 |
| Yuan, L | 1 |
| Leong, DT | 1 |
| Kang, ET | 1 |
| Chua, KL | 1 |
| Hsu, LY | 1 |
| Afriyie, DK | 1 |
| Gyansa-Lutterodt, M | 1 |
| Amponsah, SK | 1 |
| Asare, G | 1 |
| Wiredu, V | 1 |
| Wormenor, E | 1 |
| Bugyei, KA | 1 |
| Hallböök, H | 1 |
| Lidström, AK | 1 |
| Pauksens, K | 1 |
| Stefan, CP | 1 |
| Koehler, JW | 1 |
| Minogue, TD | 1 |
| Pohlen, M | 1 |
| Marx, J | 1 |
| Mellmann, A | 1 |
| Becker, K | 1 |
| Mesters, RM | 1 |
| Mikesch, JH | 1 |
| Schliemann, C | 1 |
| Lenz, G | 1 |
| Müller-Tidow, C | 1 |
| Büchner, T | 1 |
| Krug, U | 1 |
| Stelljes, M | 1 |
| Karch, H | 1 |
| Peters, G | 1 |
| Gerth, HU | 1 |
| Görlich, D | 1 |
| Berdel, WE | 1 |
| Lee, Y | 1 |
| Lee, DG | 2 |
| Yoo, KH | 1 |
| Lutz, P | 1 |
| Nischalke, HD | 1 |
| Krämer, B | 1 |
| Goeser, F | 1 |
| Kaczmarek, DJ | 1 |
| Schlabe, S | 1 |
| Parcina, M | 1 |
| Nattermann, J | 1 |
| Hoerauf, A | 1 |
| Strassburg, CP | 1 |
| Spengler, U | 1 |
| Babu Rajendran, N | 1 |
| Gladstone, BP | 1 |
| Rodríguez-Baño, J | 1 |
| Sifakis, F | 1 |
| Voss, A | 1 |
| Carmeli, Y | 1 |
| Burkert, FR | 1 |
| Gkolia, P | 1 |
| Tacconelli, E | 2 |
| Al Omar, S | 1 |
| Anabtawi, N | 1 |
| Al Qasem, W | 1 |
| Rihani, R | 1 |
| Eruz, ED | 1 |
| Yalci, A | 1 |
| Ozden, E | 1 |
| Aslaner, H | 1 |
| Ogucu-Durgun, S | 1 |
| Koseoglu-Taymur, DD | 1 |
| Memikoglu, KO | 1 |
| Erdem, H | 1 |
| Kurt, H | 1 |
| Catal, F | 1 |
| Bavbek, N | 1 |
| Bayrak, O | 1 |
| Karabel, M | 1 |
| Karabel, D | 1 |
| Odemis, E | 1 |
| Uz, E | 1 |
| Pea, F | 2 |
| Işeri, L | 1 |
| Bayraktar, MR | 1 |
| Farhat, H | 1 |
| Chachaty, E | 1 |
| Antoun, S | 1 |
| Nitenberg, G | 1 |
| Singh, B | 1 |
| Sunil, HV | 1 |
| Sharma, S | 1 |
| Prasad, V | 1 |
| Kashyap, R | 1 |
| Bhattacharya, A | 1 |
| Mittal, BR | 1 |
| Taneja, A | 1 |
| Rai, R | 1 |
| Goni, VG | 1 |
| Aggarwal, S | 1 |
| Gill, SS | 1 |
| Bhatnagar, A | 2 |
| Singh, AK | 1 |
| Gendrel, D | 1 |
| Cohen, R | 1 |
| Ngure, RM | 1 |
| Eckersall, PD | 2 |
| Mungatana, NK | 1 |
| Mburu, JN | 1 |
| Jennings, FW | 2 |
| Burke, J | 2 |
| Murray, M | 2 |
| Yamaguchi, K | 2 |
| Ishii, Y | 2 |
| Yamanaka, K | 2 |
| Watanabe, N | 2 |
| Uehara, N | 2 |
| Kaku, M | 2 |
| Okabe, T | 1 |
| Ito, K | 1 |
| Nagasawa, M | 1 |
| Baba, H | 1 |
| Ichiyama, S | 2 |
| Kurokawa, Y | 2 |
| Negayama, K | 1 |
| Hirakata, Y | 2 |
| Metallidis, S | 1 |
| Kollaras, P | 1 |
| Giannakakis, T | 1 |
| Seitanidis, B | 1 |
| Kordosis, T | 1 |
| Nikolaidis, J | 1 |
| Hatzitolios, A | 1 |
| Nikolaidis, P | 3 |
| Elborn, JS | 1 |
| Hodson, M | 1 |
| Bertram, C | 1 |
| Tazuma, S | 1 |
| Igarashi, Y | 1 |
| Tsuyuguchi, T | 1 |
| Ohara, H | 1 |
| Inui, K | 1 |
| Ohya, T | 1 |
| Pucar, D | 1 |
| Janković, Z | 1 |
| Dugonjić, S | 1 |
| Popović, Z | 1 |
| Diec, J | 1 |
| Carnt, N | 1 |
| Tilia, D | 1 |
| Evans, V | 1 |
| Rao, V | 1 |
| Ozkan, J | 1 |
| Holden, BA | 1 |
| Ngure, R | 1 |
| Mbai, FN | 1 |
| Núñez Otero, V | 1 |
| Limeres Posse, J | 1 |
| Carmona, IT | 1 |
| Diz Dios, P | 1 |
| De Angelis, G | 1 |
| Cataldo, MA | 1 |
| Mantengoli, E | 1 |
| Spanu, T | 1 |
| Pan, A | 1 |
| Corti, G | 1 |
| Radice, A | 1 |
| Stolzuoli, L | 1 |
| Antinori, S | 1 |
| Paradisi, F | 1 |
| Carosi, G | 1 |
| Bernabei, R | 1 |
| Antonelli, M | 1 |
| Fadda, G | 1 |
| Rossolini, GM | 1 |
| Cauda, R | 1 |
| Zhang, H | 1 |
| Jiang, NY | 1 |
| Zhu, L | 1 |
| Hanken, I | 1 |
| Schimmer, M | 1 |
| Sander, CA | 1 |
| Kaguelidou, F | 1 |
| Turner, MA | 1 |
| Choonara, I | 1 |
| Jacqz-Aigrain, E | 1 |
| Sachin, K | 1 |
| Kim, EM | 1 |
| Cheong, SJ | 1 |
| Jeong, HJ | 1 |
| Lim, ST | 1 |
| Sohn, MH | 1 |
| Kim, DW | 2 |
| Fusconi, M | 1 |
| Chiarini, F | 1 |
| Taddei, AR | 1 |
| De Virgilio, A | 1 |
| Gallinelli, C | 1 |
| Conte, M | 1 |
| De Vincentiis, M | 1 |
| Fukui, H | 1 |
| Kim, HJ | 2 |
| Park, JH | 1 |
| Park, DI | 1 |
| Cho, YK | 1 |
| Sohn, CI | 1 |
| Jeon, WK | 1 |
| Kim, DJ | 1 |
| San-Juan, R | 1 |
| Aguado, JM | 1 |
| Lumbreras, C | 1 |
| Fortun, J | 1 |
| Len, O | 1 |
| Munoz, P | 1 |
| Montejo, M | 1 |
| Moreno, A | 1 |
| Cordero, E | 1 |
| Blanes, M | 1 |
| Ramos, A | 2 |
| Torre-Cisneros, J | 1 |
| López-Medrano, F | 1 |
| Carratala, J | 1 |
| Moreno, E | 1 |
| Saul, JM | 1 |
| Ellenburg, MD | 1 |
| de Guzman, RC | 1 |
| Van Dyke, M | 1 |
| Magri, V | 2 |
| Montanari, E | 1 |
| Škerk, V | 1 |
| Markotić, A | 1 |
| Marras, E | 2 |
| Restelli, A | 1 |
| Naber, KG | 6 |
| Perletti, G | 2 |
| Ismail, M | 1 |
| Saini, A | 1 |
| Nigam, R | 1 |
| Sideri, G | 1 |
| Kafetzis, DA | 1 |
| Vouloumanou, EK | 1 |
| Papadatos, JH | 1 |
| Papadimitriou, M | 1 |
| Falagas, ME | 3 |
| Sinkó, J | 1 |
| Kusachi, S | 1 |
| Sumiyama, Y | 1 |
| Takahashi, Y | 2 |
| Kato, K | 1 |
| Mashita, K | 1 |
| Takeyama, H | 1 |
| Oda, S | 2 |
| Kobayashi, S | 1 |
| Kloskowski, T | 1 |
| Gurtowska, N | 1 |
| Bajek, A | 1 |
| Drewa, T | 1 |
| Selvaraj, N | 1 |
| Lakshmanan, B | 1 |
| Mazumder, PM | 1 |
| Karuppasamy, M | 1 |
| Jena, SS | 1 |
| Pattnaik, AK | 1 |
| Roe, JL | 1 |
| Fuentes, JM | 1 |
| Mullins, ME | 1 |
| Hassan, S | 1 |
| Abbass, K | 1 |
| Markert, R | 1 |
| Akram, S | 1 |
| van den Heuvel, S | 1 |
| Bangma, CH | 1 |
| Schröder, FH | 1 |
| Roobol, MJ | 1 |
| Fadli, M | 1 |
| Saad, A | 1 |
| Sayadi, S | 1 |
| Chevalier, J | 1 |
| Mezrioui, NE | 1 |
| Pagès, JM | 1 |
| Hassani, L | 1 |
| Masadeh, MM | 1 |
| Mhaidat, NM | 1 |
| Alzoubi, KH | 1 |
| Al-Azzam, SI | 1 |
| Shaweesh, AI | 1 |
| Saribas, Z | 1 |
| Ergun, H | 1 |
| Mamuk, S | 1 |
| Köseoglu-Eser, O | 1 |
| Melli, M | 1 |
| Yazdi, HR | 1 |
| Shirazi, MR | 1 |
| Hoseini, MG | 1 |
| Masdari, Z | 1 |
| Caramia, G | 1 |
| Ruffini, E | 1 |
| Ignatavicius, P | 1 |
| Vitkauskiene, A | 1 |
| Pundzius, J | 1 |
| Dambrauskas, Z | 1 |
| Barauskas, G | 1 |
| Gil-Vernet Sedo, JM | 1 |
| Alvarez-Vijande García, R | 1 |
| Lema, T | 1 |
| Woldeamanuel, Y | 1 |
| Asrat, D | 1 |
| Hunegnaw, M | 1 |
| Baraki, A | 1 |
| Kebede, Y | 1 |
| Yamuah, L | 1 |
| Aseffa, A | 1 |
| Vesole, DH | 1 |
| Oken, MM | 1 |
| Heckler, C | 1 |
| Greipp, PR | 1 |
| Katz, MS | 1 |
| Jacobus, S | 1 |
| Morrow, GR | 1 |
| Velasco-Loera, N | 1 |
| De Alba-Vazquez, Y | 1 |
| Garrocho-Rangel, A | 1 |
| Gonzalez-Amaro, AM | 1 |
| Flores-Reyes, H | 1 |
| Pozos-Guillen, AJ | 1 |
| Gharibi, O | 1 |
| Zangene, S | 1 |
| Mohammadi, N | 1 |
| Mirzaei, K | 1 |
| Karimi, A | 1 |
| Gharibi, A | 1 |
| Khajehiean, A | 1 |
| Palou, J | 2 |
| Angulo, JC | 1 |
| Ramón de Fata, F | 1 |
| García-Tello, A | 1 |
| González-Enguita, C | 1 |
| Boada, A | 1 |
| Sanz, M | 1 |
| Rodríguez Collar, TL | 1 |
| Valdés Estévez, B | 1 |
| Nuñez Roca, A | 1 |
| Germán Meliz, JL | 1 |
| Dancer, SJ | 1 |
| Kirkpatrick, P | 1 |
| Corcoran, DS | 1 |
| Christison, F | 1 |
| Farmer, D | 1 |
| Robertson, C | 1 |
| Ohki, E | 1 |
| Yamagishi, Y | 1 |
| Mikamo, H | 1 |
| Atlas, RM | 1 |
| Kurzer, E | 1 |
| Kaplan, S | 1 |
| Das, SS | 6 |
| Wareham, DW | 3 |
| Britton, KE | 8 |
| Solanki, KK | 4 |
| Amaral, H | 1 |
| Katamihardja, AH | 1 |
| Malamitsi, J | 2 |
| Moustafa, HM | 1 |
| Soroa, VE | 1 |
| Sundram, FX | 2 |
| Padhy, AK | 1 |
| Cormio, L | 1 |
| Berardi, B | 1 |
| Callea, A | 1 |
| Fiorentino, N | 1 |
| Sblendorio, D | 1 |
| Zizzi, V | 1 |
| Traficante, A | 1 |
| Behra-Miellet, J | 1 |
| Dubreuil, L | 1 |
| Jumas-Bilak, E | 1 |
| Hong, SN | 1 |
| Kim, BJ | 1 |
| Lee, SY | 1 |
| Lee, CY | 1 |
| Ryu, MK | 1 |
| Choi, MS | 1 |
| Rhee, PL | 1 |
| Koh, KC | 1 |
| Kim, JJ | 1 |
| Paik, SW | 1 |
| Rhee, JC | 1 |
| Choi, KW | 1 |
| Starakis, I | 1 |
| Karravias, D | 1 |
| Asimakopoulos, C | 1 |
| Kolaras, P | 1 |
| Harlaftis, N | 1 |
| Skoutelis, A | 1 |
| Bassaris, H | 2 |
| Minenko, SV | 1 |
| Dmitrieva, NV | 1 |
| Chimishkian, KL | 1 |
| Zhukov, NV | 1 |
| Sokolova, EN | 1 |
| Larionova, VB | 1 |
| Ptushkin, VV | 1 |
| Sauter, C | 1 |
| Blum, S | 1 |
| Matsuzaki, K | 2 |
| Watabe, E | 1 |
| Yoshimori, K | 1 |
| Shikano, M | 1 |
| Sato, Y | 2 |
| Hasegawa, M | 2 |
| Kobayashi, I | 2 |
| Wakefield, MC | 1 |
| Kan, VL | 1 |
| Weiswasser, J | 1 |
| Sidawy, AN | 1 |
| Horcajada, JP | 2 |
| Vilana, R | 1 |
| Moreno-Martínez, A | 1 |
| Alvarez-Vijande, R | 1 |
| Bru, C | 1 |
| Bargalló, X | 1 |
| Buñesch, L | 1 |
| Martínez, JA | 1 |
| Mensa, J | 1 |
| Mateos, JJ | 1 |
| Lomena, F | 1 |
| Velasco, M | 1 |
| Ortega, M | 1 |
| Fuertes, S | 1 |
| Pons, F | 1 |
| Akyol, S | 1 |
| Mas, MR | 2 |
| Comert, B | 2 |
| Ateskan, U | 2 |
| Yasar, M | 2 |
| Aydogan, H | 1 |
| Deveci, S | 1 |
| Akay, C | 1 |
| Mas, N | 2 |
| Yener, N | 2 |
| Kocar, IH | 1 |
| Larikka, MJ | 2 |
| Ahonen, AK | 2 |
| Niemelä, O | 2 |
| Junila, JA | 2 |
| Hämäläinen, MM | 2 |
| Syrjälä, HP | 2 |
| Piddock, LJ | 1 |
| Johnson, MM | 1 |
| Webber, MA | 1 |
| Lee, SM | 1 |
| Seong, DW | 1 |
| Kim, S | 2 |
| Choe, W | 2 |
| Moon, Y | 1 |
| Pai, SH | 1 |
| Bundrick, W | 1 |
| Heron, SP | 1 |
| Ray, P | 1 |
| Schiff, WM | 1 |
| Tennenberg, AM | 2 |
| Wiesinger, BA | 1 |
| Wright, PA | 1 |
| Wu, SC | 2 |
| Zadeikis, N | 1 |
| Kahn, JB | 2 |
| Kadurugamuwa, JL | 1 |
| Sin, LV | 1 |
| Yu, J | 1 |
| Francis, KP | 1 |
| Kimura, R | 1 |
| Purchio, T | 1 |
| Contag, PR | 1 |
| Cinar, E | 1 |
| Baysan, A | 1 |
| Ozyurt, M | 1 |
| Ozkomur, E | 1 |
| Altinatmaz, K | 1 |
| Philpott-Howard, J | 1 |
| Burroughs, A | 1 |
| Fisher, N | 1 |
| Hastings, M | 1 |
| Kibbler, C | 1 |
| Mutimer, D | 1 |
| Patch, D | 1 |
| Rolando, N | 1 |
| Wade, J | 1 |
| Wendon, J | 1 |
| O'Grady, J | 1 |
| Castiglione, F | 1 |
| Rispo, A | 1 |
| Di Girolamo, E | 1 |
| Cozzolino, A | 1 |
| Manguso, F | 1 |
| Grassia, R | 1 |
| Mazzacca, G | 1 |
| Mullen, CA | 2 |
| Takushige, T | 1 |
| Cruz, EV | 1 |
| Asgor Moral, A | 1 |
| Hoshino, E | 1 |
| Artiko, V | 2 |
| Obradović, V | 2 |
| Davidović, B | 2 |
| Petrović, M | 1 |
| Nikolić, N | 2 |
| Petrović, N | 2 |
| Vlajković, M | 1 |
| Matić, S | 1 |
| Kecmanović, D | 1 |
| Bosnjaković, V | 2 |
| Milovanović, V | 1 |
| Iinuma, Y | 1 |
| Hayashi, M | 1 |
| Bartnicki, A | 1 |
| Bischoff, W | 1 |
| Hanus, M | 1 |
| Milutinovic, S | 1 |
| van Belle, F | 1 |
| Schönwald, S | 3 |
| Weitz, P | 2 |
| Ankel-Fuchs, D | 2 |
| Talan, DA | 1 |
| Elkharrat, D | 1 |
| Cometta, A | 2 |
| Kern, W | 1 |
| Harnett, SJ | 1 |
| Fraise, AP | 2 |
| Andrews, JM | 3 |
| Jevons, G | 1 |
| Brenwald, NP | 2 |
| Wise, R | 3 |
| Gemmel, F | 1 |
| De Winter, F | 2 |
| Van Laere, K | 1 |
| Vogelaers, D | 1 |
| Uyttendaele, D | 1 |
| Dierckx, RA | 2 |
| Allin, DM | 1 |
| Clarysse, L | 1 |
| Haworth, DA | 1 |
| James, IG | 1 |
| Raini, C | 1 |
| Schneider, H | 1 |
| Wall, A | 1 |
| Hopkins, G | 1 |
| Sable, D | 1 |
| Murakawa, GJ | 1 |
| Lobmann, R | 1 |
| Ambrosch, A | 1 |
| Seewald, M | 1 |
| Dietlein, M | 1 |
| Zink, K | 1 |
| Kullmann, KH | 1 |
| Lehnert, H | 1 |
| Oyen, WJ | 1 |
| Corstens, FH | 1 |
| Boerman, OC | 1 |
| Cárcamo, C | 1 |
| Hooton, T | 1 |
| Wener, MH | 1 |
| Weiss, NS | 1 |
| Gilman, R | 1 |
| Arevalo, J | 1 |
| Carrasco, J | 1 |
| Seas, C | 1 |
| Caballero, M | 1 |
| Holmes, KK | 1 |
| Aubert, G | 1 |
| Carricajo, A | 1 |
| Vautrin, AC | 1 |
| Guyomarc'h, S | 1 |
| Fonsale, N | 1 |
| Page, D | 1 |
| Brunel, P | 1 |
| Rusch, P | 1 |
| Zéni, F | 1 |
| Langer, O | 1 |
| Brunner, M | 2 |
| Zeitlinger, M | 1 |
| Ziegler, S | 1 |
| Müller, U | 1 |
| Dobrozemsky, G | 1 |
| Lackner, E | 1 |
| Joukhadar, C | 2 |
| Mitterhauser, M | 1 |
| Wadsak, W | 1 |
| Minar, E | 2 |
| Dudczak, R | 1 |
| Kletter, K | 1 |
| Müller, M | 2 |
| Bezrukova, IV | 1 |
| Dmitrieva, NA | 1 |
| Gerchikov, LN | 1 |
| Meyer, E | 1 |
| Schwab, F | 1 |
| Jonas, D | 1 |
| Ruden, H | 1 |
| Gastmeier, P | 1 |
| Daschner, FD | 1 |
| Kamble, R | 1 |
| Pant, S | 1 |
| Selby, GB | 1 |
| Kharfan-Dabaja, MA | 1 |
| Sethi, S | 1 |
| Kratochvil, K | 1 |
| Kohrt, N | 1 |
| Ozer, H | 1 |
| Schaeffer, AJ | 2 |
| Gous, A | 1 |
| Lipman, J | 1 |
| Scribante, J | 1 |
| Tshukutsoane, S | 1 |
| Hon, H | 1 |
| Pinder, M | 1 |
| Mathivha, R | 1 |
| Verhoef, L | 1 |
| Stass, H | 1 |
| Perrin-Guyomard, A | 1 |
| Poul, JM | 1 |
| Corpet, DE | 1 |
| Sanders, P | 1 |
| Fernández, AH | 1 |
| Bartholomew, M | 1 |
| Terzi, C | 1 |
| Kiliç, D | 1 |
| Unek, T | 1 |
| Hoşgörler, F | 1 |
| Füzün, M | 1 |
| Ergör, G | 1 |
| Phaneuf, MD | 2 |
| Bide, MJ | 2 |
| Hannel, SL | 1 |
| Platek, MJ | 1 |
| Monahan, TS | 1 |
| Contreras, MA | 1 |
| Phaneuf, TM | 1 |
| LoGerfo, FW | 2 |
| West, RL | 1 |
| Van der Woude, CJ | 1 |
| Endtz, HP | 1 |
| Hansen, BE | 1 |
| Ouwedijk, M | 1 |
| Boelens, HA | 1 |
| Kusters, JG | 1 |
| Kuipers, EJ | 1 |
| Rókusz, L | 1 |
| László, L | 1 |
| Iakovlev, VP | 3 |
| Blatun, LA | 1 |
| Terekhova, RP | 1 |
| Federspil, P | 1 |
| Koch, A | 1 |
| Tiesler, E | 1 |
| Peralta, S | 1 |
| Accursio, A | 1 |
| Filaci, G | 1 |
| Vitale, B | 1 |
| D'Aiello, G | 1 |
| Scarsi, C | 1 |
| Collura, D | 1 |
| Rini, GB | 1 |
| Bassaris, HP | 3 |
| Chrysanthopoulos, CJ | 3 |
| Skouelis, AT | 1 |
| Starakis, JC | 2 |
| Nemes, G | 1 |
| Heuser, Y | 1 |
| Stolle, D | 1 |
| Piroth, HD | 1 |
| Nemes, P | 1 |
| Esposito, S | 3 |
| Miniero, M | 1 |
| D'Errico, G | 1 |
| Montanaro, C | 1 |
| Giusti, G | 1 |
| Abbas, AM | 1 |
| Chandra, V | 1 |
| Dongaonkar, PP | 1 |
| Goel, PK | 1 |
| Kacker, P | 1 |
| Patel, NA | 1 |
| Shrivastava, OP | 1 |
| Thakkar, B | 1 |
| Tillotson, GS | 4 |
| Loendersloot, E | 1 |
| Branolte, JH | 1 |
| De Wilde, R | 2 |
| Kögler, J | 1 |
| Hancke, E | 1 |
| Marklein, G | 2 |
| Stark, GB | 1 |
| Vestweber, KH | 1 |
| Viell, B | 1 |
| Schaaf, S | 1 |
| Scholl, H | 2 |
| Vucetić, C | 1 |
| Lesić, A | 1 |
| Sudjić, V | 1 |
| Marinković, V | 1 |
| Valotassiou, VJ | 1 |
| Papadouli, D | 1 |
| Papadopoulos, A | 1 |
| Olapade-Olaopa, EO | 1 |
| Adebayo, SA | 1 |
| Valdevenito, JP | 1 |
| Valdevenito, R | 1 |
| Gómez, A | 1 |
| Russo, M | 1 |
| Poz, D | 1 |
| Viale, P | 1 |
| Pavan, F | 1 |
| Furlanut, M | 1 |
| Lindstedt, S | 1 |
| Lindström, U | 1 |
| Ljunggren, E | 1 |
| Wullt, B | 1 |
| Grabe, M | 2 |
| Taylor, DN | 1 |
| Bourgeois, AL | 1 |
| Ericsson, CD | 1 |
| Steffen, R | 1 |
| Jiang, ZD | 1 |
| Halpern, J | 1 |
| Haake, R | 1 |
| Dupont, HL | 1 |
| Song, JY | 1 |
| Park, CW | 1 |
| Sohn, JW | 1 |
| Kim, WJ | 1 |
| Kim, MJ | 1 |
| Cheong, HJ | 1 |
| Matthaiou, DK | 1 |
| Peppas, G | 1 |
| Bliziotis, IA | 1 |
| Wacha, H | 1 |
| Warren, B | 1 |
| Yüksel, S | 1 |
| Oztürk, B | 1 |
| Kavaz, A | 1 |
| Ozçakar, ZB | 1 |
| Acar, B | 1 |
| Güriz, H | 1 |
| Aysev, D | 1 |
| Ekim, M | 1 |
| Yalçinkaya, F | 1 |
| Patel, SM | 1 |
| Saravolatz, LD | 2 |
| Koch, H | 1 |
| Landen, H | 1 |
| Stauch, K | 1 |
| Altraja, A | 1 |
| Naaber, P | 1 |
| Tamm, E | 1 |
| Meriste, S | 1 |
| Kullamaa, A | 1 |
| Leesik, H | 1 |
| Catero, M | 1 |
| Ivanov, DV | 1 |
| Budanov, SV | 1 |
| Papp, M | 1 |
| Farkas, A | 1 |
| Udvardy, M | 1 |
| Tornai, I | 1 |
| Schwarz, M | 1 |
| Poch, B | 1 |
| Isenmann, R | 1 |
| Kriese, D | 1 |
| Rozdzinski, E | 1 |
| Beger, HG | 1 |
| Gansauge, F | 1 |
| Grobbel, M | 1 |
| Lübke-Becker, A | 1 |
| Wieler, LH | 1 |
| Froyman, R | 1 |
| Friederichs, S | 1 |
| Filios, S | 1 |
| Montorsi, F | 1 |
| Scattoni, V | 1 |
| Perroncel, R | 1 |
| Song, J | 1 |
| Haverstock, DC | 2 |
| Pertel, PE | 1 |
| Trinchieri, A | 1 |
| Ceriani, I | 1 |
| Sipsas, NV | 1 |
| Kosmas, C | 1 |
| Ziakas, PD | 1 |
| Karabelis, A | 1 |
| Vadiaka, M | 1 |
| Skopelitis, E | 1 |
| Kordossis, T | 1 |
| Tsavaris, N | 1 |
| Lansky, P | 1 |
| Sanda, P | 1 |
| Weiss, M | 1 |
| Zurbuchen, U | 1 |
| Ritz, JP | 1 |
| Lehmann, KS | 1 |
| Groene, J | 1 |
| Heidari, M | 1 |
| Buhr, HJ | 1 |
| Germer, CT | 1 |
| Terg, R | 1 |
| Fassio, E | 1 |
| Guevara, M | 1 |
| Cartier, M | 1 |
| Longo, C | 1 |
| Lucero, R | 1 |
| Landeira, C | 1 |
| Romero, G | 1 |
| Dominguez, N | 1 |
| Muñoz, A | 1 |
| Levi, D | 1 |
| Miguez, C | 1 |
| Abecasis, R | 1 |
| Zeiler, HJ | 1 |
| Grohe, K | 1 |
| Pohlod, DJ | 1 |
| Giamarellou, H | 2 |
| Efstratiou, A | 1 |
| Tsagarakis, J | 1 |
| Petrikkos, G | 1 |
| Daikos, GK | 1 |
| Eliopoulos, GM | 1 |
| Gardella, A | 1 |
| Moellering, RC | 1 |
| Khan, DM | 1 |
| Bhutta, ZA | 1 |
| Tutkun, A | 1 |
| Ozagar, A | 1 |
| Koç, A | 1 |
| Batman, C | 1 |
| Uneri, C | 1 |
| Sehitoglu, MA | 1 |
| Carlson, JW | 2 |
| Fowler, JM | 2 |
| Saltzman, AK | 1 |
| Carter, JR | 1 |
| Chen, MD | 1 |
| Mitchell, SK | 2 |
| Dunn, D | 1 |
| Carson, LF | 2 |
| Adcock, LL | 1 |
| Twiggs, LB | 1 |
| Rolachon, A | 1 |
| Cordier, L | 1 |
| Bacq, Y | 1 |
| Nousbaum, JB | 1 |
| Franza, A | 1 |
| Paris, JC | 1 |
| Fratte, S | 1 |
| Bohn, B | 1 |
| Kitmacher, P | 1 |
| Stahl, JP | 1 |
| Klesel, N | 1 |
| Geweniger, KH | 1 |
| Koletzki, P | 1 |
| Isert, D | 1 |
| Limbert, M | 1 |
| Markus, A | 1 |
| Riess, G | 1 |
| Schramm, H | 1 |
| Iyer, P | 1 |
| Ketley, NJ | 1 |
| Kelsey, SM | 6 |
| Newland, AC | 8 |
| Scaglione, F | 1 |
| Scamazzo, F | 1 |
| Arcidiacono, MM | 1 |
| Cogo, R | 1 |
| Monzani, GP | 1 |
| Fraschini, F | 1 |
| Maiche, AG | 1 |
| Muhonen, T | 1 |
| Datsenko, BM | 1 |
| Tamm, TI | 1 |
| Haraoka, M | 1 |
| Matsumoto, T | 1 |
| Takahashi, K | 1 |
| Kubo, S | 1 |
| Tanaka, M | 3 |
| Kumazawa, J | 1 |
| Murase, T | 1 |
| Alder, J | 1 |
| Clement, J | 1 |
| Meulbroek, J | 1 |
| Shipkowitz, N | 2 |
| Mitten, M | 1 |
| Jarvis, K | 1 |
| Oleksijew, A | 1 |
| Hutch, T | 1 |
| Paige, L | 1 |
| Flamm, B | 1 |
| Lew, MA | 2 |
| Kehoe, K | 2 |
| Ritz, J | 2 |
| Antman, KH | 2 |
| Nadler, L | 2 |
| Kalish, LA | 1 |
| Finberg, R | 2 |
| Kaminski, N | 1 |
| Bogomolski, V | 1 |
| Stalnikowicz, R | 1 |
| Legent, F | 2 |
| Bordure, P | 2 |
| Beauvillain, C | 2 |
| Berche, P | 2 |
| Fombeur, JP | 1 |
| Barrault, S | 1 |
| Koubbi, G | 1 |
| Laurier, JN | 1 |
| Ebbo, D | 1 |
| Lecomte, F | 1 |
| Sorrel, N | 1 |
| Dobler, S | 1 |
| Darouiche, RO | 1 |
| Smith, MS | 1 |
| Markowski, J | 1 |
| Gupta, BL | 1 |
| Singh, S | 1 |
| Rattan, A | 1 |
| Bhujwala, RA | 1 |
| Jiang, SC | 1 |
| Wang, XF | 1 |
| Miao, JZ | 1 |
| Lorian, V | 2 |
| Pavletich, K | 2 |
| Kumar, R | 1 |
| Anand, AC | 1 |
| Dham, SK | 1 |
| Caldwell, JB | 1 |
| Nilsen, AK | 1 |
| Thornsberry, C | 1 |
| Dekker, AW | 4 |
| Verdonck, LF | 1 |
| Rozenberg-Arska, M | 4 |
| Aldridge, KE | 1 |
| Counsell, R | 1 |
| Pratt, J | 1 |
| Williams, MV | 1 |
| Deguchi, K | 2 |
| Yokota, N | 1 |
| Koguchi, M | 1 |
| Suzuki, Y | 1 |
| Fukayama, S | 1 |
| Ishihara, R | 1 |
| Tanaka, S | 1 |
| Nakane, Y | 1 |
| Fukumoto, T | 1 |
| Jones, RN | 2 |
| Hoban, DJ | 1 |
| Dholakia, N | 1 |
| Rolston, KV | 9 |
| Ho, DH | 5 |
| LeBlanc, B | 5 |
| Bodey, GP | 8 |
| Usberti, M | 1 |
| Gazzotti, RM | 1 |
| Mileti, M | 1 |
| Brazzoli, A | 1 |
| Zucca, F | 1 |
| Depetri, G | 1 |
| Braga, B | 1 |
| Losio, R | 1 |
| D'Antonio, D | 2 |
| Piccolomini, R | 1 |
| Iacone, A | 1 |
| Fioritoni, G | 1 |
| Parruti, G | 1 |
| Betti, S | 1 |
| Quaglietta, AM | 1 |
| Accorsi, P | 1 |
| Dell'Isola, M | 1 |
| Favalli, C | 1 |
| Fischbach, F | 1 |
| Deckardt, R | 1 |
| Graeff, H | 1 |
| MacGowan, AP | 3 |
| White, LO | 2 |
| Brown, NM | 1 |
| Lovering, AM | 1 |
| McMullin, CM | 1 |
| Reeves, DS | 2 |
| López, A | 1 |
| Soler, JA | 1 |
| Juliá, A | 1 |
| Novo, A | 1 |
| Bueno, J | 1 |
| Gilbert, C | 1 |
| Meisenberg, B | 1 |
| Vredenburgh, J | 1 |
| Ross, M | 1 |
| Hussein, A | 1 |
| Perfect, J | 1 |
| Peters, WP | 1 |
| Jansen, J | 1 |
| Cromer, M | 1 |
| Akard, L | 1 |
| Black, JR | 1 |
| Wheat, LJ | 1 |
| Allen, SD | 2 |
| Quartieri, F | 1 |
| Bolognesi, S | 1 |
| Sconosciuto, F | 1 |
| Wiseman, LR | 2 |
| Balfour, JA | 3 |
| Ozaki, CK | 1 |
| Quist, WC | 1 |
| Alessi, JM | 1 |
| Ganz, H | 3 |
| Cooke, J | 1 |
| Cairns, CJ | 1 |
| Conner, S | 1 |
| Lewin, SK | 1 |
| Nicholls, J | 1 |
| Tredree, RL | 1 |
| Willis, JV | 1 |
| Hitchings, CR | 1 |
| Grekas, D | 1 |
| Thanos, V | 1 |
| Dioudis, C | 1 |
| Alivanis, P | 1 |
| Tourkantonis, A | 1 |
| Lobo, IM | 2 |
| Silva, NF | 1 |
| Assef, MC | 1 |
| Mangini, C | 1 |
| Silva, ML | 2 |
| Bortoletto, ML | 2 |
| Mendonça, JS | 2 |
| Levi, GC | 2 |
| Yamaguti, A | 1 |
| Trevisanello, C | 1 |
| Carvalho, MC | 1 |
| Brasil Filho, R | 1 |
| Malmborg, AS | 1 |
| Ahlén, S | 1 |
| Sollich, V | 1 |
| Klöditz, E | 1 |
| Schuster, R | 1 |
| Handrick, W | 1 |
| Brömme, S | 1 |
| Rumler, W | 1 |
| Patsch, R | 1 |
| Kharari, H | 1 |
| Spencker, FB | 1 |
| Fukuoka, Y | 1 |
| Ikeda, Y | 1 |
| Yamashiro, Y | 2 |
| Takahata, M | 2 |
| Todo, Y | 2 |
| Narita, H | 2 |
| Parks, DJ | 1 |
| Abrams, DA | 1 |
| Sarfarazi, FA | 1 |
| Katz, HR | 1 |
| García Rodríguez, JA | 1 |
| García Sánchez, JE | 1 |
| García García, MI | 1 |
| García Sánchez, E | 1 |
| Muñoz Bellido, JL | 1 |
| Ramos Macías, A | 1 |
| Rubenstein, EB | 1 |
| Rolston, K | 1 |
| Benjamin, RS | 1 |
| Loewy, J | 1 |
| Escalante, C | 1 |
| Manzullo, E | 1 |
| Hughes, P | 1 |
| Moreland, B | 1 |
| Fender, A | 1 |
| Kennedy, K | 1 |
| Fanci, R | 1 |
| Leoni, F | 1 |
| Bosi, A | 1 |
| Guidi, S | 1 |
| Ciolli, S | 1 |
| Longo, G | 1 |
| Donnini, E | 1 |
| Rossi Ferrini, P | 1 |
| Forrest, A | 1 |
| Nix, DE | 3 |
| Ballow, CH | 1 |
| Goss, TF | 1 |
| Birmingham, MC | 1 |
| Schentag, JJ | 5 |
| McArdle, CS | 1 |
| Morran, CG | 1 |
| Anderson, JR | 1 |
| Pettit, L | 1 |
| Gemmell, CG | 1 |
| Sleigh, JD | 1 |
| Mithöfer, K | 1 |
| Fernández-del Castillo, C | 1 |
| Ferraro, MJ | 1 |
| Lewandrowski, K | 1 |
| Rattner, DW | 1 |
| Warshaw, AL | 1 |
| Speirs, GE | 1 |
| Fenelon, LE | 1 |
| Speller, DC | 1 |
| Smyth, EG | 1 |
| Wilcox, MH | 1 |
| Cahana, Z | 1 |
| Gilboa, A | 1 |
| Raz, R | 3 |
| Speciale, A | 1 |
| Blandino, G | 1 |
| Caccamo, F | 1 |
| Serra, A | 1 |
| Oh, HM | 1 |
| Koh, WH | 1 |
| Boey, ML | 1 |
| Tack, KJ | 1 |
| McGuire, NM | 1 |
| Eiseman, IA | 1 |
| Vinjamuri, S | 3 |
| Hall, AV | 3 |
| Bomanji, J | 2 |
| Siraj, Q | 1 |
| O'Shaughnessy, E | 1 |
| Levy, MJ | 1 |
| DiPalma, JA | 1 |
| Masuda, N | 1 |
| Otsuki, M | 2 |
| Ibuki, E | 1 |
| Miyoshi, H | 1 |
| Nishino, T | 2 |
| Abdulla, AM | 1 |
| Beckebaum, S | 1 |
| Bircher, J | 1 |
| Gallenkamp, H | 1 |
| Bouza, P | 1 |
| García Falcón, T | 1 |
| Pérez Fontán, M | 1 |
| Rodríguez-Carmona, A | 1 |
| López Vázquez, M | 1 |
| Tresancos, C | 1 |
| Valdés, F | 1 |
| Puri, AS | 1 |
| Puri, J | 1 |
| Ghoshal, UC | 1 |
| Sharma, BC | 1 |
| Saraswat, VA | 1 |
| Ayyagari, A | 1 |
| Naik, SR | 1 |
| Patrick, CC | 1 |
| Green, S | 1 |
| Tillotson, G | 1 |
| Schierholz, JM | 1 |
| Rump, A | 1 |
| Pulverer, G | 1 |
| Ghosh, G | 1 |
| Chakraborty, S | 1 |
| Ray, J | 1 |
| Mukherjee, SK | 1 |
| Dorrian, I | 1 |
| Lee, RM | 1 |
| Eckhardt, A | 1 |
| Borner, K | 2 |
| Keller, F | 1 |
| Zellner, D | 1 |
| Sakamoto, M | 1 |
| Weber, A | 1 |
| Morlin, G | 1 |
| Cohen, M | 1 |
| Williams-Warren, J | 1 |
| Ramsey, B | 1 |
| Smith, A | 1 |
| Solanki, K | 3 |
| Siraj, QH | 1 |
| Das, S | 1 |
| Choi, KH | 2 |
| Hong, JS | 1 |
| Kim, SK | 1 |
| Lee, DK | 1 |
| Yoon, SJ | 1 |
| Choi, EC | 3 |
| Mayer, AR | 1 |
| Copeland, LJ | 1 |
| Leblanc, M | 1 |
| Gross, RD | 1 |
| Hoffman, RO | 1 |
| Lindsay, RN | 1 |
| Sidorenko, SV | 1 |
| Murphy, M | 1 |
| Brown, AE | 1 |
| Sepkowitz, KA | 1 |
| Bernard, EM | 1 |
| Kiehn, TE | 1 |
| Armstrong, D | 1 |
| Kim, JH | 2 |
| Kang, JA | 1 |
| Kim, YG | 1 |
| Kim, BK | 2 |
| Gerbes, AL | 1 |
| Vallejo, C | 1 |
| Caballero, MD | 1 |
| García-Sanz, R | 1 |
| Hernández, JM | 1 |
| Vázquez, L | 1 |
| Cañizo, MC | 1 |
| Galende, J | 1 |
| Colino, CI | 2 |
| Gil-Hurlé, A | 1 |
| San Miguel, JF | 1 |
| Ferrà, C | 1 |
| de Sanjosé, S | 1 |
| Lastra, CF | 1 |
| Martí, F | 1 |
| Mariño, EL | 1 |
| Sureda, A | 1 |
| Brunet, S | 1 |
| Gallardo, D | 1 |
| Berlanga, JJ | 1 |
| García, J | 1 |
| Grañena, A | 1 |
| Vaessen, C | 1 |
| Janssen, T | 1 |
| Schulman, C | 1 |
| Haahr, V | 1 |
| Peterslund, NA | 1 |
| Møller, JK | 1 |
| Goldstein, EJ | 3 |
| Citron, DM | 2 |
| Hudspeth, M | 1 |
| Hunt Gerardo, S | 1 |
| Merriam, CV | 1 |
| Felmingham, D | 1 |
| Robbins, MJ | 1 |
| Tesfaslasie, Y | 1 |
| Harding, I | 1 |
| Shrimpton, S | 1 |
| Grüneberg, RN | 1 |
| Naccari, F | 1 |
| Salpietro, DC | 1 |
| De Sarro, A | 1 |
| Masaracchio, A | 1 |
| Barberi, I | 1 |
| Borzio, M | 1 |
| Salerno, F | 1 |
| Saudelli, M | 1 |
| Galvagno, D | 1 |
| Piantoni, L | 1 |
| Fragiacomo, L | 1 |
| Hsieh, WJ | 1 |
| Lin, HC | 1 |
| Hwang, SJ | 1 |
| Hou, MC | 1 |
| Lee, FY | 1 |
| Chang, FY | 1 |
| Lee, SD | 1 |
| Cohen, MA | 1 |
| Huband, MD | 1 |
| Yoder, SL | 1 |
| Gage, JW | 1 |
| Roland, GE | 1 |
| Griggs, JJ | 1 |
| Blair, EA | 1 |
| Norton, JR | 1 |
| Rowe, JM | 1 |
| Flesher, WR | 1 |
| Betts, RF | 1 |
| Cardoso, EM | 1 |
| Santoianni, JE | 1 |
| De Paulis, AN | 1 |
| Andrada, JA | 1 |
| Predari, SC | 1 |
| Arregger, AL | 1 |
| Zuck, P | 1 |
| Weber, P | 1 |
| DiTizio, V | 1 |
| Ferguson, GW | 1 |
| Mittelman, MW | 1 |
| Khoury, AE | 1 |
| Bruce, AW | 1 |
| DiCosmo, F | 1 |
| Manestar, D | 1 |
| Braut, T | 1 |
| Velepic, M | 1 |
| Boswell, FJ | 1 |
| Ashby, JP | 1 |
| Fogarty, C | 1 |
| Beloborodova, NV | 1 |
| Padeĭskaia, EN | 1 |
| Biriukov, AV | 1 |
| Faulds, D | 1 |
| Clifford, K | 1 |
| Huck, W | 1 |
| Shan, M | 1 |
| Tosiello, R | 1 |
| Echols, RM | 2 |
| Heyd, A | 5 |
| Mitsuyama, J | 1 |
| Yonezawa, M | 1 |
| Araki, H | 1 |
| Minami, S | 1 |
| Watanabe, Y | 1 |
| Minotti, V | 1 |
| Gentile, G | 1 |
| Bucaneve, G | 2 |
| Iori, AP | 1 |
| Micozzi, A | 2 |
| Cavicchi, F | 1 |
| Barbabietola, G | 1 |
| Landonio, G | 2 |
| Menichetti, F | 1 |
| Martino, P | 2 |
| Del Favero, A | 2 |
| Petropoulos, D | 1 |
| Roberts, WM | 1 |
| Rytting, M | 1 |
| Zipf, T | 1 |
| Chan, KW | 1 |
| Culbert, SJ | 1 |
| Danielson, M | 1 |
| Jeha, SS | 1 |
| Kuttesch, JF | 1 |
| Freifeld, A | 1 |
| Marchigiani, D | 1 |
| Walsh, T | 1 |
| Chanock, S | 1 |
| Lewis, L | 1 |
| Hiemenz, J | 1 |
| Hiemenz, S | 1 |
| Hicks, JE | 1 |
| Gill, V | 1 |
| Steinberg, SM | 1 |
| Pizzo, PA | 1 |
| Hollenstein, U | 1 |
| Schmid, R | 1 |
| Ehringer, H | 1 |
| Eichler, HG | 1 |
| Anzueto, A | 1 |
| Rizzo, JA | 1 |
| Grossman, RF | 1 |
| Bowker, KE | 1 |
| Wootton, M | 1 |
| Rogers, CA | 1 |
| Lewis, R | 1 |
| Holt, HA | 1 |
| Walia, S | 1 |
| Alster, TS | 1 |
| Antabli, BA | 1 |
| Bross, P | 1 |
| Siegel, RS | 1 |
| Small, CD | 1 |
| Tabbara, IA | 1 |
| Javaloyas de Morlius, M | 1 |
| Monreal Portella, M | 1 |
| Walters, DJ | 1 |
| Solomkin, JS | 1 |
| Paladino, JA | 2 |
| McElvanney, AM | 1 |
| Sánchez-Recio, MM | 1 |
| Sánchez-Navarro, A | 1 |
| Varela, JE | 1 |
| Cohn, SM | 2 |
| Brown, M | 1 |
| Ward, CG | 1 |
| Namias, N | 1 |
| Spalding, PB | 1 |
| Busch, W | 1 |
| Focht, J | 2 |
| Toivanen, A | 1 |
| Koyama, H | 1 |
| Chiba, A | 1 |
| Omika, K | 1 |
| Harada, S | 1 |
| Kaneko, A | 1 |
| Sasaki, J | 1 |
| Riddle, C | 1 |
| Lemons, CL | 1 |
| Altier, C | 1 |
| Amaro Martins, VC | 1 |
| Goissis, G | 1 |
| Markman, M | 1 |
| Kennedy, A | 1 |
| Webster, K | 1 |
| Peterson, G | 1 |
| Kulp, B | 1 |
| Belinson, J | 1 |
| Raizenberg, C | 1 |
| Rohana, Y | 1 |
| Unamba-Oparah, I | 1 |
| Korfman, G | 1 |
| Yaniv, I | 1 |
| Lipsett, PA | 1 |
| Buchman, TG | 1 |
| Cheadle, WG | 1 |
| Milsom, JW | 1 |
| O'Marro, S | 1 |
| Yellin, AE | 1 |
| Jungerwirth, S | 1 |
| Rochefort, EV | 1 |
| Kowalsky, SF | 1 |
| Kosrirukvongs, P | 1 |
| Buranapongs, W | 1 |
| Baum, HV | 1 |
| Franz, U | 1 |
| Geiss, HK | 1 |
| Delarive, P | 1 |
| Baumgartner, JD | 1 |
| Glauser, MP | 1 |
| Wareham, D | 1 |
| Nejjari, N | 1 |
| Benomar, S | 1 |
| Lahbabi, MS | 1 |
| Wong, WY | 1 |
| Ang, ES | 1 |
| Goh, AS | 1 |
| Ng, DC | 1 |
| Yu, S | 1 |
| Zargar, AH | 1 |
| Masoodi, SR | 1 |
| Laway, BA | 1 |
| Wani, AI | 1 |
| Bashir, MI | 1 |
| Wlazłowski, J | 1 |
| Krzyzańska-Oberbek, A | 1 |
| Sikora, JP | 1 |
| Chlebna-Sokół, D | 1 |
| Wada, K | 1 |
| Sato, K | 1 |
| Sonmezoglu, K | 1 |
| Sonmezoglu, M | 1 |
| Halac, M | 1 |
| Akgün, I | 1 |
| Türkmen, C | 1 |
| Onsel, C | 1 |
| Kanmaz, B | 1 |
| Uslu, I | 1 |
| Welling, MM | 1 |
| Lupetti, A | 1 |
| Balter, HS | 1 |
| Lanzzeri, S | 1 |
| Souto, B | 1 |
| Rey, AM | 1 |
| Savio, EO | 1 |
| Paulusma-Annema, A | 1 |
| Pauwels, EK | 1 |
| Nibbering, PH | 1 |
| Van de Wiele, C | 1 |
| Dumont, F | 1 |
| Van Durme, J | 1 |
| Britton, K | 2 |
| Slegers, G | 1 |
| Thierens, H | 1 |
| Finch, RG | 1 |
| Lelièvre, G | 1 |
| Oldfield, EC | 1 |
| Wallace, MR | 1 |
| Garg, PK | 1 |
| Khanna, S | 1 |
| Bohidar, NP | 1 |
| Kapil, A | 1 |
| Tandon, RK | 1 |
| Pellizzer, G | 1 |
| Strazzabosco, M | 1 |
| Presi, S | 1 |
| Furlan, F | 1 |
| Lora, L | 1 |
| Benedetti, P | 1 |
| Bonato, M | 1 |
| Erle, G | 1 |
| de Lalla, F | 1 |
| Prentice, HG | 1 |
| Hann, IM | 1 |
| Nazareth, B | 1 |
| Paterson, P | 1 |
| Bhamra, A | 1 |
| Kibbler, CC | 1 |
| Gallowitsch, HJ | 1 |
| Heinisch, M | 1 |
| Mikosch, P | 1 |
| Kresnik, E | 1 |
| Kumnig, G | 1 |
| Gomez, I | 1 |
| Lind, P | 1 |
| Frère, P | 1 |
| Hermanne, JP | 1 |
| Debouge, MH | 1 |
| Fillet, G | 1 |
| Beguin, Y | 1 |
| Choi, SM | 1 |
| Choi, JH | 1 |
| Yoo, JH | 1 |
| Park, YH | 1 |
| Kim, YJ | 1 |
| Lee, S | 1 |
| Min, CK | 1 |
| Lee, JW | 1 |
| Min, WS | 1 |
| Shin, WS | 1 |
| Kim, CC | 1 |
| Stahlmann, R | 1 |
| Chung, MH | 1 |
| Kim, WH | 1 |
| Kan Ryu, J | 1 |
| Jin Kang, K | 1 |
| Fridkin, SK | 1 |
| Hill, HA | 1 |
| Volkova, NV | 1 |
| Edwards, JR | 1 |
| Lawton, RM | 1 |
| Gaynes, RP | 1 |
| McGowan, JE | 1 |
| Akaniro, JC | 1 |
| Stutman, HR | 1 |
| Arguedas, AG | 1 |
| Vargas, OM | 1 |
| Hosaka, M | 2 |
| Yasue, T | 1 |
| Fukuda, H | 1 |
| Tomizawa, H | 1 |
| Aoyama, H | 2 |
| Hirai, K | 2 |
| Di Cesare, P | 1 |
| Hoffmann, P | 1 |
| Kessler, R | 1 |
| Pye, KG | 1 |
| Legnani, D | 1 |
| Lombardo, VM | 1 |
| Negretto, GG | 1 |
| Beghi, G | 1 |
| Caratozzolo, O | 1 |
| Weinhardt, B | 1 |
| Collins, PW | 2 |
| Poole, MD | 1 |
| Drinovec, J | 1 |
| Bailie, GR | 1 |
| Eisele, G | 1 |
| O'Keeffe, BJ | 1 |
| Monif, GR | 1 |
| Osborne, NG | 1 |
| Sander, J | 1 |
| Sanders, CC | 2 |
| Nicolau, D | 1 |
| Quintiliani, R | 1 |
| Nightingale, CH | 1 |
| Gulati, S | 1 |
| Marwaha, RK | 1 |
| Parish, LC | 2 |
| Jungkind, DL | 1 |
| Wimperis, JZ | 1 |
| Baglin, TP | 1 |
| Marcus, RE | 1 |
| Warren, RE | 1 |
| Szmeja, Z | 1 |
| Kulczyński, B | 1 |
| Pietkiewicz, K | 1 |
| Kwiatek, G | 1 |
| Michalska, W | 1 |
| Chylak, J | 1 |
| Brody, T | 1 |
| Pensak, ML | 1 |
| Maccato, ML | 1 |
| Faro, S | 1 |
| Martens, MG | 1 |
| Hammill, HA | 1 |
| Lee, BL | 1 |
| Padula, AM | 1 |
| Kimbrough, RC | 1 |
| Jones, SR | 1 |
| Chaisson, RE | 1 |
| Mills, J | 1 |
| Sande, MA | 1 |
| Meunier, F | 2 |
| Zinner, SH | 2 |
| Gaya, H | 1 |
| Calandra, T | 1 |
| Viscoli, C | 1 |
| Klastersky, J | 1 |
| Glauser, M | 1 |
| Santini, C | 1 |
| Baiocchi, P | 1 |
| Venditti, M | 1 |
| Gelfusa, V | 1 |
| Tarasi, A | 1 |
| Brandimarte, C | 1 |
| Serra, P | 1 |
| Skala, LZ | 1 |
| Nasonov, VN | 1 |
| Nekhorosheva, AG | 1 |
| Dutova, EN | 1 |
| Cherniakov, VL | 1 |
| Barsić, B | 1 |
| Himbele, J | 1 |
| Beus, I | 2 |
| Marton, E | 1 |
| Lisić, M | 2 |
| Petersen, PJ | 1 |
| Jacobus, NV | 1 |
| Weiss, WJ | 1 |
| Testa, RT | 1 |
| Arakawa, S | 1 |
| Takagi, S | 1 |
| Matsumoto, O | 1 |
| Kamidono, S | 1 |
| Sengoku, A | 1 |
| Hazama, M | 1 |
| Yamazaki, H | 1 |
| Hamami, G | 1 |
| Okamoto, Y | 1 |
| Tanaka, H | 1 |
| Matsuda, S | 1 |
| Cho, N | 1 |
| Satoh, K | 1 |
| Minaguchi, H | 1 |
| Yagami, Y | 1 |
| Okada, H | 1 |
| Hirabayashi, K | 1 |
| Messer, M | 2 |
| Nguyen, H | 2 |
| Ho, D | 1 |
| Cokingtin, CD | 1 |
| Hyndiuk, RA | 1 |
| Leibowitz, HM | 2 |
| Sperry, HE | 1 |
| Backes, JM | 1 |
| Gelber, JA | 1 |
| Serrianne, DJ | 1 |
| Cumbo, TJ | 3 |
| Tauchnitz, C | 1 |
| Moody, JA | 2 |
| Fasching, CE | 3 |
| Sinn, LM | 1 |
| Gerding, DN | 4 |
| Peterson, LR | 5 |
| Takvorian, T | 1 |
| Mayer, R | 1 |
| Kalish, L | 1 |
| Ippolito, A | 1 |
| La Gioia, G | 1 |
| Matarrese, M | 1 |
| Resta, F | 1 |
| Angelini, P | 1 |
| Ruffo, F | 1 |
| Marchbanks, CR | 1 |
| Graham, KK | 1 |
| Barnes, J | 1 |
| Dudley, MN | 2 |
| Muder, RR | 1 |
| Brennen, C | 1 |
| Goetz, AM | 1 |
| Wagener, MM | 1 |
| Rihs, JD | 1 |
| Kresnicka, D | 1 |
| Lowry, T | 1 |
| Holzworth, P | 1 |
| Moussalli, ST | 1 |
| Whalen, J | 1 |
| White, C | 1 |
| Swanson, RN | 1 |
| Hardy, DJ | 1 |
| Shipkowitz, NL | 1 |
| Clement, JJ | 1 |
| Gargallo-Viola, D | 1 |
| Esteve, M | 1 |
| Llovera, S | 1 |
| Roca, X | 1 |
| Guinea, J | 1 |
| Fuchs, PC | 1 |
| Barry, AL | 1 |
| Pfaller, MA | 2 |
| Gerlach, EH | 1 |
| Une, T | 1 |
| Dronova, OM | 1 |
| Beskid, G | 1 |
| Siebelist, J | 1 |
| McGarry, CM | 1 |
| Cleeland, R | 1 |
| Chan, K | 1 |
| Keith, DD | 1 |
| Moriuchi, Y | 1 |
| Kamihira, S | 1 |
| Yamamura, M | 1 |
| Mori, H | 1 |
| Miyazaki, Y | 1 |
| Tokunaga, S | 1 |
| Nonaka, H | 1 |
| Amagasaki, T | 1 |
| Yamada, Y | 1 |
| Yoshida, Y | 1 |
| Delord, C | 1 |
| Weinhard, B | 1 |
| Kulshrestha, SP | 1 |
| Barar, FS | 1 |
| Miglani, N | 1 |
| Girard, AE | 1 |
| Girard, D | 1 |
| Retsema, JA | 1 |
| Goodman, LJ | 1 |
| Trenholme, GM | 1 |
| Kaplan, RL | 1 |
| Segreti, J | 1 |
| Hines, D | 1 |
| Petrak, R | 1 |
| Nelson, JA | 1 |
| Mayer, KW | 1 |
| Landau, W | 1 |
| Parkhurst, GW | 1 |
| Wood, ME | 4 |
| Shaw, E | 2 |
| Jenkins, GC | 1 |
| De Pauw, BE | 1 |
| Donnelly, JP | 1 |
| De Witte, T | 2 |
| Nováková, IR | 1 |
| Schattenberg, A | 1 |
| Karimi, K | 1 |
| Fass, RJ | 4 |
| Sesin, GP | 1 |
| Paszko, A | 1 |
| O'Keefe, E | 1 |
| Ludlam, H | 1 |
| Dryden, M | 1 |
| Barton, I | 1 |
| Phillips, I | 1 |
| Aswapokee, N | 1 |
| Pruksachatvuthi, S | 1 |
| Aswapokee, P | 1 |
| Krcméry, V | 1 |
| Horníková, M | 1 |
| Koza, I | 1 |
| Fuchsberger, P | 1 |
| Spánik, S | 1 |
| Sufliarsky, J | 1 |
| Mardiak, J | 1 |
| Sitáni, L | 1 |
| Milosovic, P | 1 |
| Fazio, A | 1 |
| Arning, M | 1 |
| Wolf, HH | 1 |
| Aul, C | 1 |
| Heyll, A | 1 |
| Scharf, RE | 1 |
| Scheider, W | 1 |
| Johnson, PR | 1 |
| Yin, JA | 1 |
| Tooth, JA | 1 |
| Philpott-Howard, JN | 1 |
| Barker, KF | 1 |
| Wade, JJ | 1 |
| Kaczmarski, RS | 1 |
| Smedley, JC | 1 |
| Mufti, GJ | 1 |
| Goldman, MP | 1 |
| Schwartz, MT | 1 |
| Calvert, JF | 1 |
| Gu, JW | 1 |
| Neu, HC | 8 |
| Smith, SP | 1 |
| Slama, TG | 1 |
| Loos, U | 1 |
| Schwabe, HK | 1 |
| Powers, T | 1 |
| Bingham, DH | 1 |
| Azanza, JR | 1 |
| Rubio, A | 1 |
| Suárez, J | 1 |
| Catalán, M | 1 |
| Honorato, J | 1 |
| López, JC | 1 |
| offcenado, E | 1 |
| Rodríguez-Créixems, M | 1 |
| Romero, J | 1 |
| García de la Torre, M | 1 |
| Bouza, E | 1 |
| Parras, F | 1 |
| Torroba, L | 1 |
| Buzón, L | 1 |
| Martínez-Beltrán, J | 1 |
| Loza, E | 1 |
| Baquero, F | 1 |
| Humphreys, H | 1 |
| Lovering, A | 1 |
| Williams, EW | 1 |
| Davidson, S | 1 |
| Briones, F | 1 |
| Kujath, P | 1 |
| van Ogtrop, ML | 1 |
| Mattie, H | 2 |
| Guiot, HF | 1 |
| van Furth, R | 1 |
| Minetti, B | 1 |
| Ricci, P | 1 |
| Montillo, M | 1 |
| Malleo, C | 1 |
| Dellamonica, P | 2 |
| Bernard, E | 2 |
| Etesse, H | 2 |
| Garraffo, R | 2 |
| Drugeon, HB | 1 |
| Haron, E | 2 |
| Cunningham, C | 2 |
| Holmes, F | 1 |
| Umsawasdi, T | 1 |
| Hann, JR | 1 |
| Sudderth, BF | 1 |
| Baker, RV | 1 |
| Harrison, RE | 1 |
| Bricaire, F | 1 |
| Godeau, B | 1 |
| Salmon, D | 1 |
| Karam, D | 1 |
| Leport, C | 1 |
| Vildé, JL | 1 |
| Rotowa, NA | 1 |
| Montefiore, D | 1 |
| Adeyemi-Doro, FA | 1 |
| Brown, RB | 1 |
| Phillips, D | 1 |
| Barker, MJ | 1 |
| Pieczarka, R | 1 |
| Sands, M | 1 |
| Teres, D | 1 |
| Valtonen, V | 1 |
| Karppinen, L | 1 |
| Kariniemi, AL | 1 |
| Stanley, GL | 1 |
| Mori, M | 1 |
| Wenzel, RP | 1 |
| LeFrock, JL | 1 |
| Canton, P | 1 |
| Hoen, B | 1 |
| Richet, H | 1 |
| Ravoire, S | 1 |
| Acar, JF | 1 |
| Apuzzio, JJ | 1 |
| Stankiewicz, R | 1 |
| Ganesh, V | 1 |
| Jain, S | 1 |
| Kaminski, Z | 1 |
| Louria, D | 1 |
| Plouffe, JF | 1 |
| Russell, JA | 1 |
| Abadie-Kemmerly, S | 1 |
| Pankey, GA | 1 |
| Skoutelis, AT | 1 |
| Gudiol, F | 1 |
| Cabellos, C | 1 |
| Pallares, R | 1 |
| Linares, J | 1 |
| Ariza, J | 1 |
| Daly, JS | 1 |
| Worthington, MG | 1 |
| Razvi, SA | 1 |
| Robillard, R | 1 |
| Gelfand, MS | 1 |
| Simmons, BP | 1 |
| Craft, RB | 1 |
| Grogan, JT | 1 |
| Greenberg, RN | 2 |
| Wilson, KM | 1 |
| Brusca, PA | 1 |
| Car, V | 1 |
| Gmajnicki, B | 1 |
| Gombert, ME | 1 |
| duBouchet, L | 1 |
| Aulicino, TM | 1 |
| Berkowitz, LB | 1 |
| Macchia, RJ | 1 |
| Christensen, MM | 1 |
| Nelsen, KT | 1 |
| Knes, J | 1 |
| Madsen, PO | 1 |
| Andriole, VT | 3 |
| Snoeck, R | 1 |
| Gerain, J | 1 |
| Leleux, A | 1 |
| Libert, J | 1 |
| Kotera, Y | 1 |
| Mitsuhashi, S | 1 |
| Belovezhdov, N | 1 |
| Monova, D | 1 |
| Rottensterich, E | 1 |
| Hefter, H | 1 |
| Kennes, Y | 1 |
| Potasman, I | 1 |
| Waldvogel, FA | 1 |
| Childs, SJ | 1 |
| Fong, IW | 1 |
| Naumann, P | 1 |
| Dopp, C | 1 |
| Simmons, JF | 1 |
| Cowley, CE | 1 |
| Dozier, DB | 1 |
| Galdini, AM | 1 |
| Manes, MR | 1 |
| Nungester, GH | 1 |
| Schreeder, MT | 1 |
| Strother, KD | 1 |
| Chun, BW | 1 |
| Chan, CC | 1 |
| Oppenheim, BA | 1 |
| Anderson, H | 1 |
| Swindell, R | 1 |
| Scarffe, JH | 1 |
| Nord, CE | 3 |
| Edlund, C | 2 |
| Thadepalli, H | 2 |
| Mathai, D | 1 |
| Chuah, SK | 1 |
| Bansal, MB | 1 |
| Chevis, SA | 1 |
| Oakes, WT | 1 |
| Lissack, LM | 1 |
| Canter, K | 1 |
| Clabots, C | 1 |
| Limon, L | 1 |
| Norrby, SR | 1 |
| Palmer, JP | 1 |
| Barit, MC | 1 |
| Powderly, B | 1 |
| Velasquez, BG | 1 |
| Roberts, DE | 1 |
| Williams, JD | 1 |
| Khan, FA | 3 |
| Basir, R | 1 |
| Hooper, DC | 1 |
| Wolfson, JS | 1 |
| Schito, GC | 1 |
| Sanna, A | 1 |
| Chezzi, C | 1 |
| Ravizzola, G | 1 |
| Leone, F | 1 |
| Molinari, G | 1 |
| Menozzi, MG | 1 |
| Pirali, F | 1 |
| Hays, DJ | 1 |
| Fielder, RL | 1 |
| O'Neal, ET | 1 |
| Wright, AC | 1 |
| Gentry, LO | 1 |
| Ramirez-Ronda, CH | 4 |
| Rodriguez-Noriega, E | 3 |
| del Rosal, PL | 1 |
| Ramirez, C | 1 |
| Reiter, C | 1 |
| Pfeiffer, M | 1 |
| Hullman, RN | 1 |
| Chodosh, S | 1 |
| Tuck, J | 1 |
| Stottmeier, KD | 1 |
| Pizzuto, D | 1 |
| Gaut, PL | 1 |
| Carron, WC | 1 |
| Ching, WT | 1 |
| Meyer, RD | 1 |
| Levine, DP | 1 |
| McNeil, P | 1 |
| Lerner, SA | 1 |
| Reinhardt, JF | 1 |
| Bacon, AE | 1 |
| Winslow, DL | 1 |
| Holloway, WJ | 1 |
| Gallis, HA | 1 |
| Brennan, RO | 1 |
| Goodwin, SD | 1 |
| Swinney, V | 1 |
| Rumbaugh, MM | 1 |
| Drew, RH | 1 |
| Peacock, JE | 1 |
| Pegram, PS | 1 |
| Weber, SF | 1 |
| Leone, PA | 1 |
| Villavicencio, J | 1 |
| Asensio de Fernandez, ME | 1 |
| Ramirez, CA | 2 |
| Quintero-Perez, NP | 2 |
| Andrade-Villaneuva, JF | 1 |
| Leon-Garnica, G | 1 |
| Bertin-Montano, M | 1 |
| Rodriguez-Chagollan, JJ | 2 |
| Saavedra, S | 3 |
| Rivera-Vazquez, CR | 2 |
| Sifuentes-Osornio, J | 1 |
| Macías, A | 1 |
| Amieva, RI | 1 |
| Ruiz-Palacios, GM | 1 |
| Modai, J | 1 |
| Cox, CE | 1 |
| Bayston, KF | 1 |
| Want, S | 1 |
| Cohen, J | 1 |
| Flaherty, JP | 1 |
| Waitley, D | 1 |
| Edlin, B | 1 |
| George, D | 1 |
| Arnow, P | 1 |
| O'Keefe, P | 1 |
| Weinstein, RA | 1 |
| Arcieri, GM | 1 |
| Becker, N | 4 |
| Esposito, B | 1 |
| Griffith, E | 5 |
| Neumann, C | 1 |
| O'Brien, B | 5 |
| Schacht, P | 3 |
| Arcieri, G | 5 |
| Hullmann, R | 2 |
| Hines, CH | 1 |
| Bordelon, JY | 1 |
| Jens, DK | 1 |
| Le, CV | 1 |
| McManus, LJ | 1 |
| Spurlock, WM | 1 |
| Hawkey, PM | 1 |
| Bayer, AS | 1 |
| Ruiz Contreras, J | 1 |
| Dunbar, CP | 1 |
| Ashton, RL | 1 |
| Atkinson, L | 1 |
| Crotwell, HF | 1 |
| Faris, HM | 1 |
| Royal, HG | 1 |
| Tyson, DW | 1 |
| White, CH | 1 |
| Phillips, HL | 1 |
| Nolen, TM | 1 |
| Hutchison, J | 1 |
| Desgrandchamps, D | 1 |
| Munzinger, J | 1 |
| Mohr, CP | 1 |
| Küchmeister, B | 1 |
| Reinel, D | 1 |
| Ulrich, R | 1 |
| Venezia, RA | 1 |
| Prymas, LA | 1 |
| Shayegani, A | 1 |
| Yocum, DM | 1 |
| Hellsten, S | 1 |
| Forsgren, A | 1 |
| Björk, T | 1 |
| Lahnborg, G | 1 |
| Heinonen, PK | 1 |
| Teisala, K | 1 |
| Miettinen, A | 1 |
| Aine, R | 1 |
| Punnonen, R | 1 |
| Grönroos, P | 1 |
| Desiderio, JV | 1 |
| Tsai, YH | 1 |
| Warr, G | 1 |
| Bron, A | 1 |
| Talon, D | 1 |
| Cellier, T | 1 |
| Estavoyer, JM | 1 |
| Delbosc, B | 1 |
| Royer, J | 1 |
| Chin, NX | 2 |
| Liao, WC | 1 |
| Cappell, MS | 1 |
| Nakamura, S | 1 |
| Minami, A | 1 |
| Nakata, K | 1 |
| Kurobe, N | 1 |
| Kouno, K | 1 |
| Sakaguchi, Y | 1 |
| Kashimoto, S | 1 |
| Yoshida, H | 1 |
| Kojima, T | 1 |
| Ohue, T | 1 |
| Klietmann, W | 1 |
| Nösner, K | 1 |
| LeBel, M | 1 |
| Martorana, G | 1 |
| Giberti, C | 1 |
| Pizzorno, R | 1 |
| Bonamini, A | 1 |
| Oneto, F | 1 |
| Curotto, A | 1 |
| Soro, O | 1 |
| Manzo, M | 1 |
| Bran, JL | 1 |
| Mejia, CR | 1 |
| Garcia, JF | 1 |
| Weber, AH | 1 |
| Scribner, RK | 1 |
| Marks, MI | 1 |
| Guimaraes, MA | 1 |
| Noone, P | 1 |
| Davies, BI | 3 |
| Maesen, FP | 3 |
| Teengs, JP | 2 |
| Baur, C | 3 |
| Haller, I | 2 |
| Shenep, JL | 1 |
| Kelley, SG | 1 |
| Bertram, MA | 1 |
| Young, LS | 1 |
| Eron, LJ | 1 |
| Harvey, L | 1 |
| Hixon, DL | 1 |
| Poretz, DM | 1 |
| August, R | 3 |
| Doyle, C | 1 |
| Gruenwaldt, G | 4 |
| Mehtar, S | 1 |
| Drabu, Y | 1 |
| Blakemore, P | 1 |
| Nevárez, M | 1 |
| Finch, R | 1 |
| Whitby, M | 1 |
| Craddock, C | 1 |
| Holliday, A | 1 |
| Martin, J | 1 |
| Pilkington, R | 1 |
| Oomori, Y | 1 |
| Niwata, Y | 1 |
| Suzue, S | 1 |
| Irikura, T | 1 |
| Novakova, I | 1 |
| Branolte, J | 2 |
| Muytjens, H | 1 |
| de Pauw, B | 1 |
| Karb, VB | 1 |
| Høiby, N | 1 |
| Ball, AP | 1 |
| Stratton, CW | 1 |
| Maggiolo, F | 1 |
| Bianchi, W | 4 |
| Ohnmeiss, H | 2 |
| Kobayashi, H | 1 |
| Demoleas, SE | 1 |
| Davies, GF | 1 |
| Alvarez, ME | 1 |
| Hoy, JF | 1 |
| Alderman, HC | 1 |
| Collins, MS | 1 |
| Hector, RF | 1 |
| Roby, RE | 1 |
| Edwards, AA | 1 |
| Ladehoff, DK | 1 |
| Dorsey, JH | 1 |
| Falser, N | 1 |
| Mittermayer, H | 1 |
| Weuta, H | 3 |
| Suermondt, G | 1 |
| Denamur, E | 1 |
| Laurans, G | 1 |
| Orfila, J | 1 |
| Verhoef, J | 2 |
| Meisel, C | 1 |
| Blenk, H | 1 |
| Sforza, E | 1 |
| De Gennaro, M | 1 |
| Ruggieri, A | 1 |
| Ninno, D | 1 |
| Pastore, G | 1 |
| Tolkoff-Rubin, NE | 2 |
| Rubin, RH | 2 |
| Bruck, H | 1 |
| Chyský, V | 1 |
| Konopka, CA | 1 |
| Gorkiewicz-Petkow, A | 1 |
| Jablonska, S | 1 |
| Petkow, L | 1 |
| Bielunska, S | 1 |
| Gawkonska, M | 1 |
| Galante, D | 2 |
| Barba, D | 1 |
| Gagliardi, R | 2 |
| Giusti, R | 1 |
| Polubiec, A | 1 |
| Stepka, K | 1 |
| Ktos, K | 1 |
| Strazynska, R | 1 |
| Jórasz, J | 1 |
| Berman, SJ | 1 |
| Campoli-Richards, DM | 1 |
| Monk, JP | 1 |
| Price, A | 1 |
| Benfield, P | 1 |
| Todd, PA | 1 |
| Ward, A | 1 |
| Dennig, D | 1 |
| Fülle, HH | 1 |
| Hellriegel, KP | 1 |
| Walker, RC | 1 |
| Wright, AJ | 1 |
| Lode, H | 1 |
| Wiley, R | 1 |
| Höffken, G | 1 |
| Wagner, J | 1 |
| Imbasciati, A | 1 |
| Mariani, L | 1 |
| van Poppel, H | 1 |
| Baert, L | 1 |
| Langemeyer, TN | 1 |
| Ferwerda, WH | 1 |
| Hoogkamp-Korstanje, JA | 3 |
| de Leur, EJ | 1 |
| van Oort, H | 1 |
| Schipper, JJ | 1 |
| van der Wal, T | 1 |
| Shah, PM | 1 |
| Pichler, H | 1 |
| Diridl, G | 2 |
| Stickler, K | 2 |
| Wolf, D | 2 |
| Appelbaum, PC | 1 |
| Spangler, SK | 1 |
| Strauss, M | 1 |
| Screen, P | 1 |
| Guay, DR | 1 |
| Awni, WM | 1 |
| Peterson, PK | 1 |
| Obaid, S | 1 |
| Stein, D | 1 |
| Breitenbucher, R | 1 |
| Matzke, GR | 1 |
| Cornaglia, G | 1 |
| Pompei, R | 1 |
| Dainelli, B | 1 |
| Satta, G | 1 |
| van den Broek, PJ | 1 |
| Bakker, W | 1 |
| van Gulpen, C | 1 |
| Stuyck, J | 1 |
| Verbist, L | 1 |
| Mulier, JC | 1 |
| Smith, GM | 1 |
| Leyland, MJ | 1 |
| Farrell, ID | 1 |
| Geddes, AM | 1 |
| Periti, P | 1 |
| Mazzei, T | 1 |
| Nicoletti, P | 1 |
| Wolff, M | 1 |
| Wollschlager, CM | 2 |
| Raoof, S | 3 |
| Klein, SJ | 1 |
| Dibb, WL | 1 |
| Beziau, H | 1 |
| Bower, RR | 1 |
| Jarvis, KP | 1 |
| Ramer, NR | 1 |
| Cynamon, MH | 1 |
| Wilcox, GH | 1 |
| Eggleston, M | 1 |
| Kuritzky, P | 1 |
| DeVito, JM | 1 |
| Guarneri, JJ | 1 |
| LaBombardi, V | 1 |
| Afzal, Q | 1 |
| Bosso, JA | 1 |
| Black, PG | 1 |
| Matsen, JM | 1 |
| Asper, R | 1 |
| Pérez-Ruvalcaba, JA | 1 |
| Morales-Reyes, JJ | 1 |
| Huitrón-Ramírez, JA | 1 |
| Lesse, AJ | 1 |
| Freer, C | 1 |
| Salata, RA | 1 |
| Francis, JB | 1 |
| Scheld, WM | 1 |
| Gilbert, DN | 1 |
| Tice, AD | 2 |
| Marsh, PK | 2 |
| Craven, PC | 2 |
| Preheim, LC | 2 |
| Hessen, MT | 1 |
| Ingerman, MJ | 1 |
| Kaufman, DH | 1 |
| Weiner, P | 1 |
| Santoro, J | 1 |
| Korzeniowski, OM | 1 |
| Boscia, J | 1 |
| Topiel, M | 1 |
| Bush, LM | 1 |
| Kaye, D | 1 |
| Reilly, PM | 1 |
| Bollinger, M | 1 |
| Weinandt, WJ | 1 |
| Weidner, W | 1 |
| Schiefer, HG | 1 |
| Dalhoff, A | 1 |
| Kahn, RM | 1 |
| Alpert, ML | 1 |
| Ginsberg, BP | 1 |
| Greenway, FL | 1 |
| Daikos, GL | 1 |
| Kathpalia, SB | 1 |
| Sharifi, R | 1 |
| Lolans, VT | 1 |
| Jackson, GG | 1 |
| Cuevas, TA | 1 |
| Roccaforte, JS | 1 |
| Mellencamp, MA | 1 |
| Bittner, MJ | 1 |
| Ryan, JL | 1 |
| Berenson, CS | 1 |
| Greco, TP | 1 |
| Mangi, RJ | 1 |
| Sims, M | 1 |
| Thornton, GF | 1 |
| Pichler, HE | 1 |
| Galanakis, N | 1 |
| Sands, MF | 1 |
| Peloquin, CA | 1 |
| Vari, AJ | 1 |
| Vance, JW | 1 |
| Fracasso, JE | 1 |
| Mandler, HD | 1 |
| Gilbert, D | 1 |
| Ericson, J | 1 |
| Mayer, KH | 1 |
| Scully, BE | 3 |
| Jules, K | 1 |
| Barriere, SL | 1 |
| Bryant, RE | 1 |
| Hartstein, AI | 1 |
| McCormick, EM | 1 |
| Licitra, CM | 1 |
| Brooks, RG | 1 |
| Sieger, BE | 1 |
| Sanders, WE | 1 |
| Goering, RV | 1 |
| Sziegoleit, A | 1 |
| Gleadhill, IC | 1 |
| Ferguson, WP | 1 |
| Lowry, RC | 1 |
| Wollschlager, C | 1 |
| Khan, F | 1 |
| Wood, MJ | 1 |
| Logan, MN | 1 |
| Claiborne, AK | 1 |
| Pihuleac, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacokinetics of Ciprofloxacin in Critically Ill Patients - a Screening Study to Assess the Feasibility of Renal Function Markers to Predict Ciprofloxacin Clearance (CAPOEIRA)[NCT03016845] | 40 participants (Actual) | Observational | 2017-01-01 | Completed | |||
| A Multicenter, Double-Blind Study to Compare the Safety and Efficacy of Levofloxacin to That of Ciprofloxacin in the Treatment of Chronic Prostatitis[NCT00236808] | Phase 3 | 383 participants (Actual) | Interventional | 2000-05-31 | Completed | ||
| A Comparative Clinical and Radiographic Study of 3Mixstatin vs Tri-Antibiotic Mix and Simvastatin in the Treatment of Primary Molars With Inflammatory Root Resorption A Randomized Clinical Trial[NCT03585751] | 45 participants (Anticipated) | Interventional | 2018-09-30 | Not yet recruiting | |||
| Clinical and Radiographic Evaluation of the Synergistic Effect of Nano Silver Particles and Calcium Hydroxide Versus Triple Antibiotic Paste as Antibacterial Agents for Lesion Sterilization and Tissue Repair (LSTR) in Necrotic Primary Molars: Randomized C[NCT05681221] | 22 participants (Anticipated) | Interventional | 2023-02-20 | Not yet recruiting | |||
| A Randomized Controlled Trial Comparing the Clinical and Radiographic Success of 3Mixtatin Versus Modified 3Mix in Lesion Sterilization and Tissue Repair (LSTR) for The Treatment of Necrotic Primary Molars[NCT05677945] | 24 participants (Anticipated) | Interventional | 2023-03-31 | Not yet recruiting | |||
| A Randomized Controlled Trial to Investigate the Infectious Outcomes of Intrarectal Povidone-iodine Cleansing Plus Formalin Disinfection of Needle Tip During Transrectal Ultrasound Guided Prostate Biopsy[NCT03879486] | 1,257 participants (Actual) | Interventional | 2017-05-31 | Completed | |||
| Comparison of Daily Norfloxacin Versus Weekly Ciprofloxacin for the Prevention of Spontaneous Bacterial Peritonitis in Cirrhotic Patients[NCT01542801] | Phase 4 | 124 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| Role of Doxycycline in the Management of Patients With Chronic Rhinosinusitis With Nasal Polyps[NCT05157412] | Phase 3 | 60 participants (Anticipated) | Interventional | 2022-03-01 | Not yet recruiting | ||
| Drug Utilization Evaluation Study of Ciprofloxacin Utilization and Adverse Events Occurrence in Community Pharmacy Setting: A Cross-Sectional Study[NCT05916105] | 151 participants (Actual) | Observational | 2021-09-01 | Completed | |||
| Efficacy & Cost-Effectiveness of Lactobacillus Reuteri DSM 17938 Administration to Prevent the Risk of Respiratory or Gastrointestinal Infections in Child Day Care Centers: A Randomized, Double Blind, Placebo Control Trial (RDDCT).[NCT01249911] | Phase 3 | 269 participants (Anticipated) | Interventional | 2011-01-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
77 reviews available for ciprofloxacin and Bacterial Disease
| Article | Year |
|---|---|
Comprehensive review on the anti-bacterial activity of 1,2,3-triazole hybrids.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Dose-Response Relationship, Drug; Humans; Mic | 2019 |
Nitroimidazole-containing compounds and their antibacterial and antitubercular activities.
Topics: Anti-Bacterial Agents; Bacterial Infections; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; | 2019 |
A worldwide systematic review and meta-analysis of bacteria related to antibiotic-associated diarrhea in hospitalized patients.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Chloramphenicol; Ciprofloxacin; Clostridioide | 2021 |
Comparative effectiveness and safety of antibiotic prophylaxis during induction chemotherapy in children with acute leukaemia: a systematic review and meta-analysis.
Topics: Acute Disease; Adolescent; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Chil | 2023 |
Bacteriophages: The promising therapeutic approach for enhancing ciprofloxacin efficacy against bacterial infection.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Bacteriophages; Ciprofloxacin; Mice; Pseudomon | 2023 |
Antimicrobial resistance in Africa: a systematic review.
Topics: Africa; Anti-Bacterial Agents; Bacterial Infections; Ceftriaxone; Ciprofloxacin; Drug Resistance, Ba | 2017 |
Ciprofloxacin: from infection therapy to molecular imaging.
Topics: Animals; Bacterial Infections; Ciprofloxacin; Fluorine Radioisotopes; Humans; Isotope Labeling; Mole | 2018 |
Resistance profile of clinically relevant bacterial isolates against fluoroquinolone in Ethiopia: a systematic review and meta-analysis.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Drug Resistance, Bacterial; Et | 2018 |
Norfloxacin, ciprofloxacin, trimethoprim-sulfamethoxazole, and rifaximin for the prevention of spontaneous bacterial peritonitis: a network meta-analysis.
Topics: Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Humans; Network Meta-Analysis; Norfloxac | 2019 |
[Spontaneous bacterial peritonitis in liver cirrhosis: optimization issues of prevention and treatment].
Topics: Anti-Infective Agents; Ascitic Fluid; Bacterial Infections; Ciprofloxacin; Female; Humans; Liver Cir | 2012 |
Complications of prostate biopsy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bacterial Infections; Biopsy; Ciprofloxacin; Drug | 2013 |
Role of prophylactic antibiotics in cirrhotic patients with variceal bleeding.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Ciprofloxacin; Endoscopy; Esoph | 2014 |
Adverse effects of common oral antibiotics.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Bacterial Infections; Cephalex | 2014 |
Antimicrobial therapy of acute diarrhoea: a clinical review.
Topics: Acute Disease; Aminoglycosides; Anti-Bacterial Agents; Azithromycin; Bacterial Infections; Campyloba | 2016 |
Efficacy of fluoroquinolones against pathogenic oral bacteria.
Topics: Aza Compounds; Bacteria; Bacterial Infections; Ciprofloxacin; Fluoroquinolones; Humans; Levofloxacin | 2009 |
Ciprofloxacin use in neonates: a systematic review of the literature.
Topics: Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Drug Utilization; Humans; Infant, Newbor | 2011 |
[Treatment and prevention of infections in cancer patients with neutropenia].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antifungal Agents; Antineoplastic Agents; Bacterial In | 2011 |
[Proper antibiotic therapy. From penicillin to pharmacogenomic].
Topics: Anti-Bacterial Agents; Bacterial Infections; Cephalexin; Chloramphenicol; Ciprofloxacin; Cross Infec | 2012 |
Bioterriorism: from threat to reality.
Topics: Animals; Anthrax; Bacterial Infections; Bioterrorism; Botulism; Cattle; Ciprofloxacin; Humans; Plagu | 2002 |
Nonoperative management of diabetic foot infections.
Topics: Anti-Infective Agents; Bacterial Infections; Cellulitis; Ciprofloxacin; Diabetic Foot; Humans; Osteo | 2003 |
Ciprofloxacin in treatment of fever and neutropenia in pediatric cancer patients.
Topics: Ambulatory Care; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Bacterial I | 2003 |
Extended-release ciprofloxacin (Cipro XR) for treatment of urinary tract infections.
Topics: Bacterial Infections; Ciprofloxacin; Delayed-Action Preparations; Escherichia coli Infections; Trime | 2004 |
[Treatment with oral antibiotics of febrile neutropenia in onco-haematology. The experience of the EORTC antimicrobial group].
Topics: Administration, Oral; Amoxicillin-Potassium Clavulanate Combination; Bacterial Infections; Ceftazidi | 2004 |
Quinolones in dermatology.
Topics: Anti-Infective Agents; Area Under Curve; Bacterial Infections; Biological Availability; Ciprofloxaci | 2004 |
Ciprofloxacin/metronidazole versus beta-lactam-based treatment of intra-abdominal infections: a meta-analysis of comparative trials.
Topics: Abdomen; Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Ciprofloxacin; Drug Therapy, Com | 2006 |
Monotherapy versus combination therapy.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Bacterial Infections; Cellulit | 2006 |
Dysglycemia and fluoroquinolones: are you putting patients at risk?
Topics: Adolescent; Adult; Aza Compounds; Bacterial Infections; Blood Glucose; Ciprofloxacin; Dose-Response | 2007 |
[Ciprofloxacin and antibacterial therapy of respiratory tract infections].
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Fluoroquinolones; Humans; Resp | 2006 |
[Bacterial infections in liver cirrhosis].
Topics: Administration, Oral; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Ascites; | 2007 |
Ciprofloxacin. A review of its pharmacological profile and therapeutic use in the elderly.
Topics: Bacterial Infections; Ciprofloxacin; Drug Interactions; Humans; Premedication; Respiratory Tract Inf | 1994 |
[Ciprofloxacin in the treatment of intestinal infections of bacterial etiology].
Topics: Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Drug Resistance, Microbial; Dysentery, B | 1997 |
[Ciprofloxacin in the therapy of severe infections in children].
Topics: Anti-Infective Agents; Bacterial Infections; Child; Child, Preschool; Ciprofloxacin; Humans; Infant; | 1998 |
Oral ciprofloxacin: a pharmacoeconomic evaluation of its use in the treatment of serious infections.
Topics: Administration, Oral; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Costs and Cost Ana | 1993 |
Moxifloxacin.
Topics: Anti-Infective Agents; Area Under Curve; Aza Compounds; Bacterial Infections; Ciprofloxacin; Drug In | 1999 |
[Use of ciprofloxacin in the treatment and prevention of surgical infections].
Topics: Anti-Infective Agents; Bacterial Infections; Bone Diseases, Infectious; Ciprofloxacin; Humans; Joint | 1999 |
Managing reactive arthritis.
Topics: Animals; Arthritis, Reactive; Bacterial Infections; Ciprofloxacin; Disease Models, Animal; Humans; Y | 2000 |
[Injectable quinolones].
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Humans; Injections, Intravenous | 2001 |
The role of antibiotics in the treatment of infectious diarrhea.
Topics: Aged; Anti-Bacterial Agents; Bacterial Infections; Child; Child, Preschool; Ciprofloxacin; Clostridi | 2001 |
Continuous ambulatory peritoneal dialysis: a review of its mechanics, advantages, complications, and areas of controversy.
Topics: Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Humans; Peritoneal Dialysis, Continuous | 1992 |
[Fluoroquinolones--a new and important group of antimicrobial agents].
Topics: Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Drug Resistance, Microbial; Humans; Oflo | 1992 |
Review of preclinical studies with ofloxacin.
Topics: Animals; Bacteria; Bacterial Infections; Ciprofloxacin; Disease Models, Animal; Drug Resistance, Mic | 1992 |
Ofloxacin vs ciprofloxacin: a comparison.
Topics: Bacterial Infections; Ciprofloxacin; Humans; Metabolic Clearance Rate; Microbial Sensitivity Tests; | 1992 |
Insights from experimental data on ciprofloxacin in the treatment of bacterial keratitis and ocular infections.
Topics: Bacterial Infections; Ciprofloxacin; Drug Resistance, Microbial; Eye Diseases; Humans; Keratitis; Ps | 1991 |
[Effective microbiologic spectrum of gyrase inhibitors--indications and contraindications].
Topics: Bacteria; Bacterial Infections; Ciprofloxacin; Drug Resistance, Microbial; Humans; Topoisomerase II | 1990 |
Ciprofloxacin.
Topics: Bacterial Infections; Ciprofloxacin; Drug Interactions; Humans | 1990 |
Ciprofloxacin. Best use of this new broad-spectrum antibiotic.
Topics: Bacterial Infections; Biological Availability; Ciprofloxacin; Clinical Trials as Topic; Drug Interac | 1990 |
Ciprofloxacin as treatment for genitourinary tract infection.
Topics: Bacterial Infections; Ciprofloxacin; Female; Genital Diseases, Female; Genital Diseases, Male; Human | 1989 |
Clinical impact of newer quinolones: influence on normal microflora.
Topics: Bacterial Infections; Ciprofloxacin; Humans; Immune Tolerance; Intestinal Mucosa; Norfloxacin; Oroph | 1989 |
Ciprofloxacin: a fluoroquinolone antimicrobial. Part 1.
Topics: Bacterial Infections; Ciprofloxacin; Humans | 1989 |
Ciprofloxacin in the treatment of acute and chronic osteomyelitis: a review.
Topics: Bacterial Infections; Ciprofloxacin; Drug Evaluation; Gram-Negative Bacteria; Humans; Osteomyelitis; | 1989 |
Suppression of the oropharyngeal and gastrointestinal microflora by ciprofloxacin: microbiological and clinical consequences.
Topics: Bacteria; Bacterial Infections; Ciprofloxacin; Digestive System; Humans; Immune Tolerance; Male; Oro | 1989 |
Ciprofloxacin in renal failure.
Topics: Bacterial Infections; Ciprofloxacin; Humans; Kidney Failure, Chronic | 1989 |
Norfloxacin, ciprofloxacin, and ofloxacin: current clinical roles.
Topics: Bacteria; Bacterial Infections; Ciprofloxacin; Drug Tolerance; Humans; Norfloxacin; Ofloxacin | 1989 |
Safety of intravenous ciprofloxacin. A review.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections; Ceftazidime; | 1989 |
Safety of oral ciprofloxacin. An update based on clinical trial results.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections; Child; Child | 1989 |
Where are we now with ciprofloxacin?
Topics: Animals; Bacteria; Bacterial Infections; Ciprofloxacin; Humans | 1989 |
Clinical utility of new quinolones in treatment of osteomyelitis and lower respiratory tract infections.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Cross Infection; Cystic Fibrosi | 1989 |
[New antibiotics in pediatrics].
Topics: Anti-Bacterial Agents; Bacterial Infections; Child; Ciprofloxacin; Humans; Imipenem; Pediatrics | 1989 |
Ciprofloxacin: chemistry, mechanism of action, resistance, antimicrobial spectrum, pharmacokinetics, clinical trials, and adverse reactions.
Topics: Bacteria; Bacterial Infections; Chromosomes, Bacterial; Ciprofloxacin; Clinical Trials as Topic; DNA | 1988 |
Two new fluoroquinolones: ciprofloxacin and norfloxacin.
Topics: Bacterial Infections; Ciprofloxacin; Humans; Norfloxacin | 1988 |
Overview of clinical experience with ciprofloxacin.
Topics: Administration, Oral; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Enteritis; Enterob | 1986 |
Susceptibility testing today: myth, reality, and new direction.
Topics: Animals; Bacterial Infections; Ciprofloxacin; Humans; Legionnaires' Disease; Microbial Sensitivity T | 1988 |
[[New antimicrobial agent series XXXII]: ciprofloxacin].
Topics: Adult; Bacteria; Bacterial Infections; Chemical Phenomena; Chemistry; Ciprofloxacin; Humans; Microbi | 1988 |
Quinolones. Oral antibiotics of the future.
Topics: Administration, Oral; Bacterial Infections; Ciprofloxacin; Foot Diseases; Humans; Microbial Sensitiv | 1988 |
Ciprofloxacin.
Topics: Bacterial Infections; Ciprofloxacin; Humans; Respiratory Tract Infections | 1988 |
Ciprofloxacin in management of urinary tract infection.
Topics: Bacterial Infections; Ciprofloxacin; Humans; Male; Microbial Sensitivity Tests; Prostatitis; Urinary | 1988 |
Worldwide clinical data on efficacy and safety of ciprofloxacin.
Topics: Bacterial Infections; Ciprofloxacin; Clinical Trials as Topic; Female; Humans; Male | 1988 |
Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
Topics: Animals; Bacteria; Bacterial Infections; Ciprofloxacin; Humans | 1988 |
Ciprofloxacin--an important new antimicrobial.
Topics: Animals; Bacteria; Bacterial Infections; Ciprofloxacin; Drug Interactions; Humans | 1987 |
Symposium on antimicrobial agents. The quinolones.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Drug Resistance, Micr | 1987 |
Quinolones.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Enoxacin | 1987 |
Animal models: the in-vivo evaluation of ciprofloxacin.
Topics: Animals; Bacterial Infections; Ciprofloxacin; Disease Models, Animal | 1986 |
New antibiotics: areas of appropriate use.
Topics: Anti-Bacterial Agents; Aztreonam; Bacterial Infections; beta-Lactamase Inhibitors; Cephalosporins; C | 1987 |
The role of 4-quinolones in the treatment of infections.
Topics: Bacterial Infections; Ciprofloxacin; Humans; Kinetics; Norfloxacin; Ofloxacin; Oxazines; Urinary Tra | 1987 |
Review of the 4-quinolones.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Drug Interactions; Drug Resist | 1987 |
New approaches to the treatment of urinary tract infection.
Topics: Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Female; Humans; Male; Pyelonephritis; Ur | 1987 |
Efficacy of ciprofloxacin in animal models of infection.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Disease Models, Animal; Drug Ev | 1987 |
200 trials available for ciprofloxacin and Bacterial Disease
| Article | Year |
|---|---|
Response-Guided Therapy With Cefotaxime, Ceftriaxone, or Ciprofloxacin for Spontaneous Bacterial Peritonitis: A Randomized Trial: A Validation Study of 2021 AASLD Practice Guidance for SBP.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Ascites; Bacterial Infections; Cefotaxime; Ceftriaxo | 2023 |
Daily Norfloxacin vs. Weekly Ciprofloxacin to Prevent Spontaneous Bacterial Peritonitis: A Randomized Controlled Trial.
Topics: Adult; Aged; Anti-Bacterial Agents; Ascites; Bacterial Infections; Ciprofloxacin; Disease-Free Survi | 2018 |
Infection Control in Teeth with Apical Periodontitis Using a Triple Antibiotic Solution or Calcium Hydroxide with Chlorhexidine: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Calcium Hydroxide; Chlorhexidi | 2018 |
Single-dose versus multiple-dose ciprofloxacin plus metronidazole prophylaxis in transrectal ultrasound-guided biopsy of the prostate: a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteremia; Bacterial | 2014 |
[Bacteriologic investigation of the Eustachian tube and the implications of perioperative antibiotics before balloon dilation].
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Ciprofloxacin; Eustachian Tube; | 2015 |
Efficacy of indigenously developed single vial kit preparation of 99mTc-ciprofloxacin in the detection of bacterial infection: an Indian experience.
Topics: Adolescent; Adult; Bacterial Infections; Bone Diseases, Infectious; Ciprofloxacin; Diabetic Foot; Di | 2008 |
A prospective, controlled, randomized, non-blind, comparative study of the efficacy and safety of a once daily high dose of ceftriaxone plus ciprofloxacin versus thrice daily ceftazidime plus amikacin in empirical therapy for febrile neutropenic patients.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Ceftazidime; Ceftriaxo | 2008 |
Clinical efficacy of intravenous ciprofloxacin in patients with biliary tract infection: a randomized controlled trial with carbapenem as comparator.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Bile Duct Diseases; Carbapenem | 2009 |
Increased intestinal permeability as a predictor of bacterial infections in patients with decompensated liver cirrhosis and hemorrhage.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Bacterial Infections; Bacterial Translocation; C | 2011 |
Evaluation of the efficacy and safety of intravenous ciprofloxacin versus meropenem in the treatment of postoperative infection.
Topics: Aged; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Digestive System Surgical Procedur | 2012 |
Infectious complications and hospital admissions after prostate biopsy in a European randomized trial.
Topics: Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Biopsy, Needle; Chi-Squar | 2012 |
Oral antibiotic prophylaxis of early infection in multiple myeloma: a URCC/ECOG randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Antibiotic Prophylaxis; | 2012 |
[Randomized comparative study for the assessment of a new therapeutic schedule of fosfomycin trometamol in postmenopausal women with uncomplicated lower urinary tract infection].
Topics: Aged; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Drug Administration Schedule; Fema | 2013 |
Antimicrobial prophylaxis for transrectal prostatic biopsy: a prospective study of ciprofloxacin vs piperacillin/tazobactam.
Topics: Anti-Infective Agents; Antibiotic Prophylaxis; Bacterial Infections; Biopsy; Ciprofloxacin; Drug The | 2002 |
[Prospective randomized trial of intravenous ciprofloxacin for prevention of bacterial infection in cirrhotic patients with esophageal variceal bleeding].
Topics: Adult; Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Bacterial Infections; Ciprofloxacin; End | 2002 |
[Benzylpenicillin efficacy for neutropenic infection prophylaxis in patients with cancer and postcytostatic neutropenia].
Topics: Adolescent; Adult; Anti-Infective Agents; Antibiotic Prophylaxis; Antineoplastic Agents; Bacterial I | 2002 |
Tc-99m ciprofloxacin imaging in diagnosis of chronic bacterial prostatitis.
Topics: Adult; Aged; Bacterial Infections; Chronic Disease; Ciprofloxacin; Humans; Male; Middle Aged; Organo | 2003 |
Levofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis: a randomized double-blind multicenter study.
Topics: Adult; Anti-Infective Agents; Bacterial Infections; Chronic Disease; Ciprofloxacin; Double-Blind Met | 2003 |
Piperacillin-tazobactam versus ciprofloxacin plus amoxicillin in the treatment of infective episodes after liver transplantation.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Do | 2003 |
Antibiotic treatment of small bowel bacterial overgrowth in patients with Crohn's disease.
Topics: Adult; Aged; Anti-Infective Agents; Bacterial Infections; Breath Tests; Ciprofloxacin; Colonic Disea | 2003 |
Gatifloxacin 200 mg or 400 mg once daily is as effective as ciprofloxacin 500 mg twice daily for the treatment of patients with acute pyelonephritis or complicated urinary tract infections.
Topics: Bacterial Infections; Ciprofloxacin; Dose-Response Relationship, Drug; Drug Administration Schedule; | 2004 |
99mTc ciprofloxacin imaging for the diagnosis of infection in the postoperative spine.
Topics: Adolescent; Adult; Aged; Bacterial Infections; Ciprofloxacin; Female; Humans; Male; Middle Aged; Org | 2004 |
Gatifloxacin 400 mg as a single shot or 200 mg once daily for 3 days is as effective as ciprofloxacin 250 mg twice daily for the treatment of patients with uncomplicated urinary tract infections.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Double-Blind Me | 2004 |
Antibiotic therapy for diabetic foot infections: comparison of cephalosporines with chinolones.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Ceftriaxone; Ciprofloxa | 2004 |
Impact of restricting fluoroquinolone prescription on bacterial resistance in an intensive care unit.
Topics: Bacterial Infections; Ciprofloxacin; Cross Infection; Drug Resistance, Bacterial; Drug Utilization; | 2005 |
In vitro and in vivo evaluation of [18F]ciprofloxacin for the imaging of bacterial infections with PET.
Topics: Aged; Bacterial Infections; Ciprofloxacin; Escherichia coli; Female; Fluorine Radioisotopes; Humans; | 2005 |
Treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers serum prostate specific antigen.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; | 2005 |
Single-dose oral ciprofloxacin compared with single-dose intravenous cefazolin for prophylaxis in inguinal hernia repair: a controlled randomized clinical study.
Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infectio | 2005 |
Perianal fistulas in Crohn's disease are predominantly colonized by skin flora: implications for antibiotic treatment?
Topics: Adult; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Corynebacterium Infections; Crohn | 2005 |
[Clinical efficacy of a novel antimicrobial drug combination containing ciprofloxacin and tinidazole in the treatment of patients with skin and soft tissue infections].
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Drug Com | 2005 |
Single-dose antibiotic prophylaxis in core prostate biopsy: Impact of timing and identification of risk factors.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Antibiotic Prophylaxis; Bacterial Infections; Biopsy | 2006 |
A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacterial Infections; Ciprofloxac | 2006 |
Comparison of sequential intravenous/oral ciprofloxacin plus metronidazole with intravenous ceftriaxone plus metronidazole for treatment of complicated intra-abdominal infections.
Topics: Abdomen; Abdominal Abscess; Administration, Oral; Anti-Bacterial Agents; Bacterial Infections; Cipro | 2006 |
Comparison of a 3-day with a 1-day regimen of an extended-release formulation of ciprofloxacin as antimicrobial prophylaxis for patients undergoing transrectal needle biopsy of the prostate.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Biopsy, Needle; Ciprofloxacin; Delayed-Action Pre | 2007 |
Oral vs intravenous antibiotic prophylaxis in elective laparoscopic cholecystectomy: an exploratory trial.
Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infectio | 2008 |
Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: a randomized, placebo-controlled study.
Topics: Adult; Aged; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Humans; Middle Aged; Perito | 2008 |
Experience with ciprofloxacin in vitro and in vivo.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents, Urinary; Bacteria; Bacterial Infections; | 1984 |
Treatment of chronic ear disease. Topical ciprofloxacin vs topical gentamicin.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Chi-Squ | 1995 |
Ciprofloxacin and long-term prevention of spontaneous bacterial peritonitis: results of a prospective controlled trial.
Topics: Adult; Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Ascites; Bacterial Infections; Ciproflox | 1995 |
Comparative activities of pefloxacin and ciprofloxacin in the treatment of chronic respiratory tract infections.
Topics: Adult; Bacterial Infections; Bronchi; Bronchoalveolar Lavage Fluid; Chronic Disease; Ciprofloxacin; | 1995 |
Granulocyte colony-stimulating factor (G-CSF) with or without a quinolone in the prevention of infection in cancer patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections; Ciprofloxacin; Female; Granulocyte | 1993 |
[Cifran -- clinical effectiveness in the prevention and treatment of infection].
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Appendicitis; Bacterial Infections; Cholecyst | 1994 |
[Chemoprophylaxis of bacterial infections in granulocytopenic patients with new quinolone: a comparison of trimethoprim-sulfamethoxazole (ST) alone with ST plus ciprofloxacin].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Agranulocytosis; Anti-Bacterial Agents; Bacterial Infect | 1995 |
Ciprofloxacin versus trimethoprim/sulfamethoxazole for prophylaxis of bacterial infections in bone marrow transplant recipients: a randomized, controlled trial.
Topics: Administration, Oral; Adult; Bacterial Infections; Bone Marrow Transplantation; Cause of Death; Cipr | 1995 |
Controlled prospective study of oral ciprofloxacin versus amoxycillin/clavulanic acid in chronic suppurative otitis media in adults.
Topics: Adult; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Bacterial Infections; Chronic Dis | 1994 |
Study of the efficacy and safety of ciprofloxacin in the treatment of chronic otitis.
Topics: Adult; Bacterial Infections; Chronic Disease; Ciprofloxacin; Earache; Female; Humans; Male; Middle A | 1994 |
A double-blind comparison of ciprofloxacin and amoxycillin/clavulanic acid in the treatment of chronic sinusitis.
Topics: Adolescent; Adult; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Bacterial Infections; | 1994 |
Antibiotic prophylaxis for urodynamic testing in patients with spinal cord injury: a preliminary study.
Topics: Adult; Aged; Bacterial Infections; Ciprofloxacin; Double-Blind Method; Female; Humans; Male; Middle | 1994 |
[Clinical efficacy of ciprofloxacin and ofloxacin].
Topics: Adolescent; Adult; Aged; Bacterial Infections; Ciprofloxacin; Dysentery, Bacillary; Female; Gonorrhe | 1994 |
Infection prevention in autologous bone marrow transplantation and the role of protective isolation.
Topics: Adolescent; Adult; Amphotericin B; Bacterial Infections; Bone Marrow Transplantation; Ciprofloxacin; | 1994 |
Comparison of ciprofloxacin, ofloxacin and pefloxacin for the prevention of the bacterial infection in neutropenic patients with haematological malignancies.
Topics: Adult; Aged; Agranulocytosis; Anti-Infective Agents; Bacteremia; Bacterial Infections; Ciprofloxacin | 1994 |
[Ciprofloxacin/metronidazole vs. cefoxitin/doxycycline: comparison of two therapy schedules for treatment of acute pelvic infection].
Topics: Adult; Bacterial Infections; Bacteriological Techniques; Cefoxitin; Ciprofloxacin; Dose-Response Rel | 1994 |
Sequential prophylactic oral and empiric once-daily parenteral antibiotics for neutropenia and fever after high-dose chemotherapy and autologous bone marrow support.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; B | 1994 |
Infection prevention in severely myelosuppressed patients: a comparison between ciprofloxacin and a regimen of selective antibiotic modulation of the intestinal flora.
Topics: Adolescent; Adult; Aged; Bacterial Infections; Bone Marrow Diseases; Ciprofloxacin; Drug Therapy, Co | 1994 |
[The efficacy and tolerance of Bay-o-9867 (ciprofloxacin) in the treatment of infections of the urinary tract and of the lower respiratory tract].
Topics: Adult; Aged; Aged, 80 and over; Bacterial Infections; Ciprofloxacin; Drug Tolerance; Female; Humans; | 1994 |
Comparative clinical, microbiologic, and economic audit of the use of oral ciprofloxacin and parenteral antimicrobials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacterial Infections; Ciprofloxac | 1993 |
[Oral ciprofloxacin therapy in juvenile patients with cystic fibrosis--results of a prospective pilot study].
Topics: Adolescent; Bacterial Infections; Child; Ciprofloxacin; Cystic Fibrosis; Dose-Response Relationship, | 1993 |
Efficacy of topical ciprofloxacin in the treatment of ear infections in adults.
Topics: Administration, Topical; Adult; Bacterial Infections; Chronic Disease; Ciprofloxacin; Ear Diseases; | 1993 |
Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer.
Topics: Administration, Oral; Adolescent; Adult; Aged; Ambulatory Care; Aztreonam; Bacteremia; Bacterial Inf | 1993 |
Chemoprophylaxis of bacterial infections in granulocytopenic patients with ciprofloxacin vs ciprofloxacin plus amoxicillin.
Topics: Adolescent; Adult; Aged; Agranulocytosis; Amoxicillin; Bacteria; Bacterial Infections; Ciprofloxacin | 1993 |
Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Analysis of Variance; Bacterial Infections; Ciprofloxaci | 1993 |
Oral ciprofloxacin as prophylaxis in gastroduodenal surgery.
Topics: Administration, Oral; Anti-Infective Agents; Antibiotic Prophylaxis; Bacterial Infections; Cefuroxim | 1995 |
Oral ciprofloxacin vs intravenous therapy with nonquinolone agents. A study of 291 infections.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacterial I | 1995 |
Ciprofloxacin in the treatment of serious infections in systemic lupus erythematosus.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Female; Humans; | 1995 |
Initial clinical experience with clinafloxacin in the treatment of serious infections.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Bacterial Infections; Child; Ciprofloxacin; Drug Res | 1995 |
New options for spontaneous bacterial prophylaxis: costly or cost effective?
Topics: Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Double-Blind Method; Humans; Peritonitis | 1996 |
Bioavailability of ciprofloxacin in patients with acute infectious diarrhoe.
Topics: Acute Disease; Anti-Infective Agents; Area Under Curve; Bacterial Infections; Biological Availabilit | 1996 |
Chemoprophylaxis with ciprofloxacin in ovarian cancer patients receiving paclitaxel: a randomized trial.
Topics: Administration, Oral; Adult; Aged; Anti-Infective Agents; Antineoplastic Agents, Phytogenic; Bacteri | 1997 |
A comparison of ciprofloxacin and tobramycin in bacterial conjunctivitis in children.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Child; Ciprofloxacin; Conjunctiv | 1997 |
[Antibiotic prophylaxis after gastrointestinal hemorrhage in liver cirrhosis--for which patients, with what antibiotics?].
Topics: Amoxicillin-Potassium Clavulanate Combination; Antibiotic Prophylaxis; Bacterial Infections; Ciprofl | 1997 |
Pentoxifylline, ciprofloxacin and prednisone failed to prevent transplant-related toxicities in bone marrow transplant recipients and were associated with an increased incidence of infectious complications.
Topics: Adolescent; Adult; Anti-Infective Agents; Anti-Inflammatory Agents; Bacterial Infections; Bone Marro | 1997 |
The effect of ciprofloxacin in the prevention of bacterial infection in patients with cirrhosis after upper gastrointestinal bleeding.
Topics: Acute Disease; Administration, Oral; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Fem | 1998 |
Evaluation of the efficacy of 99mTc-Infecton, a novel agent for detecting sites of infection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacteria; Bacterial Infections; C | 1998 |
Ciprofloxacin plus piperacillin is an equally effective regimen for empiric therapy in febrile neutropenic patients compared with standard therapy.
Topics: Adult; Amphotericin B; Bacterial Infections; Ciprofloxacin; Drug Therapy, Combination; Female; Fever | 1998 |
Double-blind comparative trial of ciprofloxacin versus clarithromycin in the treatment of acute bacterial sinusitis. Sinusitis Infection Study Group.
Topics: Acute Disease; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infe | 1999 |
Domiciliary treatment of febrile episodes in cancer patients: a prospective randomized trial comparing oral versus parenteral empirical antibiotic treatment.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacterial Infections; C | 1999 |
Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients.
Topics: Adolescent; Ambulatory Care; Antineoplastic Agents; Bacterial Infections; Ceftazidime; Cephalosporin | 1999 |
A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy.
Topics: Administration, Oral; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Antineoplastic Ag | 1999 |
Penetration of ciprofloxacin into the interstitial space of inflamed foot lesions in non-insulin-dependent diabetes mellitus patients.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Diabetes Mellitus, Type 2; Diabeti | 1999 |
Empiric antimicrobial therapy of febrile neutropenic patients undergoing haematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Bacterial Infections; Bone Marrow Transplantation; C | 1999 |
Cost effectiveness of ciprofloxacin plus metronidazole versus imipenem-cilastatin in the treatment of intra-abdominal infections.
Topics: Abdomen; Aged; Anti-Infective Agents; Bacterial Infections; Cilastatin; Ciprofloxacin; Cost-Benefit | 1999 |
Pharmacokinetics and burn eschar penetration of intravenous ciprofloxacin in patients with major thermal injuries.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Area Under Curve; Bacterial Infections; Burns | 2000 |
Ciprofloxacin in the treatment of chronic bacterial prostatitis: a prospective, non-comparative multicentre clinical trial with long-term follow-up. The German Prostatitis Study Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacterial Infections; Chronic Dis | 2000 |
Ciprofloxacin 250 mg twice daily versus ofloxacin 200 mg twice daily in the treatment of complicated urinary tract infections in women.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Double-Blind Method; Drug Administ | 2000 |
Comparison of intravenous/oral ciprofloxacin plus metronidazole versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections.
Topics: Abdomen; Abdominal Abscess; Administration, Oral; Anti-Infective Agents; Appendicitis; Bacterial Inf | 2000 |
Topical ciprofloxacin for bacterial corneal ulcer.
Topics: Administration, Topical; Adolescent; Adult; Aged; Anti-Infective Agents; Bacterial Infections; Cipro | 2000 |
Prevalence of ciprofloxacin-resistant Escherichia coli in hematologic-oncologic patients.
Topics: Anti-Infective Agents; Bacteremia; Bacterial Infections; Ciprofloxacin; Drug Resistance, Microbial; | 2000 |
Evaluation of technetium-99m ciprofloxacin (Infecton) in the imaging of infection.
Topics: Abscess; Adult; Aged; Bacterial Infections; Ciprofloxacin; Evaluation Studies as Topic; Female; Huma | 2000 |
Biodistribution and dosimetry of 99mTc-ciprofloxacin, a promising agent for the diagnosis of bacterial infection.
Topics: Adult; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Female; Humans; Male; Radiation D | 2001 |
Deep tissue biopsy vs. superficial swab culture monitoring in the microbiological assessment of limb-threatening diabetic foot infection.
Topics: Adult; Bacterial Infections; Biopsy; Ciprofloxacin; Clindamycin; Corynebacterium; Diabetic Foot; Dru | 2001 |
Oral ciprofloxacin plus colistin: prophylaxis against bacterial infection in neutropenic patients. A strategy for the prevention of emergence of antimicrobial resistance.
Topics: Adolescent; Adult; Aged; Antibiotic Prophylaxis; Bacterial Infections; Bone Marrow Transplantation; | 2001 |
Selective bowel decontamination for the prevention of infection in acute myelogenous leukemia: a prospective randomized trial.
Topics: Adult; Anti-Infective Agents; Antibiotic Prophylaxis; Bacterial Infections; Ciprofloxacin; Drug Ther | 2002 |
Comparison of 99mTc ciprofloxacin, 99mTc white blood cell and three-phase bone imaging in the diagnosis of hip prosthesis infections: improved diagnostic accuracy with extended imaging time.
Topics: Adult; Aged; Aged, 80 and over; Bacterial Infections; Bone and Bones; Ciprofloxacin; False Positive | 2002 |
Teicoplanin plus ciprofloxacin versus gentamicin plus piperacillin in the treatment of febrile neutropenic patients.
Topics: Bacterial Infections; Ciprofloxacin; Drug Therapy, Combination; Fever; Gentamicins; Glycopeptides; H | 1992 |
Systemic antimicrobial therapy in skin and skin structure infections: comparison of temafloxacin and ciprofloxacin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacterial Infections; Ciprofloxac | 1991 |
Ciprofloxacin versus gentamicin/clindamycin for postpartum endometritis.
Topics: Adolescent; Adult; Bacterial Infections; Ciprofloxacin; Clindamycin; Drug Resistance, Microbial; Dru | 1991 |
Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors. The European Organization for Research on Treatment of Cancer
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Amikacin; Bacterial Infections; Ciprofloxacin; Drug | 1991 |
[A study on the treatment duration of an antibacterial agent in complicated urinary tract infections. Utility and recurrence after 14-day treatment by fleroxacin].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Anti-Infective Agents, | 1991 |
Antibacterial effectiveness of ciprofloxacin 0.3% ophthalmic solution in the treatment of bacterial conjunctivitis.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Conjunctivitis; Humans; Ophtha | 1991 |
Clinical evaluation of ciprofloxacin 0.3% ophthalmic solution for treatment of bacterial keratitis.
Topics: Bacterial Infections; Chemical Precipitation; Ciprofloxacin; Cornea; Crystallization; Eye Diseases; | 1991 |
Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Costs and C | 1991 |
Prophylaxis of bacterial infections with ciprofloxacin in patients undergoing bone marrow transplantation.
Topics: Adult; Bacterial Infections; Biological Availability; Bone Marrow Transplantation; Ciprofloxacin; Fe | 1991 |
Experience with ciprofloxacin.
Topics: Bacterial Infections; Ciprofloxacin; Female; Humans; Male; Middle Aged | 1991 |
Prevention of bacterial infection in neutropenic patients with hematologic malignancies. A randomized, multicenter trial comparing norfloxacin with ciprofloxacin. The GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Female; Fever; | 1991 |
[Comparison of ciprofloxacin with polymyxin B for infection prophylaxis in neutropenic patients with acute non-lymphocytic leukemia].
Topics: Administration, Inhalation; Administration, Oral; Bacterial Infections; Ciprofloxacin; Drug Administ | 1990 |
A randomized study of teicoplanin plus ciprofloxacin versus gentamicin plus piperacillin for the empirical treatment of fever in neutropenic patients.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Bone Marrow Transplantation; Ciprofloxacin; D | 1990 |
Empiric antimicrobial therapy of domestically acquired acute diarrhea in urban adults.
Topics: Adult; Bacterial Infections; Campylobacter fetus; Campylobacter Infections; Ciprofloxacin; Diarrhea; | 1990 |
A comparative study of intravenous ciprofloxacin and benzylpenicillin versus netilmicin and piperacillin for the empirical treatment of fever in neutropenic patients.
Topics: Adult; Bacterial Infections; Ciprofloxacin; Drug Therapy, Combination; Fever; Humans; Injections, In | 1990 |
Options and limitations of long-term oral ciprofloxacin as antibacterial prophylaxis in allogeneic bone marrow transplant recipients.
Topics: Adult; Bacterial Infections; Bone Marrow Transplantation; Chi-Square Distribution; Ciprofloxacin; Cl | 1990 |
Clinical experience with ciprofloxacin: analysis of a multicenter study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections; Child; Child, Preschool; Ciproflox | 1990 |
Ciprofloxacin. Best use of this new broad-spectrum antibiotic.
Topics: Bacterial Infections; Biological Availability; Ciprofloxacin; Clinical Trials as Topic; Drug Interac | 1990 |
Ciprofloxacin in severe infections.
Topics: Adolescent; Adult; Aged; Bacterial Infections; Ciprofloxacin; Female; Humans; Male; Middle Aged; Pse | 1990 |
Infection prophylaxis in neutropenic patients with acute leukaemia--a randomized, comparative study with ofloxacin, ciprofloxacin and co-trimoxazole/colistin.
Topics: Bacterial Infections; Ciprofloxacin; Colistin; Humans; Neutropenia; Ofloxacin; Precursor Cell Lympho | 1990 |
High dose intravenous ciprofloxacin in febrile neutropenic patients.
Topics: Adolescent; Adult; Aged; Bacterial Infections; Ciprofloxacin; Female; Fever; Gram-Negative Bacteria; | 1990 |
Randomized multicentre study of ciprofloxacin and azlocillin versus gentamicin and azlocillin in the treatment of febrile neutropenic patients.
Topics: Adolescent; Adult; Azlocillin; Bacterial Infections; Ciprofloxacin; Drug Therapy, Combination; Femal | 1990 |
Antibiotic prophylaxis in biliary tract surgery. Ciprofloxacin versus ceftriaxone.
Topics: Bacterial Infections; Bile; Biliary Tract Surgical Procedures; Ceftriaxone; Ciprofloxacin; Female; H | 1989 |
[Prophylaxis using quinolones in neutropenic patients. Preliminary results of a cooperative study by the Grupo Italiano Malattie Ematologiche maligne dell'adulto (GIMEMEA)].
Topics: Agranulocytosis; Anti-Bacterial Agents; Bacterial Infections; Bone Marrow Transplantation; Ciproflox | 1989 |
Clinical experience with ciprofloxacin.
Topics: Adult; Aged; Bacterial Infections; Ciprofloxacin; Female; Humans; Male; Middle Aged; Multicenter Stu | 1989 |
A comparative study of ciprofloxacin and conventional therapy in the treatment of patients with chronic lower leg ulcers infected with Pseudomonas aeruginosa or other gram-negative rods.
Topics: Administration, Oral; Aged; Bacterial Infections; Chlorhexidine; Ciprofloxacin; Disinfectants; Drug | 1989 |
Comparative efficacy of ciprofloxacin versus josamycin in the treatment of acute, recurrent, or exacerbated bronchitis.
Topics: Acute Disease; Bacteria; Bacterial Infections; Bronchitis; Ciprofloxacin; Humans; Josamycin; Microbi | 1989 |
Comparison of parenteral ciprofloxacin with clindamycin-gentamicin in the treatment of pelvic infection.
Topics: Acute Disease; Adult; Bacterial Infections; Ciprofloxacin; Clindamycin; Drug Therapy, Combination; E | 1989 |
Intravenous/oral ciprofloxacin versus ceftazidime in the treatment of serious infections.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections; Ciprofloxaci | 1989 |
Intravenous ciprofloxacin versus cefotaxime prophylaxis during transurethral surgery.
Topics: Adult; Aged; Aged, 80 and over; Bacterial Infections; Cefotaxime; Ciprofloxacin; Double-Blind Method | 1989 |
Single-dose preoperative prophylaxis in transurethral surgery. Ciprofloxacin versus cefotaxime.
Topics: Aged; Bacterial Infections; Cefotaxime; Ciprofloxacin; Humans; Male; Middle Aged; Postoperative Comp | 1989 |
Intravenous ciprofloxacin as empirical treatment of febrile neutropenic patients.
Topics: Adult; Agranulocytosis; Bacteria; Bacterial Infections; Ciprofloxacin; Drug Therapy, Combination; Fe | 1989 |
Single-dose ciprofloxacin in the treatment of uncomplicated urinary tract infection in women.
Topics: Adolescent; Adult; Bacterial Infections; Ciprofloxacin; Double-Blind Method; Drug Administration Sch | 1989 |
The role of fluoroquinolones in the management of skin, soft tissue, and bone infections.
Topics: Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Clinical Trials as Topic; Dermatitis; En | 1989 |
Clinical experience with ciprofloxacin: analysis of a multicenter study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alabama; Bacterial Infections; Child; Ciprofloxacin; Fem | 1989 |
Randomized trial comparing ciprofloxacin plus netilmicin versus piperacillin plus netilmicin for empiric treatment of fever in neutropenic patients.
Topics: Administration, Oral; Adolescent; Adult; Aged; Agranulocytosis; Bacterial Infections; Bone Marrow Tr | 1989 |
Ciprofloxacin versus ceftazidime in skin and soft tissue infections.
Topics: Administration, Oral; Bacterial Infections; Ceftazidime; Ciprofloxacin; Clinical Trials as Topic; Co | 1989 |
Clinical experience with ciprofloxacin: analysis of a multicenter study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections; Ciprofloxacin; Clinical Trials as | 1989 |
Therapy of lower extremity infections with ciprofloxacin in patients with diabetes mellitus, peripheral vascular disease, or both.
Topics: Adult; Bacteria; Bacterial Infections; Ciprofloxacin; Clinical Trials as Topic; Diabetes Complicatio | 1989 |
Clinical experience with ciprofloxacin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections; Ciprofloxacin; Clinical Trials as | 1989 |
Sequential intravenous-oral administration of ciprofloxacin vs ceftazidime in serious bacterial respiratory tract infections.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bacterial Infections; Ceftazidime; Ciprofloxac | 1989 |
In-vitro activity of meropenem against clinical isolates in a multicentre study in Italy.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Carbapenems; Ciprofloxacin; | 1989 |
Clinical experience with ciprofloxacin: analysis of a multicenter study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections; Ciprofloxacin; Female; Humans; Mal | 1989 |
Oral ciprofloxacin vs parenteral cefotaxime in the treatment of difficult skin and skin structure infections. A multicenter trial.
Topics: Administration, Oral; Bacterial Infections; Cefotaxime; Ciprofloxacin; Double-Blind Method; Female; | 1989 |
Safety of ciprofloxacin based on phase IV studies ("Anwendungsbeobachtung") in the Federal Republic of Germany.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections; Child; Ciprofloxacin; Clinical Tri | 1989 |
Comparison of ciprofloxacin with ampicillin in acute infectious exacerbations of chronic bronchitis. A double-blind crossover study.
Topics: Adult; Aged; Ampicillin; Bacteria; Bacterial Infections; Bronchitis; Ciprofloxacin; Clinical Trials | 1989 |
Intravenous/oral ciprofloxacin therapy versus intravenous ceftazidime therapy for selected bacterial infections.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bacterial Infections; Ceftazidime; Ciprofloxac | 1989 |
Randomized, double-blind comparative study of intravenous ciprofloxacin versus ceftazidime in the treatment of serious infections.
Topics: Bacterial Infections; Ceftazidime; Ciprofloxacin; Double-Blind Method; Female; Humans; Infusions, In | 1989 |
Ciprofloxacin versus ceftazidime in serious infections.
Topics: Bacterial Infections; Ceftazidime; Ciprofloxacin; Clinical Trials as Topic; Humans; Middle Aged | 1989 |
Comparison of the safety and efficacy of intravenous ciprofloxacin and intravenous ceftazidime in the treatment of selected infections.
Topics: Adult; Aged; Aged, 80 and over; Bacterial Infections; Ceftazidime; Ciprofloxacin; Female; Humans; In | 1989 |
Prospective, randomized comparison of sequential intravenous followed by oral ciprofloxacin with intravenous ceftazidime in the treatment of serious infections.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bacterial Infections; Ceftazidime; Ciprofloxac | 1989 |
Intravenous ciprofloxacin or ceftazidime in selected infections. A prospective, randomized, controlled study.
Topics: Adult; Bacterial Infections; Ceftazidime; Ciprofloxacin; Female; Humans; Infusions, Intravenous; Mal | 1989 |
Efficacy and safety of intravenous ciprofloxacin in the treatment of serious infections. A comparison with ceftazidime.
Topics: Adult; Aged; Bacterial Infections; Ceftazidime; Ciprofloxacin; Enterobacteriaceae; Female; Humans; I | 1989 |
Comparative, double-blind study of intravenous ciprofloxacin and intravenous ceftazidime in serious infection.
Topics: Adult; Aged; Aged, 80 and over; Bacteria; Bacterial Infections; Ceftazidime; Ciprofloxacin; Double-B | 1989 |
Intravenous ciprofloxacin and ceftazidime in serious infections. A prospective, controlled clinical trial with third-party blinding.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacteria; Bacterial Infections; Ceftazidime; Ciprofloxac | 1989 |
Treatment of serious infections with intravenous ciprofloxacin. French Multicenter Study Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacteria; Bacterial Infections; Ciprofloxacin; Female; H | 1989 |
Comparison of intravenous ciprofloxacin and intravenous cefotaxime for antimicrobial prophylaxis in transurethral surgery.
Topics: Adult; Aged; Bacterial Infections; Cefotaxime; Ciprofloxacin; Clinical Trials as Topic; Double-Blind | 1989 |
A prospective, randomized comparison of ceftazidime and ciprofloxacin as initial empiric therapy in neutropenic patients with fever.
Topics: Adolescent; Adult; Agranulocytosis; Bacterial Infections; Ceftazidime; Ciprofloxacin; Female; Fever; | 1989 |
Multicenter, randomized trial of ciprofloxacin plus azlocillin versus ceftazidime plus amikacin for empiric treatment of febrile neutropenic patients.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Amikacin; Azlocillin; Bacterial Infections; Ceftazi | 1989 |
Safety of intravenous ciprofloxacin. A review.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections; Ceftazidime; | 1989 |
Safety of oral ciprofloxacin. An update based on clinical trial results.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections; Child; Child | 1989 |
Clinical experience with ciprofloxacin: analysis of a multicenter study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections; Ciprofloxacin; Female; Humans; Mal | 1989 |
A comparison of ciprofloxacin with doxycycline plus metronidazole in the treatment of acute pelvic inflammatory disease.
Topics: Acute Disease; Adolescent; Adult; Bacterial Infections; Ciprofloxacin; Doxycycline; Drug Evaluation; | 1989 |
Ciprofloxacin: chemistry, mechanism of action, resistance, antimicrobial spectrum, pharmacokinetics, clinical trials, and adverse reactions.
Topics: Bacteria; Bacterial Infections; Chromosomes, Bacterial; Ciprofloxacin; Clinical Trials as Topic; DNA | 1988 |
Treatment of urinary tract infections with ciprofloxacin.
Topics: Adolescent; Adult; Aged; Bacterial Infections; Child; Ciprofloxacin; Female; Humans; Male; Middle Ag | 1988 |
Clinical experience with ciprofloxacin in the USA.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacteria; Bacterial Infections | 1986 |
Ciprofloxacin in the treatment of urinary tract infections caused by Pseudomonas aeruginosa and multiresistant bacteria.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Clinical Trials a | 1986 |
Long-term oral ciprofloxacin for infection prophylaxis in allogeneic bone marrow transplantation.
Topics: Administration, Oral; Bacterial Infections; Bone Marrow Transplantation; Ciprofloxacin; Clinical Tri | 1987 |
Therapy of acute and chronic gram-negative osteomyelitis with ciprofloxacin. Report from a Swedish Study Group.
Topics: Acute Disease; Administration, Oral; Arthritis; Bacterial Infections; Chronic Disease; Ciprofloxacin | 1988 |
Antibacterial treatment of otitis and sinusitis with ciprofloxacin and penicillin V--a comparison.
Topics: Adult; Bacterial Infections; Ciprofloxacin; Clinical Trials as Topic; Frontal Sinus; Humans; Maxilla | 1988 |
Worldwide clinical data on efficacy and safety of ciprofloxacin.
Topics: Bacterial Infections; Ciprofloxacin; Clinical Trials as Topic; Female; Humans; Male | 1988 |
Bacterial infections of the skin treated with ciprofloxacin.
Topics: Adult; Bacterial Infections; Ciprofloxacin; Clinical Trials as Topic; Female; Humans; Male; Skin Dis | 1988 |
Efficacy and safety of ciprofloxacin in the treatment of UTIs and RTIs in patients affected by liver diseases.
Topics: Adult; Bacterial Infections; Ciprofloxacin; Clinical Trials as Topic; Female; Humans; Liver Diseases | 1988 |
Bacterial infections of the lower urinary tract treated with ciprofloxacin or cefalexin--a comparative study.
Topics: Adult; Bacterial Infections; Cephalexin; Ciprofloxacin; Clinical Trials as Topic; Humans; Random All | 1988 |
Clinical use of ciprofloxacin: an interesting new oral antibiotic.
Topics: Administration, Oral; Adult; Aged; Bacterial Infections; Ciprofloxacin; Clinical Trials as Topic; Do | 1988 |
Prospective randomized controlled study of ciprofloxacin versus imipenem-cilastatin in severe clinical infections.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections; Cilastatin; Ciprofloxacin; Clinica | 1987 |
Results of clinical trials with ciprofloxacin in Italy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections; Child; Ciprofloxacin; Clinical Tri | 1987 |
Ciprofloxacin for infection prevention in patients with acute leukemia.
Topics: Adult; Bacterial Infections; Ciprofloxacin; Clinical Trials as Topic; Colistin; Drug Combinations; D | 1987 |
Treatment of multi-resistant urinary tract infections in patients with multiple sclerosis.
Topics: Bacterial Infections; Ciprofloxacin; Clinical Trials as Topic; Drug Resistance, Microbial; Humans; M | 1987 |
Treatment of chronic bacterial prostatitis with ciprofloxacin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections; Ciprofloxacin; Clinical Trials as | 1987 |
Treatment of chronic postsurgical osteomyelitis with ciprofloxacin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections; Chronic Disease; Ciprofloxacin; Cl | 1987 |
Ciprofloxacin versus placebo in the treatment of acute bacterial diarrhea.
Topics: Acute Disease; Adult; Bacteria; Bacterial Infections; Ciprofloxacin; Clinical Trials as Topic; Diarr | 1987 |
Infection prophylaxis in acute leukemia: a comparison of ciprofloxacin with trimethoprim-sulfamethoxazole and colistin.
Topics: Acute Disease; Agranulocytosis; Bacterial Infections; Ciprofloxacin; Colistin; Drug Combinations; Dr | 1987 |
Oral ciprofloxacin in the treatment of serious soft tissue and bone infections. Efficacy, safety, and pharmacokinetics.
Topics: Administration, Oral; Aged; Bacterial Infections; Ciprofloxacin; Clinical Trials as Topic; Diabetes | 1987 |
Controlled, comparative study of ciprofloxacin versus ampicillin in treatment of bacterial respiratory tract infections.
Topics: Adult; Aged; Aged, 80 and over; Ampicillin; Bacterial Infections; Ciprofloxacin; Clinical Trials as | 1987 |
Ciprofloxacin versus tobramycin plus azlocillin in pulmonary exacerbations in adult patients with cystic fibrosis.
Topics: Adult; Anti-Bacterial Agents; Azlocillin; Bacterial Infections; Ciprofloxacin; Clinical Trials as To | 1987 |
Efficacy and safety of oral ciprofloxacin in the treatment of serious respiratory infections.
Topics: Administration, Oral; Adult; Aged; Bacterial Infections; Bronchitis; Ciprofloxacin; Clinical Trials | 1987 |
Efficacy and safety of oral ciprofloxacin in the treatment of respiratory tract infections associated with chronic hepatitis.
Topics: Administration, Oral; Adult; Aged; Bacterial Infections; Candidiasis, Oral; Ciprofloxacin; Clinical | 1987 |
Systemic treatment of cutaneous infections. A comparative study of ciprofloxacin and cefotaxime.
Topics: Administration, Oral; Aged; Bacterial Infections; Cefotaxime; Ciprofloxacin; Clinical Trials as Topi | 1987 |
Comparative, double-blind study of oral ciprofloxacin and intravenous cefotaxime in skin and skin structure infections.
Topics: Administration, Oral; Adult; Aged; Bacterial Infections; Cefotaxime; Ciprofloxacin; Clinical Trials | 1987 |
Double-blind comparison of ciprofloxacin with cefotaxime in the treatment of skin and skin structure infections.
Topics: Administration, Oral; Adult; Aged; Bacterial Infections; Cefotaxime; Ciprofloxacin; Clinical Trials | 1987 |
Oral ciprofloxacin therapy for gram-negative bacillary osteomyelitis.
Topics: Bacterial Infections; Ciprofloxacin; Clinical Trials as Topic; Drug Tolerance; Female; Gram-Negative | 1987 |
Oral ciprofloxacin therapy for chronic contiguous osteomyelitis caused by aerobic gram-negative bacilli.
Topics: Adult; Aged; Bacterial Infections; Ciprofloxacin; Clinical Trials as Topic; Digestive System; Female | 1987 |
Clinical efficacy of ciprofloxacin therapy for gram-negative bacillary osteomyelitis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bacterial Infections; Ciprofloxacin; Clinical | 1987 |
Randomized trial of ciprofloxacin compared with other antimicrobial therapy in the treatment of osteomyelitis.
Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Clini | 1987 |
Treatment of chronic bacterial prostatitis with ciprofloxacin. Results of a one-year follow-up study.
Topics: Adult; Bacterial Infections; Ciprofloxacin; Clinical Trials as Topic; Escherichia coli Infections; F | 1987 |
Ciprofloxacin versus cinoxacin in therapy of urinary tract infections. A randomized, double-blind trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections; Cinoxacin; Ciprofloxacin; Clinical | 1987 |
Comparison of ciprofloxacin and beta-lactam antibiotics in the treatment of urinary tract infections and alteration of fecal flora.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Ciproflox | 1987 |
Oral ciprofloxacin in the treatment of elderly patients with complicated urinary tract infections due to trimethoprim/sulfamethoxazole-resistant bacteria.
Topics: Administration, Oral; Aged; Aged, 80 and over; Bacterial Infections; Ciprofloxacin; Clinical Trials | 1987 |
Oral ciprofloxacin in resistant urinary tract infections.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bacterial Infections; Ciprofloxacin; Clinical | 1987 |
Clinical efficacy of ciprofloxacin compared with placebo in bacterial diarrhea.
Topics: Adult; Aged; Aged, 80 and over; Bacterial Infections; Campylobacter fetus; Campylobacter Infections; | 1987 |
Use of intravenous ciprofloxacin in difficult-to-treat infections.
Topics: Adult; Aged; Aged, 80 and over; Bacterial Infections; Ciprofloxacin; Clinical Trials as Topic; Drug | 1987 |
Dual individualization of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections.
Topics: Aged; Aged, 80 and over; Bacterial Infections; Ciprofloxacin; Clinical Trials as Topic; Cross Infect | 1987 |
Treatment of serious infections with intravenous ciprofloxacin.
Topics: Administration, Oral; Adult; Aged; Arthritis, Infectious; Bacterial Infections; Ciprofloxacin; Clini | 1987 |
Ciprofloxacin: an update on clinical experience.
Topics: Bacterial Infections; Ciprofloxacin; Clinical Trials as Topic; Digestive System; Drug Resistance, Mi | 1987 |
Efficacy and safety of ciprofloxacin in patients with respiratory infections in comparison with amoxycillin.
Topics: Aged; Aged, 80 and over; Amoxicillin; Bacterial Infections; Ciprofloxacin; Female; Humans; Male; Ran | 1986 |
Intravenous ciprofloxacin in the treatment of infection in immunocompromised patients.
Topics: Adolescent; Adult; Bacterial Infections; Ciprofloxacin; Drug Therapy, Combination; Humans; Immune To | 1986 |
475 other studies available for ciprofloxacin and Bacterial Disease
| Article | Year |
|---|---|
Synthesis and structure-activity relationships of 7-diazabicycloalkylquinolones, including danofloxacin, a new quinolone antibacterial agent for veterinary medicine.
Topics: Actinobacillus Infections; Actinobacillus pleuropneumoniae; Aerobiosis; Anaerobiosis; Animals; Anti- | 1992 |
New 8-(trifluoromethyl)-substituted quinolones. The benefits of the 8-fluoro group with reduced phototoxic risk.
Topics: 4-Quinolones; Administration, Oral; Animals; Anti-Infective Agents; Bacterial Infections; Female; In | 1992 |
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
Topics: Alkylation; Aminoquinolines; Animals; Anti-Bacterial Agents; Bacterial Infections; Chemical Phenomen | 1991 |
Fluoronaphthyridines and -quinolones as antibacterial agents. 3. Synthesis and structure-activity relationships of new 1-(1,1-dimethyl-2-fluoroethyl), 1-[1-methyl-1-(fluoromethyl)-2-fluoroethyl], and 1-[1,1-(difluoromethyl)-2-fluoroethyl] substituted deri
Topics: 4-Quinolones; Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Dogs; Indicators and R | 1991 |
Design, synthesis, and properties of (4S)-7-(4-amino-2-substituted-pyrrolidin-1-yl)quinolone-3-carboxylic acids.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Chemical Phenomena; Chemistry; Dogs; Fluoroqui | 1988 |
Synthesis and structure-activity relationship of 1-aryl-6,8-difluoroquinolone antibacterial agents.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Female; Fluorine; Magnetic Resonance Spectrosc | 1987 |
7-azetidinylquinolones as antibacterial agents. 2. Synthesis and biological activity of 7-(2,3-disubstituted-1-azetidinyl)-4-oxoquinoline- and -1,8-naphthyridine-3-carboxylic acids. Properties and structure-activity relationships of quinolones with an aze
Topics: 4-Quinolones; Animals; Anti-Infective Agents; Azetidines; Bacteria; Bacterial Infections; Crystallog | 1994 |
7-Azetidinylquinolones as antibacterial agents. Synthesis and structure-activity relationships.
Topics: 4-Quinolones; Animals; Anti-Infective Agents; Bacterial Infections; Mice; Microbial Sensitivity Test | 1993 |
Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.
Topics: Adsorption; Animals; Anti-Bacterial Agents; Bacterial Infections; Carbon Radioisotopes; Culture Medi | 2008 |
Discovery and characterization of QPT-1, the progenitor of a new class of bacterial topoisomerase inhibitors.
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Bacteria; Bacterial Infections; Bacterial Proteins | 2008 |
Arginine-pyrimidine conjugates with therapeutic and prophylactic activity in lethal bacterial infections.
Topics: Animals; Anti-Bacterial Agents; Arginine; Bacterial Infections; Cross Infection; Drug Interactions; | 2009 |
Synthesis and antimicrobial activity of novel fluorine containing 4-(substituted-2-hydroxybenzoyl)-1H-pyrazoles and pyrazolyl benzo[d]oxazoles.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antifungal Agents; Bacillus subtilis; Bacteria; Bacter | 2010 |
Synthesis, antimicrobial, and mosquito larvicidal activity of 1-aryl-4-methyl-3,6-bis-(5-methylisoxazol-3-yl)-2-thioxo-2,3,6,10b-tetrahydro-1H-pyrimido[5,4-c]quinolin-5-ones.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antifungal Agents; Bacteria; Bacterial Infect | 2010 |
In vitro and in vivo activities of LCB01-0371, a new oxazolidinone.
Topics: Acetamides; Animals; Anti-Bacterial Agents; Bacterial Infections; Gram-Positive Bacteria; Linezolid; | 2010 |
Synthesis and evaluation of 1-(1H-indol-3-yl)ethanamine derivatives as new antibacterial agents.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Humans; Indoles; Microbial Sensitivity Tests; | 2011 |
Synthesis and biological evaluation of dihydroindeno and indeno [1,2-e] [1,2,4]triazolo [3,4-b] [1,3,4]thiadiazines as antimicrobial agents.
Topics: Anti-Infective Agents; Antifungal Agents; Bacteria; Bacterial Infections; Fungi; Humans; Indans; Mic | 2011 |
Synthesis of lipophilic dimeric C-7/C-7-linked ciprofloxacin and C-6/C-6-linked levofloxacin derivatives. Versatile in vitro biological evaluations of monomeric and dimeric fluoroquinolone derivatives as potential antitumor, antibacterial or antimycobacte
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Bacteria; Bacterial Infections; Cell Line, Tumor; Cipr | 2011 |
Design, synthesis of some new (2-aminothiazol-4-yl)methylester derivatives as possible antimicrobial and antitubercular agents.
Topics: Anti-Infective Agents; Antitubercular Agents; Bacteria; Bacterial Infections; Crystallography, X-Ray | 2012 |
Green synthesis and anti-infective activities of fluorinated pyrazoline derivatives.
Topics: Anti-Infective Agents; Antitubercular Agents; Bacteria; Bacterial Infections; Fungi; Green Chemistry | 2012 |
Synthesis and evaluation of novel 1,3,4-oxadiazole derivatives of marine bromopyrrole alkaloids as antimicrobial agent.
Topics: Alkaloids; Anti-Infective Agents; Antitubercular Agents; Bacteria; Bacterial Infections; Fungi; Halo | 2012 |
Synthesis and pharmacological evaluation of a novel series of 3-aryl-2-(2-substituted-4-methylthiazole-5-yl)thiazolidin-4-one as possible anti-inflammatory and antimicrobial agents.
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Bacteria; Bacterial Infections; Carrageena | 2012 |
Synthesis and biological evaluation of novel piperazine derivatives of flavone as potent anti-inflammatory and antimicrobial agent.
Topics: Anti-Infective Agents; Anti-Inflammatory Agents; Bacteria; Bacterial Infections; Flavones; Fungi; Hu | 2012 |
Studies on the antimicrobial properties of N-acylated ciprofloxacins.
Topics: Acylation; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Bartonella; Bartonella Infections; | 2012 |
Synthesis of β-ionone derived chalcones as potent antimicrobial agents.
Topics: Anti-Infective Agents; Bacteria; Bacterial Infections; Chalcones; Fungi; Humans; Methicillin-Resista | 2012 |
Synthesis and study of 1-ethyl-3-carbohydrazide and 3-[1-oxo-2-hydrazino-3-{p-toluenesulfon}]quinolone derivatives against bacterial infections.
Topics: Anti-Bacterial Agents; Bacterial Infections; Dose-Response Relationship, Drug; Escherichia coli; Hyd | 2013 |
Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.
Topics: Anti-Infective Agents; Bacterial Infections; Drug Resistance, Multiple; Fungi; Gram-Negative Bacteri | 2013 |
Synthesis and characterization of new N-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)amide/sulfonamide derivatives as possible antimicrobial and antitubercular agents.
Topics: Amides; Anti-Infective Agents; Antitubercular Agents; Bacteria; Bacterial Infections; Fungi; Humans; | 2014 |
Synthesis and antimicrobial evaluation of amide derivatives of benzodifuran-2-carboxylic acid.
Topics: Amides; Anti-Infective Agents; Bacterial Infections; Benzofurans; Candida albicans; Candidiasis; Car | 2014 |
Synthesis, docking and evaluation of antioxidant and antimicrobial activities of novel 1,2,4-triazolo[3,4-b][1,3,4]thiadiazol-6-yl)selenopheno[2,3-d]pyrimidines.
Topics: Anti-Infective Agents; Antioxidants; Bacteria; Bacterial Infections; Benzene Derivatives; Fungi; Hum | 2014 |
Synthesis of novel amide functionalized 2H-chromene derivatives by Ritter amidation of primary alcohol using HBF4·OEt2 as a mild and versatile reagent and evaluation of their antimicrobial and anti-biofilm activities.
Topics: Amides; Anti-Infective Agents; Bacteria; Bacterial Infections; Benzopyrans; Biofilms; Borates; Boric | 2015 |
Synthesis of novel coumarin appended bis(formylpyrazole) derivatives: Studies on their antimicrobial and antioxidant activities.
Topics: Anti-Infective Agents; Antioxidants; Bacteria; Bacterial Infections; Coumarins; Fungi; Humans; Micro | 2016 |
Synthesis of novel ethyl 1-ethyl-6-fluoro-7-(fatty amido)-1,4-dihydro-4-oxoquinoline-3-carboxylate derivatives and their biological evaluation.
Topics: 4-Quinolones; Anti-Bacterial Agents; Anti-Infective Agents; Antineoplastic Agents; Antioxidants; Bac | 2016 |
Metal-based biologically active azoles and β-lactams derived from sulfa drugs.
Topics: Anti-Bacterial Agents; Azoles; Bacteria; Bacterial Infections; beta-Lactams; Coordination Complexes; | 2016 |
Novel morpholinoquinoline nucleus clubbed with pyrazoline scaffolds: Synthesis, antibacterial, antitubercular and antimalarial activities.
Topics: Anti-Infective Agents; Antimalarials; Antitubercular Agents; Bacteria; Bacterial Infections; Fungi; | 2016 |
Development of a Dual-Acting Antibacterial Agent (TNP-2092) for the Treatment of Persistent Bacterial Infections.
Topics: Anti-Bacterial Agents; Bacterial Infections; Dose-Response Relationship, Drug; Microbial Sensitivity | 2016 |
The Rational Design, Synthesis, and Antimicrobial Properties of Thiophene Derivatives That Inhibit Bacterial Histidine Kinases.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Drug Design; Enzyme Inhibitors; Histidine Kin | 2016 |
Allicin-inspired thiolated fluoroquinolones as antibacterials against ESKAPE pathogens.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Disulfides; Fluoroquinolones; Humans; Methici | 2016 |
Design, Synthesis, and Antimicrobial Evaluation of a Novel Bone-Targeting Bisphosphonate-Ciprofloxacin Conjugate for the Treatment of Osteomyelitis Biofilms.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Biofilms; Bone and Bones; Ciprofloxa | 2017 |
Novel Design of Heptad Amphiphiles To Enhance Cell Selectivity, Salt Resistance, Antibiofilm Properties and Their Membrane-Disruptive Mechanism.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Biofilms; Circular Dichr | 2017 |
Synthesis and antimicrobial evaluation of amino sugar-based naphthoquinones and isoquinoline-5,8-diones and their halogenated compounds.
Topics: Amino Sugars; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Halogenation; Hemolysis; Humans | 2018 |
Design and synthesis of novel 1H-tetrazol-5-amine based potent antimicrobial agents: DNA topoisomerase IV and gyrase affinity evaluation supported by molecular docking studies.
Topics: Amination; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Cell Line; DNA Gyrase; DNA Topoiso | 2018 |
Discovery of novel arylethenesulfonyl fluorides as potential candidates against methicillin-resistant of Staphylococcus aureus (MRSA) for overcoming multidrug resistance of bacterial infections.
Topics: Bacterial Infections; Biofilms; Drug Resistance, Multiple; Electron Transport Chain Complex Proteins | 2019 |
Virtual Screening Approach and Investigation of Structure-Activity Relationships To Discover Novel Bacterial Topoisomerase Inhibitors Targeting Gram-Positive and Gram-Negative Pathogens.
Topics: Amino Acid Sequence; Bacterial Infections; DNA Gyrase; DNA Topoisomerase IV; Escherichia coli; Micro | 2019 |
Novel C-7 carbon substituted fourth generation fluoroquinolones targeting N. Gonorrhoeae infections.
Topics: Anti-Bacterial Agents; Bacterial Infections; Carbon; Dose-Response Relationship, Drug; Fluoroquinolo | 2020 |
Synthesis and biological screening of thiosemicarbazones of substituted 3-acetylcoumarins having d-glucose moiety.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antifungal Agents; Bacteria; Bacterial Infections; Cou | 2020 |
Transrectal povidone-iodine efficiency in reducing infections occurring after transrectal ultrasound guided biopsy of the prostate.
Topics: Administration, Rectal; Aged; Anti-Bacterial Agents; Anti-Infective Agents, Local; Antibiotic Prophy | 2021 |
Titanium carbide MXene-based hybrid hydrogel for chemo-photothermal combinational treatment of localized bacterial infection.
Topics: Abscess; Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Hydrogels; M | 2022 |
Selective treatment of intracellular bacterial infections using host cell-targeted bioorthogonal nanozymes.
Topics: Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Gold; Humans; Metal Nanoparticles; Salmo | 2022 |
Dual acting acid-cleavable self-assembling prodrug from hyaluronic acid and ciprofloxacin: A potential system for simultaneously targeting bacterial infections and cancer.
Topics: Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Drug Delivery Systems; Humans; Hyaluroni | 2022 |
Pseudomonas aeruginosa persister cell formation upon antibiotic exposure in planktonic and biofilm state.
Topics: Anti-Bacterial Agents; Antitoxins; Bacterial Infections; Biofilms; Ceftazidime; Ciprofloxacin; Genta | 2022 |
Enterobacter agglomerans, an uncommon cause of community-acquired bacterial infection in neonates.
Topics: Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Community-Acquired Infections; Enterobac | 2022 |
Preparation of pectin-chitosan hydrogels based on bioadhesive-design micelle to prompt bacterial infection wound healing.
Topics: Anti-Bacterial Agents; Bacterial Infections; Chitosan; Ciprofloxacin; Humans; Hydrogels; Micelles; P | 2023 |
Formulation development and in Vitro-Ex vivo characterization of hot-melt extruded ciprofloxacin hydrochloride inserts for ocular applications: Part I.
Topics: Animals; Bacterial Infections; Ciprofloxacin; Delayed-Action Preparations; Drug Delivery Systems; Ey | 2023 |
Formulation development and in Vitro-Ex vivo characterization of hot-melt extruded ciprofloxacin hydrochloride inserts for ocular applications: Part I.
Topics: Animals; Bacterial Infections; Ciprofloxacin; Delayed-Action Preparations; Drug Delivery Systems; Ey | 2023 |
Formulation development and in Vitro-Ex vivo characterization of hot-melt extruded ciprofloxacin hydrochloride inserts for ocular applications: Part I.
Topics: Animals; Bacterial Infections; Ciprofloxacin; Delayed-Action Preparations; Drug Delivery Systems; Ey | 2023 |
Formulation development and in Vitro-Ex vivo characterization of hot-melt extruded ciprofloxacin hydrochloride inserts for ocular applications: Part I.
Topics: Animals; Bacterial Infections; Ciprofloxacin; Delayed-Action Preparations; Drug Delivery Systems; Ey | 2023 |
Formulation development and in Vitro-Ex vivo characterization of hot-melt extruded ciprofloxacin hydrochloride inserts for ocular applications: Part I.
Topics: Animals; Bacterial Infections; Ciprofloxacin; Delayed-Action Preparations; Drug Delivery Systems; Ey | 2023 |
Formulation development and in Vitro-Ex vivo characterization of hot-melt extruded ciprofloxacin hydrochloride inserts for ocular applications: Part I.
Topics: Animals; Bacterial Infections; Ciprofloxacin; Delayed-Action Preparations; Drug Delivery Systems; Ey | 2023 |
Formulation development and in Vitro-Ex vivo characterization of hot-melt extruded ciprofloxacin hydrochloride inserts for ocular applications: Part I.
Topics: Animals; Bacterial Infections; Ciprofloxacin; Delayed-Action Preparations; Drug Delivery Systems; Ey | 2023 |
Formulation development and in Vitro-Ex vivo characterization of hot-melt extruded ciprofloxacin hydrochloride inserts for ocular applications: Part I.
Topics: Animals; Bacterial Infections; Ciprofloxacin; Delayed-Action Preparations; Drug Delivery Systems; Ey | 2023 |
Formulation development and in Vitro-Ex vivo characterization of hot-melt extruded ciprofloxacin hydrochloride inserts for ocular applications: Part I.
Topics: Animals; Bacterial Infections; Ciprofloxacin; Delayed-Action Preparations; Drug Delivery Systems; Ey | 2023 |
Design of Phage-Cocktail-Containing Hydrogel for the Treatment of
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Bacteriophages; Ciprofloxacin; Disease Models, | 2023 |
Bacterial profile, their antibiotic susceptibility pattern, and associated factors of urinary tract infections in children at Hiwot Fana Specialized University Hospital, Eastern Ethiopia.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Child; Ciprofloxacin; Escherichia coli; Ethio | 2023 |
Intelligent Jellyfish-type Janus Nanoreactor Targeting Synergistic Treatment of Bacterial Infections.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Humans; Nanoparticles; Nanotec | 2023 |
Antibiotics Used in Regenerative Endodontics Modify Immune Response of Macrophages to Bacterial Infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Humans; Macrophages; Metron | 2019 |
Enhanced Clearing of Wound-Related Pathogenic Bacterial Biofilms Using Protease-Functionalized Antibiotic Nanocarriers.
Topics: Anti-Bacterial Agents; Bacterial Infections; Biocatalysis; Biofilms; Ciprofloxacin; Drug Carriers; D | 2019 |
Fortified hyperbranched PEGylated chitosan-based nano-in-micro composites for treatment of multiple bacterial infections.
Topics: Anti-Bacterial Agents; Bacteria, Aerobic; Bacteria, Anaerobic; Bacterial Infections; Bentonite; Chit | 2020 |
Etiology of childhood diarrhoea among under five children and molecular analysis of antibiotic resistance in isolated enteric bacterial pathogens from a tertiary care hospital, Eastern Odisha, India.
Topics: Anti-Bacterial Agents; Bacterial Infections; Child, Preschool; Ciprofloxacin; Cross-Sectional Studie | 2019 |
Higher Dosage of Ciprofloxacin Necessary in Critically Ill Patients: A New Dosing Algorithm Based on Renal Function and Pathogen Susceptibility.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Anti-Bacterial Agents; Bacteria; Bacterial Infections; C | 2020 |
Antibiotic-loaded chitosan-gelatin scaffolds for infected seawater immersion wound healing.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Cell Line, Tumor; Chitosan; Ciprofloxacin; Col | 2020 |
Primary Infectious Acute Pancreatitis: A 9 Case Series.
Topics: Acute Disease; Acyclovir; Adult; Anti-Bacterial Agents; Antiviral Agents; Bacterial Infections; Ceph | 2020 |
Evaluation of the Effect of Routine Antibiotic Administration after Uterine Artery Embolization on Infection Rates.
Topics: Adult; Anti-Bacterial Agents; Antimicrobial Stewardship; Bacterial Infections; Ciprofloxacin; Drug A | 2020 |
Prevalence, distribution and antimicrobial susceptibility pattern of bacterial isolates from a tertiary Hospital in Malawi.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Cerebrospinal Fluid; Child | 2021 |
Repositioning of antidepressant drugs and synergistic effect with ciprofloxacin against multidrug-resistant bacteria.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Antidepressive Agents; Bac | 2021 |
Ciprofloxacin-loaded lipid-core nanocapsules as mucus penetrating drug delivery system intended for the treatment of bacterial infections in cystic fibrosis.
Topics: Bacterial Infections; Ciprofloxacin; Cystic Fibrosis; Delayed-Action Preparations; Drug Carriers; Li | 2017 |
Ciprofloxacin Pharmacokinetics in Clinical Canine Patients.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Dog Diseases; Dogs; Female; Hal | 2017 |
Ciprofloxacin vs levofloxacin for prophylaxis during hematopoietic stem-cell transplantation.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Ciprofloxacin; Female; Follow-U | 2018 |
Low ascitic fluid total protein levels is not associated to the development of spontaneous bacterial peritonitis in a cohort of 274 patients with cirrhosis.
Topics: Anti-Bacterial Agents; Ascites; Ascitic Fluid; Bacterial Infections; Biomarkers; Ciprofloxacin; Denm | 2018 |
Calcium alginate-based antimicrobial film dressings for potential healing of infected foot ulcers.
Topics: Alginates; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Bandages; Biocompatib | 2018 |
Wicked: The untold story of ciprofloxacin.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Drug Resistance, Bacterial; Hu | 2018 |
Magnetic graphene oxide inlaid with silver nanoparticles as antibacterial and drug delivery composite.
Topics: A549 Cells; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Drug Delivery Syst | 2018 |
Addition of doxycycline to ciprofloxacin for infection prophylaxis during autologous stem cell transplants for multiple myeloma.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Doxycycline; Female; Hemato | 2018 |
Trial Comparing a Combined Regimen of Amikacin and Ciprofloxacin to Ciprofloxacin Alone as Transrectal Prostate Biopsy Prophylaxis in the Era of High Fluoroquinolone-Resistant Rectal Flora.
Topics: Aged; Amikacin; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteria; Bacterial Infections; beta- | 2018 |
Ciprofloxacin and Rifampin Dual Antibiotic-Loaded Biopolymer Chitosan Sponge for Bacterial Inhibition.
Topics: Analysis of Variance; Animals; Anti-Bacterial Agents; Bacterial Infections; Biopolymers; Chitosan; C | 2018 |
Design, Synthesis and Antibacterial Evaluation of 1-[(1R,2S)-2-Fluorocyclopropyl]ciprofloxacin-1,2,4-triazole-5(4H)-thione Hybrids.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Drug Design; Halogenation; Hum | 2018 |
Medium chain unsaturated fatty acid ethyl esters inhibit persister formation of Escherichia coli via antitoxin HipB.
Topics: Anti-Bacterial Agents; Antitoxins; Bacterial Infections; Ciprofloxacin; DNA-Binding Proteins; Escher | 2018 |
Prevalence and antimicrobial susceptibility pattern of Salmonella and Shigella among food handlers in catering establishments at Debre Markos University, Northwest Ethiopia.
Topics: Adolescent; Adult; Ampicillin; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Cross-Sec | 2018 |
Ciprofloxacin prophylaxis during autologous stem cell transplantation for multiple myeloma in patients with a high rate of fluoroquinolone-resistant gram-negative bacteria colonization.
Topics: Adult; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Carrier State; Cip | 2019 |
Preparing and immobilizing antimicrobial osteogenic growth peptide on titanium substrate surface.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Cells, Cultured; Ciprofloxacin; Coated Materia | 2018 |
Particle-coated electrospun scaffold: A semi-conductive drug eluted scaffold with layered fiber/particle arrangement.
Topics: Aniline Compounds; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Biocompatible Materials; C | 2018 |
Optimization of a dry powder inhaler of ciprofloxacin-loaded polymeric nanomicelles by spray drying process.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Desiccation; | 2019 |
Comparing infective complications from transrectal ultrasound guided prostate biopsy following transition to single dose oral ciprofloxacin prophylaxis.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Cip | 2019 |
Selection of an appropriate empiric antibiotic regimen in hematogenous vertebral osteomyelitis.
Topics: Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Bacterial Infections; be | 2019 |
Sniffing out resistance - Rapid identification of urinary tract infection-causing bacteria and their antibiotic susceptibility using volatile metabolite profiles.
Topics: Anti-Bacterial Agents; Bacterial Infections; Cephalexin; Ciprofloxacin; Drug Resistance, Bacterial; | 2019 |
Biceps tendon rupture associated with ciprofloxacin use for spontaneous bacterial peritonitis prophylaxis.
Topics: Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Ciprofloxacin; Emergency | 2019 |
Synthesis and investigations of ciprofloxacin loaded engineered selenium lipid nanocarriers for effective drug delivery system for preventing lung infections of interstitial lung disease.
Topics: Animals; Anti-Bacterial Agents; Antioxidants; Bacterial Infections; Catalase; Ciprofloxacin; Drug Ca | 2019 |
Bacterial profile and antimicrobial susceptibility patterns in chronic suppurative otitis media at the University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Chronic Disease; Ciprofloxacin; Clarithromyci | 2019 |
Ciprofloxacin modulates cytokine/chemokine profile in serum, improves bone marrow repopulation, and limits apoptosis and autophagy in ileum after whole body ionizing irradiation combined with skin-wound trauma.
Topics: Animals; Anti-Infective Agents; Apoptosis; Autophagy; Bacterial Infections; Ciprofloxacin; Cytokines | 2013 |
Bloodstream infection among adults in Phnom Penh, Cambodia: key pathogens and resistance patterns.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Blood; Camb | 2013 |
Mutant prevention concentration of orbifloxacin: comparison between Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus pseudintermedius of canine origin.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Dog Diseases; Dogs; Drug Resist | 2013 |
Effect of ciprofloxacin combined with sulfamethoxazole-trimethoprim prophylaxis on the incidence of urinary tract infections after kidney transplantation.
Topics: Adult; Aged; Anti-Infective Agents, Urinary; Antibiotic Prophylaxis; Bacterial Infections; Ciproflox | 2013 |
Current ciprofloxacin usage in children hospitalized in a referral hospital in Paris.
Topics: Adolescent; Anti-Bacterial Agents; Bacterial Infections; Child; Child, Preschool; Ciprofloxacin; Cys | 2013 |
Screening rectal culture to identify fluoroquinolone-resistant organisms before transrectal prostate biopsy: do the culture results between office visit and biopsy correlate?
Topics: Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Area Under Curve; Bacterial Infections; Biopsy, | 2013 |
Editorial comment.
Topics: Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Drug Resistance, Bacterial; Humans; Male | 2013 |
The antimicrobial screening of a Barbadian medicinal plant with indications for use in the treatment of diabetic wound infections.
Topics: Anti-Bacterial Agents; Bacterial Infections; Barbados; Ciprofloxacin; Colony-Forming Units Assay; Di | 2012 |
Methotrexate toxicity induced by ciprofloxacin leading to psoriatic plaque ulceration: a case report.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Dermatologic Agents; | 2013 |
Are clindamycin and ciprofloxacin appropriate for the empirical treatment of diabetic foot infections?
Topics: Aged; Amputation, Surgical; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Clindamycin; | 2014 |
Epidemiology of bloodstream infections in patients with acute myeloid leukemia undergoing levofloxacin prophylaxis.
Topics: Adult; Aged; Antibiotic Prophylaxis; Bacteremia; Bacteria; Bacterial Infections; Ciprofloxacin; Fema | 2013 |
Microbicidal effects of α- and θ-defensins against antibiotic-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
Topics: alpha-Defensins; Amino Acid Sequence; Bacteremia; Bacterial Infections; Ciprofloxacin; Defensins; Dr | 2015 |
Steroid-decorated antibiotic microparticles for inhaled anti-infective therapy.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Bacterial Infections; Beclomethasone; Ciprofloxac | 2014 |
[Infection of the hand: evaluation of a two-stage therapy].
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial I | 2014 |
Feasibility, efficacy, and adverse effects of outpatient antibacterial prophylaxis in children with acute myeloid leukemia.
Topics: Administration, Oral; Adolescent; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteremia; Bacteri | 2014 |
Interaction of vanadium (IV) solvates (L) with second-generation fluoroquinolone antibacterial drug ciprofloxacin: spectroscopic, structure, thermal analyses, kinetics and biological evaluation (L=An, DMF, Py and Et3N).
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Humans; Spectrum Analysis; Van | 2014 |
Acute pancreatitis secondary to ciprofloxacin therapy in patients with infectious colitis.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infectio | 2014 |
A new approach to the analysis of antibiotic resistance data from hospitals.
Topics: Anti-Bacterial Agents; Bacterial Infections; Ceftazidime; Ciprofloxacin; Drug Resistance, Multiple, | 2014 |
Hepatic cyst infection following aspiration sclerotherapy: a case series.
Topics: Abdominal Pain; Aged; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Cross Infection; C | 2014 |
Reduction in hospital admissions with the addition of prophylactic intramuscular ceftriaxone before transrectal ultrasonography-guided prostate biopsies.
Topics: Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Ceftriaxone; Ciprofloxaci | 2015 |
Editorial comment.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Ceftriaxone; Ciprofloxacin; End | 2015 |
Comparison of antibiotic prophylaxis with cotrimoxazole/colistin (COT/COL) versus ciprofloxacin (CIP) in patients with acute myeloid leukemia.
Topics: Adult; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antineoplastic Agents; Bacterial Infecti | 2015 |
Chronic bacterial seminal vesiculitis as a potential disease entity in men with chronic prostatitis.
Topics: Adult; Bacterial Infections; Chronic Disease; Ciprofloxacin; Humans; Male; Middle Aged; Organotechne | 2015 |
For Single Dosing, Levofloxacin Is Superior to Ciprofloxacin When Combined With an Aminoglycoside in Preventing Severe Infections After Prostate Biopsy.
Topics: Aminoglycosides; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Ciprofloxacin; | 2015 |
Editorial Comment.
Topics: Aminoglycosides; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Ciprofloxacin; | 2015 |
Epidemiology of antimicrobial resistance in an oncology center in eastern India.
Topics: Acinetobacter; Amikacin; Anti-Bacterial Agents; Antifungal Agents; Bacterial Infections; Cancer Care | 2015 |
Ciprofloxacin pharmacokinetics in critically ill patients receiving concomitant continuous venovenous hemodialysis.
Topics: Aged; Anti-Bacterial Agents; Area Under Curve; Bacterial Infections; Ciprofloxacin; Critical Illness | 2015 |
Disassembling bacterial extracellular matrix with DNase-coated nanoparticles to enhance antibiotic delivery in biofilm infections.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Biofilms; Cell Line; Ciprofloxacin; Deoxyribon | 2015 |
A seashell by the seashore.
Topics: Animal Shells; Animals; Anti-Bacterial Agents; Bacterial Infections; Cefazolin; Child; Ciprofloxacin | 2015 |
Purple urine bag syndrome in an elderly patient from Colombia.
Topics: Aged; Anti-Bacterial Agents; Bacterial Infections; Catheter-Related Infections; Chemical Phenomena; | 2015 |
Povidone Iodine Rectal Preparation at Time of Prostate Needle Biopsy is a Simple and Reproducible Means to Reduce Risk of Procedural Infection.
Topics: Anti-Infective Agents, Local; Antibiotic Prophylaxis; Bacterial Infections; Biopsy, Needle; Ciproflo | 2015 |
(68) Ga-labeled Ciprofloxacin Conjugates as Radiotracers for Targeting Bacterial Infection.
Topics: Animals; Bacterial Infections; Ciprofloxacin; Gallium Radioisotopes; Proton Magnetic Resonance Spect | 2016 |
Sugar-Grafted Cyclodextrin Nanocarrier as a "Trojan Horse" for Potentiating Antibiotic Activity.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacteria; Bacterial Infections; beta-Cyclodextrins; | 2016 |
Susceptibility pattern of uropathogens to ciprofloxacin at the Ghana police hospital.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Cross-Sectional Studies; Drug | 2015 |
Ciprofloxacin prophylaxis delays initiation of broad-spectrum antibiotic therapy and reduces the overall use of antimicrobial agents during induction therapy for acute leukaemia: A single-centre study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Bacterial Infections; Carbapenems | 2016 |
Targeted next-generation sequencing for the detection of ciprofloxacin resistance markers using molecular inversion probes.
Topics: Bacillus anthracis; Bacterial Infections; Bacterial Proteins; Ciprofloxacin; Drug Resistance, Microb | 2016 |
Ciprofloxacin (Otiprio) for tympanostomy tube insertion.
Topics: Adolescent; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Cerebrospinal Fluid | 2016 |
Ciprofloxacin versus colistin prophylaxis during neutropenia in acute myeloid leukemia: two parallel patient cohorts treated in a single center.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antineopl | 2016 |
Risk Factor Analysis of Ciprofloxacin-Resistant and Extended Spectrum Beta-Lactamases Pathogen-Induced Acute Bacterial Prostatitis in Korea.
Topics: Acute Disease; Adult; Age Factors; Aged; Amikacin; Anti-Bacterial Agents; Bacterial Infections; beta | 2016 |
Antibiotic resistance in healthcare-related and nosocomial spontaneous bacterial peritonitis.
Topics: Aged; Anti-Bacterial Agents; Bacterial Infections; Ceftriaxone; Ciprofloxacin; Cross Infection; Drug | 2017 |
EpideMiology and control measures of outBreaks due to Antibiotic-Resistant orGanisms in EurOpe (EMBARGO): a systematic review protocol.
Topics: Acinetobacter baumannii; Bacterial Infections; Bacterial Proteins; beta-Lactam Resistance; beta-Lact | 2017 |
Bacterial Infections in Children With Acute Myeloid Leukemia Receiving Ciprofloxacin Prophylaxis.
Topics: Adolescent; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteremia; Bacterial Infections; Child; | 2017 |
Risk factors for infection development after transrectal prostate biopsy and the role of resistant bacteria in colonic flora.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteria; Bacterial I | 2017 |
Antimicrobial resistance patterns of urinary tract pathogens and rationale for empirical therapy in Turkish children for the years 2000-2006.
Topics: Adolescent; Amikacin; Ampicillin; Analysis of Variance; Antibiotic Prophylaxis; Bacterial Infections | 2009 |
[Mutant Prevention Concentration: is it significant in the clinical practice?].
Topics: Anti-Bacterial Agents; Bacterial Infections; Bacterial Proteins; Ciprofloxacin; DNA Gyrase; Dose-Res | 2008 |
Changes in the rates of antimicrobial resistance among clinical isolates of Pseudomonas aeruginosa between 2002 and 2004 in a tertiary-care teaching hospital in Turkey.
Topics: Amikacin; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Drug Resistance, Bacterial; Ho | 2008 |
[Two cases of Bacillus infection and immunodepression].
Topics: Amoxicillin; Anti-Bacterial Agents; Bacillus; Bacterial Infections; Ceftriaxone; Ciprofloxacin; Clav | 2008 |
[Bacterial diarrheas and antibiotics: European recommendations].
Topics: Anti-Bacterial Agents; Azithromycin; Bacterial Infections; Campylobacter Infections; Campylobacter j | 2008 |
Lipopolysaccharide binding protein in the acute phase response of experimental murine Trypanosoma brucei brucei infection.
Topics: Acute-Phase Proteins; Animals; Anti-Bacterial Agents; Bacterial Infections; Carrier Proteins; Ciprof | 2009 |
[Nationwide susceptibility surveillance of ciprofloxacin and various parenteral antimicrobials against bacteria isolated from patients with severe infections--third ciproxan injection special survey (2005)].
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Data Collection; Drug Resistan | 2008 |
Implementation of European standards of care for cystic fibrosis--control and treatment of infection.
Topics: Administration, Inhalation; Adult; Anti-Bacterial Agents; Bacterial Infections; Burkholderia cepacia | 2009 |
Estimation of 99mTc-ciprofloxacin accumulation indexes in bone and joint bacterial infections.
Topics: Arthritis, Infectious; Bacterial Infections; Bone and Bones; Bone Diseases, Infectious; Ciprofloxaci | 2009 |
Prompt diagnosis and treatment of microbial keratitis in a daily wear lens.
Topics: Administration, Topical; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Contact Lenses; | 2009 |
Secondary bacterial infection in plasma endotoxin levels and the acute-phase response of mice infected with Trypanosoma brucei brucei.
Topics: Acute-Phase Reaction; Animals; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Endotoxem | 2009 |
Antibiotic usage and risk of colonization and infection with antibiotic-resistant bacteria: a hospital population-based study.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Carbapenems; Ciprofloxacin; Cohort Studies | 2009 |
Experimental studies on imaging of infected site with (99m)Tc-labeled ciprofloxacin in mice.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Disease Models, Animal; Isotope | 2009 |
Basic measures and systemic medical treatment of patients with toxic epidermal necrolysis.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antico | 2010 |
Synthesis of N₄'-[¹⁸F]fluoroalkylated ciprofloxacin as a potential bacterial infection imaging agent for PET study.
Topics: Alkylation; Animals; Bacterial Infections; Binding, Competitive; Biological Transport; Ciprofloxacin | 2010 |
Chemical ear peeling: a simple technique for the treatment of chronic external otitis: how we do it.
Topics: Acetic Acid; Bacterial Infections; Chemexfoliation; Chronic Disease; Ciprofloxacin; Cortisone; Drug | 2010 |
How leaky gut and endotoxemia induce bacterial infection in cirrhosis and gastrointestinal hemorrhage?
Topics: Administration, Oral; Anti-Bacterial Agents; Bacterial Infections; Bacterial Translocation; Cephalos | 2011 |
Selective intestinal decontamination with fluoroquinolones for the prevention of early bacterial infections after liver transplantation.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Female; Fluoroquinolones; H | 2011 |
Keratin hydrogels support the sustained release of bioactive ciprofloxacin.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Biocompatible Materials; Ciprofloxacin; Delaye | 2011 |
Fluoroquinolone-macrolide combination therapy for chronic bacterial prostatitis: retrospective analysis of pathogen eradication rates, inflammatory findings and sexual dysfunction.
Topics: Anti-Bacterial Agents; Azithromycin; Bacterial Infections; Chronic Disease; Ciprofloxacin; Cohort St | 2011 |
Ciprofloxacin-resistant infection after transrectal ultrasonography-guided prostate biopsy: should we reassess our practice?
Topics: Anti-Infective Agents; Antibiotic Prophylaxis; Bacterial Infections; Biopsy, Needle; Ciprofloxacin; | 2011 |
Ciprofloxacin in critically ill children.
Topics: Anti-Bacterial Agents; Bacteremia; Bacterial Infections; Child, Preschool; Ciprofloxacin; Critical C | 2011 |
Ciprofloxacin as a prophylactic agent against prostate cancer: a "two hit" hypothesis.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antineoplastic Agents; Bacterial Infection | 2012 |
Evaluation of wound healing and antimicrobial potentials of Ixora coccinea root extract.
Topics: Animals; Anti-Bacterial Agents; Antifungal Agents; Bacterial Infections; Chloramphenicol; Ciprofloxa | 2011 |
Underdosing of common antibiotics for obese patients in the ED.
Topics: Anti-Bacterial Agents; Bacterial Infections; Body Weight; Cefazolin; Cefepime; Cephalosporins; Cipro | 2012 |
Emphysematous gastritis associated with ulcerative esophagitis.
Topics: Aged; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Diabetes Mellitus, Type 2; Emphyse | 2011 |
Antibacterial activity of Thymus maroccanus and Thymus broussonetii essential oils against nosocomial infection - bacteria and their synergistic potential with antibiotics.
Topics: Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Cross Infection; Cymenes; Drug Synergism | 2012 |
Ciprofloxacin-induced antibacterial activity is reversed by vitamin E and vitamin C.
Topics: Anti-Bacterial Agents; Ascorbic Acid; Bacteria; Bacterial Infections; Ciprofloxacin; Drug Antagonism | 2012 |
Critical appraisal of air pouch infection model in rats.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Disease Models, Animal; Dose-Re | 2012 |
Fulminant spread of a femur anaerobic osteomyelitis to abdomen in a 17-year-old boy.
Topics: Abdominal Cavity; Adolescent; Anti-Bacterial Agents; Bacteria, Anaerobic; Bacterial Infections; Bact | 2012 |
Effects of prophylactic antibiotics in acute pancreatitis.
Topics: Adult; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Ciprofloxacin; Deb | 2012 |
Effect of intrarectal povidone-iodine in the incidence of infectious complications after transrectal prostatic biopsy.
Topics: Administration, Rectal; Adult; Aged; Aged, 80 and over; Anti-Infective Agents, Local; Bacterial Infe | 2012 |
The pattern of bacterial isolates and drug sensitivities of infected ulcers in patients with leprosy in ALERT, Kuyera and Gambo hospitals, Ethiopia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections; Ciprofloxacin; Cross-Sectional Stu | 2012 |
Comparison of the antibacterial effect of modified 3-mix paste versus Ultrapex over anaerobic microorganisms from infected root canals of primary teeth: an in vitro study.
Topics: Actinomyces; Anti-Bacterial Agents; Bacteria, Anaerobic; Bacterial Infections; Bacteroides; Bifidoba | 2012 |
Increasing antimicrobial resistance among Shigella isolates in the Bushehr, Iran.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Bacterial Typing Techniques; Cip | 2012 |
Infected simple renal cyst. Case report.
Topics: Adult; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Female; Fever; Humans; Kidney Dis | 2012 |
Approaching zero: temporal effects of a restrictive antibiotic policy on hospital-acquired Clostridium difficile, extended-spectrum β-lactamase-producing coliforms and meticillin-resistant Staphylococcus aureus.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Ceftriaxone; Ciprofloxa | 2013 |
Relationship between the clinical efficacy and AUC/MIC of intravenous ciprofloxacin in Japanese patients with intraabdominal infections.
Topics: Aged; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Female; Humans; Intraabd | 2013 |
Cost effectiveness model comparing trimethoprim sulfamethoxazole and ciprofloxacin for the treatment of chronic bacterial prostatitis.
Topics: Anti-Infective Agents; Bacterial Infections; Chronic Disease; Ciprofloxacin; Cost-Benefit Analysis; | 2002 |
99mTc-labeled antimicrobial peptides for detection of bacterial and Candida albicans infections.
Topics: Bacterial Infections; Candidiasis; Ciprofloxacin; Humans; Organotechnetium Compounds; Radionuclide I | 2002 |
Imaging bacterial infection with (99m)Tc-ciprofloxacin (Infecton).
Topics: Abscess; Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections; Child; Child, Preschool; | 2002 |
Antianaerobic activity of moxifloxacin compared with that of ofloxacin, ciprofloxacin, clindamycin, metronidazole and beta-lactams.
Topics: Anaerobiosis; Anti-Bacterial Agents; Aza Compounds; Bacterial Infections; beta-Lactams; Ciprofloxaci | 2002 |
Results of a prospective, randomized, double blind comparison of the efficacy and the safety of sequential ciprofloxacin (intravenous/oral)+metronidazole (intravenous/oral) with ceftriaxone (intravenous)+metronidazole (intravenous/oral) for the treatment
Topics: Abdominal Abscess; Adult; Aged; Bacterial Infections; Ceftriaxone; Ciprofloxacin; Double-Blind Metho | 2003 |
Regression of lung lesions in Hodgkin's disease by antibiotics: case report and hypothesis on the etiology of Hodgkin's disease.
Topics: Adult; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Clarithromycin; DNA, Bacterial; F | 2003 |
[Antibacterial activity of gatifloxacin against various fresh clinical isolates in 2002].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Cefdinir; Cephalosporins; Ciprof | 2002 |
Transrectal prostatic ultrasonography in acute bacterial prostatitis: findings and clinical implications.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Bacterial Infections; Ceftriaxone; Ciprofloxacin; | 2003 |
Diagnosis and follow-up of acute bacterial prostatitis and orchiepididymitis detected by In-111-labeled leukocyte imaging.
Topics: Acute Disease; Bacterial Infections; Ciprofloxacin; Epididymitis; Follow-Up Studies; Humans; Indium | 2003 |
The effect of antibiotic and probiotic combination therapy on secondary pancreatic infections and oxidative stress parameters in experimental acute necrotizing pancreatitis.
Topics: Analysis of Variance; Animals; Anti-Bacterial Agents; Bacterial Infections; Bacterial Translocation; | 2003 |
Specificity of 99mTc-ciprofloxacin imaging.
Topics: Bacterial Infections; Candidiasis; Ciprofloxacin; Humans; Organotechnetium Compounds; Radionuclide I | 2003 |
Activity of faropenem and imipenem for ciprofloxacin-resistant bacteria.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; beta-Lactams; Ciprofloxacin; Drug Resistance, | 2003 |
Rapid direct method for monitoring antibiotics in a mouse model of bacterial biofilm infection.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Biofilms; Catheterization; Ciprofloxacin; Colo | 2003 |
Is late antibiotic prophylaxis effective in the prevention of secondary pancreatic infection?
Topics: Animals; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Ciprofloxacin; Drug Ad | 2003 |
Endodontic treatment of primary teeth using a combination of antibacterial drugs.
Topics: Adolescent; Anti-Infective Agents, Local; Bacterial Infections; Child; Child, Preschool; Ciprofloxac | 2004 |
Endodontic treatment of primary teeth using a combination of antibacterial drugs.
Topics: Adolescent; Anti-Infective Agents, Local; Bacterial Infections; Child; Child, Preschool; Ciprofloxac | 2004 |
Endodontic treatment of primary teeth using a combination of antibacterial drugs.
Topics: Adolescent; Anti-Infective Agents, Local; Bacterial Infections; Child; Child, Preschool; Ciprofloxac | 2004 |
Endodontic treatment of primary teeth using a combination of antibacterial drugs.
Topics: Adolescent; Anti-Infective Agents, Local; Bacterial Infections; Child; Child, Preschool; Ciprofloxac | 2004 |
Endodontic treatment of primary teeth using a combination of antibacterial drugs.
Topics: Adolescent; Anti-Infective Agents, Local; Bacterial Infections; Child; Child, Preschool; Ciprofloxac | 2004 |
Endodontic treatment of primary teeth using a combination of antibacterial drugs.
Topics: Adolescent; Anti-Infective Agents, Local; Bacterial Infections; Child; Child, Preschool; Ciprofloxac | 2004 |
Endodontic treatment of primary teeth using a combination of antibacterial drugs.
Topics: Adolescent; Anti-Infective Agents, Local; Bacterial Infections; Child; Child, Preschool; Ciprofloxac | 2004 |
Endodontic treatment of primary teeth using a combination of antibacterial drugs.
Topics: Adolescent; Anti-Infective Agents, Local; Bacterial Infections; Child; Child, Preschool; Ciprofloxac | 2004 |
Endodontic treatment of primary teeth using a combination of antibacterial drugs.
Topics: Adolescent; Anti-Infective Agents, Local; Bacterial Infections; Child; Child, Preschool; Ciprofloxac | 2004 |
[Detection of abdominal infections using radio-labeled antibiotics].
Topics: Abdomen; Abdominal Abscess; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Humans; Radi | 2003 |
[Nationwide sensitivity surveillance of ciprofloxacin and various parenteral antibiotics against bacteria isolated from patients with severe infections--the first Ciproxan IV special investigation in 2001].
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Dosage Forms; D | 2003 |
Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; Bacterial Infections; Chlamydia trachomatis; | 2004 |
Discriminating infection from sterile inflammation: can radiolabelled antibiotics solve the problem?
Topics: Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Diagnosis, Differential; Fluorine Radioi | 2005 |
Etiologies and manifestations of persistent diarrhea in adults with HIV-1 infection: a case-control study in Lima, Peru.
Topics: Adult; Aeromonas; Animals; Anti-Infective Agents; Bacterial Infections; Campylobacter; Case-Control | 2005 |
[Clinical-laboratory study of the efficacy of combined drug Cifran CT in complex therapy of inflammatory periodontal disease].
Topics: Adult; Bacteria; Bacterial Infections; Chronic Disease; Ciprofloxacin; Female; Fluoroquinolones; Hum | 2005 |
[Bacterial infections in cancer patients].
Topics: Administration, Oral; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Bacteria | 2005 |
Temporal changes in bacterial resistance in German intensive care units, 2001-2003: data from the SARI (surveillance of antimicrobial use and antimicrobial resistance in intensive care units) project.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Cross Infection; Drug Resistan | 2005 |
Microbial contamination of hematopoietic progenitor cell grafts-incidence, clinical outcome, and cost-effectiveness: an analysis of 735 grafts.
Topics: Anti-Infective Agents; Antibiotic Prophylaxis; Bacterial Infections; Bone Marrow Cells; Ciprofloxaci | 2005 |
Fluid shifts have no influence on ciprofloxacin pharmacokinetics in intensive care patients with intra-abdominal sepsis.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Bacterial Infections; Body Fluid Compartments; Ciprofloxac | 2005 |
Impact of residual and therapeutic doses of ciprofloxacin in the human-flora-associated mice model.
Topics: Animals; Anti-Infective Agents; Bacteria; Bacteria, Anaerobic; Bacterial Infections; beta-Glucosidas | 2005 |
Development of an infection-resistant, bioactive wound dressing surface.
Topics: Bacterial Infections; Bandages; Biocompatible Materials; Blood Coagulation; Ciprofloxacin; Ethylened | 2005 |
Infections of febrile neutropenic patients in malignant hematological diseases (second study period).
Topics: Antibiotic Prophylaxis; Antineoplastic Agents; Bacteremia; Bacterial Infections; Ciprofloxacin; Fema | 2005 |
Ciprofloxacin--clincal and pharmacokinetic studies in ear, nose and throat infections.
Topics: Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Female; Humans; Male; Nose Diseases; Oti | 1989 |
Ciprofloxacin in the treatment of infections at different sites.
Topics: Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Escherichia coli Infections; Female; Hum | 1989 |
Follow-up therapy with ciprofloxacin in severe infection, an alternative to parenteral treatment.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial I | 1989 |
Ciprofloxacin treatment of acute infections in immunocompromised host.
Topics: Acute Disease; Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Clinical Tri | 1989 |
Low-dose ciprofloxacin in the treatment of bacterial pharyngo-tonsillitis.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Clinical Trials as Topic; F | 1989 |
Ciprofloxacin versus amoxycillin/clavulanic acid in the treatment of urinary tract infections in general practice.
Topics: Adult; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Bacterial Infections; C | 1989 |
Efficacy and safety of ciprofloxacin in gynaecological infections.
Topics: Acute Disease; Administration, Oral; Anti-Infective Agents; Bacterial Infections; Chronic Disease; C | 1989 |
Clinical efficacy and safety of oral ciprofloxacin in pelvic inflammatory disease.
Topics: Administration, Oral; Adult; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Female; Hum | 1989 |
Clinical and antibacterial efficacy of ciprofloxacin after single-shot prophylaxis during cholecystectomy.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteria; Bacterial Infections; Cholecystectomy; Cipr | 1989 |
Perioperative prophylaxis in colorectal surgery: is a single shot with 200 mg ciprofloxacin sufficient to maintain therapeutic levels in gut tissues?
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Ciprofloxacin; Colorectal Neopl | 1989 |
[Implementation of the radiolabelled antibiotic in the detection of orthopedic infections].
Topics: Arthritis, Infectious; Bacterial Infections; Bone and Bones; Ciprofloxacin; Humans; Knee Prosthesis; | 2005 |
99mTechnetium-ciprofloxacin scintigraphy for the evaluation of spinal infections: a preliminary report.
Topics: Bacterial Infections; Ciprofloxacin; Humans; Lumbar Vertebrae; Organotechnetium Compounds; Radionucl | 2006 |
Re: treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers serum prostate specific antigen.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Chronic Disease; Ciprofloxacin; | 2006 |
[Discontinuous oral ciprofloxacin for transurethral resection of the prostate. Initial results].
Topics: Administration, Oral; Anti-Infective Agents; Antibiotic Prophylaxis; Bacterial Infections; Ciproflox | 2006 |
Which reliable pharmacodynamic breakpoint should be advised for ciprofloxacin monotherapy in the hospital setting? A TDM-based retrospective perspective.
Topics: Analysis of Variance; Anti-Bacterial Agents; Area Under Curve; Bacterial Infections; Chromatography, | 2006 |
Prognostic significance of infection acquisition sites in spontaneous bacterial peritonitis: nosocomial versus community acquired.
Topics: Aged; Anti-Bacterial Agents; Bacterial Infections; Cefotaxime; Ciprofloxacin; Community-Acquired Inf | 2006 |
Antibiotic resistance of urinary tract pathogens and evaluation of empirical treatment in Turkish children with urinary tract infections.
Topics: Adolescent; Age Factors; Amikacin; Ampicillin; Antibiotic Prophylaxis; Bacterial Infections; Ceftria | 2006 |
Intravenous or sequential ciprofloxacin therapy in hospitalised patients with a broad spectrum of infections: a post-marketing surveillance study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Child; Cipr | 2006 |
Antimicrobial susceptibility of common pathogens from community-acquired lower respiratory tract infections in Estonia.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Cefuroxime; Child; C | 2006 |
Effect of early and late antibiotic treatment in experimental acute pancreatitis in rats.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Cholagogues and Choleretics; Ciprofloxacin; Di | 2007 |
Comparative quantification of the in vitro activity of veterinary fluoroquinolones.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Cattle; Cattle Diseases; Ciprofloxac | 2007 |
Eradication of unusual pathogens by combination pharmacological therapy is paralleled by improvement of signs and symptoms of chronic prostatitis syndrome.
Topics: Adrenergic alpha-Antagonists; Adult; Androgen Antagonists; Anti-Bacterial Agents; Anti-Infective Age | 2007 |
Comparison of two oral regimens for the outpatient treatment of low-risk cancer patients with chemotherapy-induced neutropenia and fever: ciprofloxacin plus cefuroxime axetil versus ciprofloxacin plus amoxicillin/clavulanate.
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Amoxicillin-Potassium Clavulanate Combination; A | 2007 |
Modeling the influence of non-adherence on antibiotic efficacy: application to ciprofloxacin.
Topics: Algorithms; Anti-Bacterial Agents; Area Under Curve; Bacterial Infections; Biological Availability; | 2007 |
The in vitro and in vivo activity of ciprofloxacin.
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Ciprofloxacin; | 1984 |
In vitro susceptibilities of 393 recent clinical isolates to WIN 49375, cefotaxime, tobramycin, and piperacillin.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Cefotaxime; Ciprofloxacin; Enterobacteriaceae | 1984 |
In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Drug Resistance, Microbial; Hu | 1984 |
Ciprofloxacin in multi-resistant infections in childhood: an audit.
Topics: Administration, Oral; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Child; Chi | 1995 |
Chemoprophylaxis with oral ciprofloxacin in ovarian cancer patients receiving taxol.
Topics: Administration, Oral; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bacteria | 1994 |
Chemotherapeutic activity of levofloxacin (HR 355, DR-3355) against systemic and localized infections in laboratory animals.
Topics: Abscess; Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Female; Granuloma; Kle | 1995 |
Teicoplanin and oral ciprofloxacin as outpatient treatment of infective episodes in patients with indwelling central venous catheters and haematological malignancy.
Topics: Administration, Oral; Adolescent; Adult; Ambulatory Care; Bacterial Infections; Catheterization, Cen | 1995 |
Effect of prednisolone on ascending renal infection due to biofilm disease and lower urinary tract obstruction in rats.
Topics: Animals; Bacterial Infections; Biofilms; Cicatrix; Ciprofloxacin; Colony Count, Microbial; Drug Ther | 1995 |
[Reevaluation of current antimicrobials. Ciprofloxacin. Discussion].
Topics: Bacteria; Bacterial Infections; Ciprofloxacin; Dosage Forms; Drug Resistance, Microbial; Humans | 1995 |
Efficacies of ABT-719 and related 2-pyridones, members of a new class of antibacterial agents, against experimental bacterial infections.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Female; Mice; Pyridones; Topois | 1995 |
Acute bacterial diarrhoea in the emergency room: therapeutic implications of stool culture results.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Ampicillin; Bacterial Infections; Bacteri | 1994 |
Choice of antibiotics for empiric treatment of serious infections.
Topics: Amikacin; Bacterial Infections; Ciprofloxacin; Gentamicins; Humans; Microbial Sensitivity Tests | 1994 |
Oral ciprofloxacin versus intravenous therapy with other non-quinolone agents: a study of 291 infections.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial I | 1994 |
Recommending antibiotics for serious infections after in vitro studies.
Topics: Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Humans; Microbial Sensitivity Tests | 1994 |
Intravenous ciprofloxacin dosing in a morbidly obese patient.
Topics: Adipose Tissue; Bacterial Infections; Body Weight; Cellulitis; Ciprofloxacin; Humans; Infusions, Int | 1994 |
Susceptibility of clinical bacterial isolates to ciprofloxacin in the United States.
Topics: Bacterial Infections; Ciprofloxacin; Drug Resistance, Microbial; Hospital Bed Capacity; Hospitals; H | 1994 |
Increased activity of a new chlorofluoroquinolone, BAY y 3118, compared with activities of ciprofloxacin, sparfloxacin, and other antimicrobial agents against anaerobic bacteria.
Topics: Anti-Infective Agents; Bacteria, Anaerobic; Bacterial Infections; Ciprofloxacin; Fluoroquinolones; M | 1994 |
Chemotherapy for germ cell tumours: prophylactic ciprofloxacin reduces the incidence of neutropenic fever.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Carbo | 1994 |
[Antimicrobial activities of ciprofloxacin against recently obtained clinical isolates].
Topics: Bacteria; Bacterial Infections; Ciprofloxacin; Drug Resistance, Microbial; Humans | 1994 |
North American (United States and Canada) comparative susceptibility of two fluoroquinolones: ofloxacin and ciprofloxacin. A 53-medical-center sample of spectra of activity. North American Ofloxacin Study Group.
Topics: Bacteria; Bacterial Infections; Canada; Ciprofloxacin; Enterobacteriaceae; Female; Genitalia; Humans | 1994 |
Susceptibilities of bacterial isolates from patients with cancer to levofloxacin and other quinolones.
Topics: Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Gram-Negative Bacteria; Gram-P | 1994 |
Treatment of acute peritonitis by temporary discontinuation of dialysis and low doses of oral ciprofloxacin in patients on CAPD.
Topics: Acute Disease; Administration, Oral; Bacterial Infections; Cefazolin; Ciprofloxacin; Clinical Protoc | 1994 |
Serum ciprofloxacin concentrations in patients with severe sepsis being treated with ciprofloxacin 200 mg i.v. bd irrespective of renal function.
Topics: Adult; Aged; Bacterial Infections; Chromatography, High Pressure Liquid; Ciprofloxacin; Creatinine; | 1994 |
[Prophylaxis with ciprofloxacin in postchemotherapy neutropenia in acute myeloid leukemia].
Topics: Adult; Aged; Bacterial Infections; Ciprofloxacin; Female; Humans; Leukemia, Myeloid, Acute; Male; Mi | 1994 |
In vivo testing of an infection-resistant vascular graft material.
Topics: Animals; Bacterial Adhesion; Bacterial Infections; Blood Vessel Prosthesis; Ciprofloxacin; Hot Tempe | 1993 |
[Bacterial otitis externa with invasion of organ limits--systemic and local combination treatment with ciprofloxacin].
Topics: Administration, Topical; Bacterial Infections; Ciprofloxacin; Humans; Microbial Sensitivity Tests; O | 1993 |
Treatment of urinary tract infections with ciprofloxacin after renal transplantation.
Topics: Administration, Oral; Adult; Bacterial Infections; Bacteriuria; Ciprofloxacin; Cystitis; Female; Hum | 1993 |
Oral ciprofloxacin for treatment of severe infections.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bacteremia; Bacterial Infections; Ciprofloxaci | 1993 |
Oral ciprofloxacin for treatment of chronic osteomyelitis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Ampicillin; Bacterial Infections; Chronic Dise | 1993 |
In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens.
Topics: Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Fluoroquinolones; Gram-Negative Bacteria | 1993 |
In vitro and in vivo antibacterial activities of T-3761, a new quinolone derivative.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Fluoroquinolones; Lung Diseases | 1993 |
Comparison of topical ciprofloxacin to conventional antibiotic therapy in the treatment of ulcerative keratitis.
Topics: Adult; Aged; Aged, 80 and over; Bacterial Infections; Cefazolin; Ciprofloxacin; Corneal Ulcer; Drug | 1993 |
Antibiotic treatment improves survival in experimental acute necrotizing pancreatitis.
Topics: Abscess; Acute Disease; Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Ciprofloxaci | 1996 |
An audit of ciprofloxacin use in a district general hospital.
Topics: Anti-Infective Agents; Bacterial Infections; Cephalosporins; Ciprofloxacin; Cross Infection; Drug Ut | 1995 |
Changes in susceptibility to ciprofloxacin in a community in northern Israel.
Topics: Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Drug Resistance, Microbial; Hu | 1995 |
In vitro antimicrobial activity of CP-99,219, a new 7-azabicyclonaphthyridone.
Topics: Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Fluoroquinolones; Humans; Micr | 1995 |
In vitro activity and clinical efficacy of ciprofloxacin in otorhinolaryngeal infections.
Topics: Adult; Aged; Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Female; Humans; M | 1995 |
Comparison of 99mTc infecton imaging with radiolabelled white-cell imaging in the evaluation of bacterial infection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections; Ciprofloxacin; Humans; Indium Radi | 1996 |
In vitro and in vivo antibacterial activities of CS-940, a new 6-fluoro-8-difluoromethoxy quinolone.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Drug Evaluation, Preclinical; F | 1996 |
An audit of ciprofloxacin use in severe life threatening infection at the AKUH.
Topics: Adult; Age Factors; Anti-Infective Agents; Bacterial Infections; Child; Ciprofloxacin; Humans; Infan | 1996 |
Treatment of CAPD-related peritonitis with ciprofloxacin: results after seven years.
Topics: Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Gram-Negative Bacterial Infections; Gram | 1996 |
Frequency, microbial spectrum and outcome of spontaneous bacterial peritonitis in north India.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Cohort Stu | 1996 |
Use of fluoroquinolones as prophylactic agents in patients with neutropenia.
Topics: Anti-Infective Agents; Antibiotic Prophylaxis; Bacterial Infections; Ciprofloxacin; Digestive System | 1997 |
Use of ciprofloxacin in developing countries.
Topics: Anti-Infective Agents; Bacterial Infections; Child; Ciprofloxacin; Developing Countries; Digestive S | 1997 |
New antiinfectious biomaterials. Ciprofloxacin containing polyurethanes as potential drug delivery systems to prevent foreign-body infections.
Topics: Anti-Infective Agents; Bacterial Adhesion; Bacterial Infections; Betaine; Biocompatible Materials; C | 1997 |
Parenteral ciprofloxacin in persistent diarrhoea in children.
Topics: Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Diarrhea, Infantile; Drug Therapy, Combi | 1995 |
'Cost-effectiveness'--is it always effective?
Topics: Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Cost-Benefit Analysis; Humans | 1997 |
Dosage adjustment of antiinfective therapy in patients with renal impairment.
Topics: Aminoglycosides; Analysis of Variance; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infec | 1997 |
[Management of infection in respiratory tract diseases].
Topics: Amoxicillin; Bacterial Infections; Bronchitis; Bronchopneumonia; Child; Ciprofloxacin; Drug Costs; H | 1995 |
[Optimal antibacterial chemotherapy for infectious diseases associated with hematological malignancies].
Topics: Adult; Aged; Aged, 80 and over; Anemia, Aplastic; Bacterial Infections; Ciprofloxacin; Drug Therapy, | 1997 |
Effect of nebulizer type and antibiotic concentration on device performance.
Topics: Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Ceftazidime; Ci | 1997 |
Clinical evaluation of technetium-99m infecton for the localisation of bacterial infection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacterial Infections; Ciprofloxac | 1997 |
In-vitro and in-vivo activities of DW-116, a new fluoroquinolone.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Dose-Response Relationship, Dru | 1997 |
Oral ciprofloxacin to treat bacterial peritonitis associated with peritoneal dialysis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Escherichia coli; Escherichia coli | 1997 |
Fluoroquinolone prophylaxis for the prevention of bacterial infections in patients with cancer--is it justified?
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Drug Therapy; Ent | 1997 |
In vitro and in vivo antibacterial efficacies of CFC-222, a new fluoroquinolone.
Topics: Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Culture Media; Fluoro | 1997 |
Sequential intravenous-oral ciprofloxacin plus amoxycillin/clavulanic acid shortens hospital stay in infected non severe neutropenic patients.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Analysis of Variance; | 1997 |
The activity of grepafloxacin against respiratory pathogens in the UK.
Topics: Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Drug Resistance, Microbial; England; Flu | 1997 |
[Transrectal prostatic biopsy: the role of preventive measures].
Topics: Adenocarcinoma; Anti-Infective Agents; Antibiotic Prophylaxis; Anticoagulants; Bacterial Infections; | 1997 |
In-vitro and in-vivo antibacterial activity of CFC-222, a new fluoroquinolone.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Fluoroquinolones; Male; Mice; M | 1998 |
The influence of antimicrobial prophylaxis on the microbial and clinical findings in patients after autologous bone marrow transplantation.
Topics: Adolescent; Adult; Anti-Infective Agents; Antibiotic Prophylaxis; Bacterial Infections; Bone Marrow | 1997 |
Trovafloxacin compared with levofloxacin, ofloxacin, ciprofloxacin, azithromycin and clarithromycin against unusual aerobic and anaerobic human and animal bite-wound pathogens.
Topics: Animals; Anti-Bacterial Agents; Azithromycin; Bacteria, Aerobic; Bacteria, Anaerobic; Bacterial Infe | 1998 |
Antimicrobial susceptibility of community-acquired lower respiratory tract bacterial pathogens isolated in the UK during the 1995-1996 cold season.
Topics: Amoxicillin-Potassium Clavulanate Combination; Ampicillin; Ampicillin Resistance; Anti-Bacterial Age | 1998 |
Tolerance and pharmacokinetics of ciprofloxacin in the chick. Preliminary experience in subjects of pediatric age with urinary tract infections (UTI).
Topics: Administration, Oral; Adolescent; Animals; Anti-Infective Agents; Bacterial Infections; Behavior, An | 1998 |
Efficacy of oral ciprofloxacin as selective intestinal decontaminant in cirrhosis.
Topics: Administration, Oral; Anti-Infective Agents; Antibiotic Prophylaxis; Bacterial Infections; Ciproflox | 1997 |
Bacterial eradication by clinafloxacin, CI-990, and ciprofloxacin employing MBC test, in-vitro time-kill and in-vivo time-kill studies.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Disease Models, Animal; Dose-Re | 1998 |
Improvement of semen quality in infected asymptomatic infertile male after bacteriological cure.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents, Urinary; Bacterial Infections; Ciprofloxacin; F | 1998 |
[The role of ciprofloxacin in the treatment of chronic bronchitis].
Topics: Acute Disease; Anti-Infective Agents; Bacterial Infections; Bronchitis; Chronic Disease; Ciprofloxac | 1998 |
[Bacteriology in community-acquired respiratory pathology].
Topics: Acute Disease; Ambulatory Care; Anti-Infective Agents; Bacterial Infections; Chronic Disease; Ciprof | 1998 |
A liposomal hydrogel for the prevention of bacterial adhesion to catheters.
Topics: Anti-Infective Agents; Bacterial Adhesion; Bacterial Infections; Biocompatible Materials; Biofilms; | 1998 |
Topical ciprofloxacin in long-lasting otorrhea.
Topics: Administration, Topical; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Dose-Response R | 1999 |
The in-vitro activity of HMR 3647, a new ketolide antimicrobial agent.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; Bacterial Infections; Chlamydia; Chlamydia I | 1998 |
In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone.
Topics: Administration, Oral; Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; | 1999 |
The infection-free interval: its use in evaluating antimicrobial treatment of acute exacerbation of chronic bronchitis.
Topics: Acute Disease; Bacterial Infections; Bronchitis; Cefuroxime; Ciprofloxacin; Clarithromycin; Humans; | 1999 |
Comparison of in-vitro pharmacodynamics of once and twice daily ciprofloxacin.
Topics: Anti-Infective Agents; Area Under Curve; Bacteria; Bacterial Infections; Ciprofloxacin; Escherichia | 1999 |
Cutaneous CO2 laser resurfacing infection rate with and without prophylactic antibiotics.
Topics: Adult; Antibiotic Prophylaxis; Bacterial Infections; Carbon Dioxide; Ciprofloxacin; Face; Female; Hu | 1999 |
[Oral antibiotic therapy in the adult bacterial osteomyelitis: results after two years of follow-up].
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Antibiotics | 1999 |
Hypopyon keratitis in corneal epithelial basement membrane dystrophy.
Topics: Adult; Anti-Infective Agents; Bacterial Infections; Basement Membrane; Ciprofloxacin; Corneal Diseas | 1999 |
A retrospective analysis of pharmacokinetic/pharmacodynamic indices as indicators of the clinical efficacy of ciprofloxacin.
Topics: Algorithms; Anti-Infective Agents; Area Under Curve; Bacterial Infections; Ciprofloxacin; Gram-Negat | 2000 |
[In vitro activities of levofloxacin and other antibiotics against fresh clinical isolates].
Topics: Ampicillin; Anti-Infective Agents; Bacteria; Bacterial Infections; Cefaclor; Cefpodoxime; Ceftizoxim | 1999 |
Evaluation of ciprofloxacin as a representative of veterinary fluoroquinolones in susceptibility testing.
Topics: Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Dog Diseases; Dogs; E | 2000 |
Nonstoichiometric hydroxyapatite-anionic collagen composite as support for the double sustained release of gentamicin and norfloxacin/ciprofloxacin.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Biocompatible Materials | 2000 |
Experience with prophylactic oral ciprofloxacin in gynecological cancer patients developing severe chemotherapy-induced neutropenia.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Antineoplastic Combined Chemotherapy Protocol | 2000 |
[Evaluation of antibiotic prophylaxis in neutropenic patients with hematologic malignancies].
Topics: Adult; Aged; Antibiotic Prophylaxis; Antineoplastic Agents; Bacterial Infections; Ciprofloxacin; Dru | 2000 |
Imaging of bacterial infections with 99mTc-labeled human neutrophil peptide-1.
Topics: alpha-Defensins; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Humans; Radionuclide Im | 2000 |
[Nosocomial infections in neonatal and pediatric intensive care. The appeal of ciprofloxacin].
Topics: Anti-Infective Agents; Bacterial Infections; Child, Preschool; Ciprofloxacin; Cross Infection; Drug | 2000 |
New medical schools and nuclear medicine in Africa: prestige or necessity?
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Drug Resistance, Microbial; Hum | 2000 |
Ciprofloxacin in the management of soft tissue infections in diabetes mellitus.
Topics: Adult; Aged; Bacterial Infections; Ciprofloxacin; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type | 2000 |
Use of the quinolones in treatment of severe bacterial infections in premature infants.
Topics: Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Humans; Infant, Newborn; Infant, Prematu | 2000 |
Usefulness of 99mTc-ciprofloxacin (infecton) scan in diagnosis of chronic orthopedic infections: comparative study with 99mTc-HMPAO leukocyte scintigraphy.
Topics: Adult; Aged; Aged, 80 and over; Bacterial Infections; Bone and Bones; Child; Child, Preschool; Chron | 2001 |
99mTc-labeled antimicrobial peptides for detection of bacterial and Candida albicans infections.
Topics: Animals; Anti-Bacterial Agents; Antimicrobial Cationic Peptides; Bacterial Infections; Candidiasis; | 2001 |
Ciprofloxacin: efficacy and indications.
Topics: Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Humans; Treatment Outcome | 2000 |
Concerns about 99mTc-labelled ciprofloxacin for infection detection.
Topics: Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Drug Resistance; Humans; Organotechnetiu | 2001 |
[Chronic ORL infections of the adult in the community. Role of ciprofloxacin].
Topics: Anti-Infective Agents; Bacterial Infections; Chronic Disease; Ciprofloxacin; Humans; Otitis Media; S | 2001 |
Incidence, spectrum and antibiotic sensitivity pattern of bacterial infections among patients with acute pancreatitis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Cefotaxime; | 2001 |
[Tc-99m ciprofloxacin in clinically selected patients for peripheral osteomyelitis, spondylodiscitis and fever of unknown origin--preliminary results].
Topics: Adult; Aged; Aged, 80 and over; Bacterial Infections; Bone and Bones; Ciprofloxacin; Diagnosis, Diff | 2002 |
Changing pattern of bacterial susceptibility to antibiotics in hematopoietic stem cell transplant recipients.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; Bacterial Infections; Belgium; Carbapenems; | 2002 |
Clinical toxicological aspects of fluoroquinolones.
Topics: Anti-Infective Agents; Bacterial Infections; Cardiovascular Diseases; Central Nervous System Disease | 2002 |
Imaging prostatitis with Tc-99m ciprofloxacin.
Topics: Acute Disease; Bacterial Infections; Chronic Disease; Ciprofloxacin; Humans; Male; Organotechnetium | 2002 |
Temporal changes in prevalence of antimicrobial resistance in 23 US hospitals.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Cross Infection; | 2002 |
In vitro activity of sparfloxacin (AT-4140), a new quinolone agent, against invasive isolates from pediatric patients.
Topics: Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Drug Resistance, Microbial; Fl | 1992 |
In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; DNA Topoisomerases, Type II; Dr | 1992 |
In vitro and in vivo evaluation of BMY 45243, a new 5-amino-naphthyridone derivative.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Female; Fluoroquinolones; Gram- | 1992 |
Outpatient treatment of Hickman catheter infections.
Topics: Adult; Ambulatory Care; Antineoplastic Agents; Bacterial Infections; Catheters, Indwelling; Ciproflo | 1992 |
Comparative clinical and microbiological study of amoxycillin-clavulanic acid and ciprofloxacin in acute purulent exacerbations of chronic bronchitis.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Bacteria | 1992 |
Limiting the use of the quinolones--ciprofloxacin and ofloxacin.
Topics: Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Drug Resistance, Microbial; Humans; Oflo | 1992 |
[The clinical use of norfloxacin (Nolicin) and ciprofloxacin (Ciprinol)].
Topics: Bacterial Infections; Ciprofloxacin; Humans; Norfloxacin | 1992 |
[Symposium "Ciflozin (ciprofloxacin)--a broad-spectrum antibacterial drug"].
Topics: Bacterial Infections; Ciprofloxacin; Drug Evaluation; Germany, West; Humans; Moscow; Respiratory Tra | 1992 |
Ciprofloxacin in bacterial diarrhoea.
Topics: Bacterial Infections; Ciprofloxacin; Diarrhea; Humans | 1992 |
Ciprofloxacin monotherapy for acute pelvic infections: a comparison with clindamycin plus gentamicin.
Topics: Bacterial Infections; Ciprofloxacin; Clindamycin; Female; Gentamicins; Humans; Pelvic Inflammatory D | 1992 |
Ciprofloxacin current status in pediatric practice.
Topics: Bacterial Infections; Child; Ciprofloxacin; Contraindications; Humans; Joint Diseases | 1992 |
An assessment of the efficacy of antimicrobial prophylaxis in bone marrow autografts.
Topics: Adolescent; Adult; Amphotericin B; Bacteremia; Bacterial Infections; Bone Marrow Transplantation; Ci | 1991 |
[Perioperative preventive use of ciprofloxacin in patients with cancer of the larynx].
Topics: Bacterial Infections; Ciprofloxacin; Humans; Injections, Intravenous; Laryngeal Neoplasms; Laryngect | 1991 |
The fluoroquinolones.
Topics: Bacterial Infections; Ciprofloxacin; Humans; Norfloxacin; Otitis Externa | 1991 |
Infectious complications with respiratory pathogens despite ciprofloxacin therapy.
Topics: Adult; Aged; Bacterial Infections; Ciprofloxacin; Drug Resistance, Microbial; Female; Humans; Male; | 1991 |
Intravenous ciprofloxacin for the treatment of severe infections.
Topics: Adult; Aged; Bacterial Infections; Ciprofloxacin; Connective Tissue Diseases; Female; Humans; Inject | 1991 |
[Clinical and laboratory evaluation of ciprofloxacin effectiveness].
Topics: Bacterial Infections; Ciprofloxacin; Dosage Forms; Humans | 1991 |
Entry of ciprofloxacin into cerebrospinal fluid during bacterial, viral and tuberculous meningitis.
Topics: Adult; Bacterial Infections; Ciprofloxacin; Humans; Meningitis; Meningitis, Viral; Middle Aged; Tube | 1991 |
In vitro and in vivo activities of LJC10,627, a new carbapenem with stability to dehydropeptidase I.
Topics: Amikacin; Animals; Bacterial Infections; Bacteroides fragilis; Carbapenems; Ceftazidime; Cilastatin; | 1991 |
[Clinical evaluation of fleroxacin in gynecological infections].
Topics: Administration, Oral; Adolescent; Adult; Bacteria; Bacterial Infections; Ciprofloxacin; Drug Evaluat | 1991 |
In vitro activity of cefpodoxime against bacterial isolates obtained from patients with cancer.
Topics: Bacteria; Bacterial Infections; Cefpodoxime; Ceftizoxime; Ciprofloxacin; Humans; Microbial Sensitivi | 1991 |
Comparative efficacy of cefoperazone, cefoperazone plus sulbactam, ciprofloxacin, clindamycin, metronidazole, and penicillin G against anaerobic bacteria in an animal model.
Topics: Animals; Anti-Bacterial Agents; Bacteria, Anaerobic; Bacterial Infections; Bacteroides fragilis; Bac | 1990 |
[The treatment of gastrointestinal infections with ciprofloxacin].
Topics: Adolescent; Adult; Bacterial Infections; Ciprofloxacin; Drug Evaluation; Drug Tolerance; Female; Gas | 1991 |
Pharmacoepidemiology of ciprofloxacin: analysis of use patterns and cost impact.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; C | 1991 |
Association with prior fluoroquinolone therapy of widespread ciprofloxacin resistance among gram-negative isolates in a Veterans Affairs medical center.
Topics: Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Drug Resistance, Microbial; Gram-Negativ | 1991 |
Activity of temafloxacin against respiratory pathogens.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Cells, Cultured; Ciprofloxacin; Dose-Response | 1991 |
In vitro and in vivo antibacterial activities of E-4497, a new 3-amine-3-methyl-azetidinyl tricyclic fluoroquinolone.
Topics: Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Drug Evaluation, Prec | 1991 |
Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates.
Topics: Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Fluoroquinolones; Humans; Micr | 1991 |
Intravenous ciprofloxacin.
Topics: Bacterial Infections; Ciprofloxacin; Drug Resistance, Microbial; Humans; Infusions, Intravenous | 1991 |
In-vitro and in-vivo activity of DR-3355, an optically active isomer of ofloxacin.
Topics: Animals; Bacteria; Bacterial Infections; Ciprofloxacin; Culture Media; Hydrogen-Ion Concentration; I | 1990 |
[Ciprofloxacin in the treatment of infections in oncology patients].
Topics: Administration, Oral; Bacteria, Aerobic; Bacterial Infections; Ciprofloxacin; Drug Resistance, Micro | 1990 |
Correlation of pharmacokinetic parameters to efficacy of antibiotics: relationships between serum concentrations, MIC values, and bacterial eradication in patients with gram-negative pneumonia.
Topics: Aged; Aged, 80 and over; Bacterial Infections; Cefmenoxime; Ciprofloxacin; Cross Infection; Female; | 1990 |
In vivo evaluation of a dual-action antibacterial, Ro 23-9424, compared to cefotaxime and fleroxacin.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Cefotaxime; Ciprofloxacin; Drug Evaluation, Pr | 1990 |
In vitro activity of sparfloxacin (CI-978; AT-4140) against clinical isolates from cancer patients.
Topics: Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Fleroxacin; Fluoroquinolones; | 1990 |
Correlation of the extravascular pharmacokinetics of azithromycin with in-vivo efficacy in models of localized infection.
Topics: Animals; Anti-Bacterial Agents; Azithromycin; Bacterial Infections; Bacteroides fragilis; Ciprofloxa | 1990 |
Oral clindamycin and ciprofloxacin therapy for diabetic foot infections.
Topics: Administration, Oral; Bacterial Infections; Ciprofloxacin; Clindamycin; Diabetes Complications; Drug | 1990 |
Short course ciprofloxacin therapy for CAPD peritonitis.
Topics: Bacterial Infections; Ciprofloxacin; Drug Resistance, Microbial; Humans; Kidney Failure, Chronic; Pe | 1990 |
In-vitro activity of PD 117 596, a new quinolone, against bacterial isolates from cancer patients.
Topics: Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Fluoroquinolones; Gram-Negativ | 1990 |
[Peroral ciprofloxacin in the therapy of infections in oncology patients].
Topics: Adolescent; Adult; Aged; Bacterial Infections; Ciprofloxacin; Female; Humans; Immune Tolerance; Male | 1990 |
Ciprofloxacin as an alternative to i.v. therapy.
Topics: Administration, Oral; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Humans; Infusions, | 1990 |
Ciprofloxacin drug utilization review and prospective drug use evaluation.
Topics: Bacterial Infections; Ciprofloxacin; Costs and Cost Analysis; Drug Utilization; Humans | 1990 |
Potential neurologic toxicity related to ciprofloxacin.
Topics: Aged; Bacterial Infections; Ciprofloxacin; Female; Humans; Nervous System Diseases; Seizures | 1990 |
In vitro activity of Ro 23-9424, a dual-action cephalosporin, compared with activities of other antibiotics.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; Bacterial Infections; Cefotaxime; Ciprofloxa | 1990 |
Ciprofloxacin in combined renal and hepatic impairment.
Topics: Bacterial Infections; Ciprofloxacin; Female; Humans; Kidney Diseases; Liver Diseases; Middle Aged | 1990 |
Serum sickness-like illness associated with ciprofloxacin.
Topics: Arthritis; Bacterial Infections; Ciprofloxacin; Drug Hypersensitivity; Humans; Liver Function Tests; | 1990 |
[Bronchopulmonary penetration of ciprofloxacin].
Topics: Bacterial Infections; Bronchi; Bronchoalveolar Lavage Fluid; Ciprofloxacin; Humans; Macrophages; Pne | 1990 |
Clinical and economic effect of ciprofloxacin as an alternative to injectable antimicrobial therapy.
Topics: Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Costs and Cost Analysis; Formularies, Ho | 1990 |
[Clinical experience with a new fluoroquinolone: ciprofloxacin].
Topics: Adult; Bacterial Infections; Ciprofloxacin; Female; Humans; Male; Middle Aged | 1989 |
[Evaluation of ciprofloxacin for the treatment of severe bacterial infections].
Topics: Adult; Aged; Aged, 80 and over; Bacterial Infections; Ciprofloxacin; Drug Administration Schedule; F | 1989 |
[Evaluation of the treatment with oral ciprofloxacin: experience with 24 patients].
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections; Ciprofloxaci | 1989 |
Flavobacterium meningosepticum infection, in a 32-day-old child on acute peritoneal dialysis, treated with ciprofloxacin.
Topics: Bacterial Infections; Ciprofloxacin; Female; Flavobacterium; Humans; Infant, Newborn; Microbial Sens | 1989 |
Intravenous/oral ciprofloxacin therapy of infections caused by multiresistant bacteria.
Topics: Administration, Oral; Adult; Bacterial Infections; Ciprofloxacin; Drug Resistance, Microbial; Female | 1989 |
Decontaminating efficacy of ciprofloxacin in an animal model.
Topics: Animals; Bacterial Infections; Cecum; Ciprofloxacin; Digestive System; Disease Models, Animal; Gastr | 1989 |
Evaluation of pefloxacin, ofloxacin and ciprofloxacin in the treatment of thirty-nine cases of chronic osteomyelitis.
Topics: Administration, Oral; Adult; Bacterial Infections; Ciprofloxacin; Drug Evaluation; Escherichia coli; | 1989 |
Oral ciprofloxacin therapy for infections in cancer patients.
Topics: Adult; Aged; Bacterial Infections; Ciprofloxacin; Female; Humans; Male; Microbial Sensitivity Tests; | 1989 |
[Chronic bone infections after surgery. Treatment with the new quinolones].
Topics: Adult; Aged; Aged, 80 and over; Bacterial Infections; Bone Diseases; Ciprofloxacin; Female; Humans; | 1989 |
An in-vitro study on ciprofloxacin and other anti-microbials against gram-negative bacteria isolated from patients in Ibadan, Nigeria.
Topics: Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Gram-Negative Bacteria; In Vitro Techniq | 1989 |
Outbreak of nosocomial Flavobacterium meningosepticum respiratory infections associated with use of aerosolized polymyxin B.
Topics: Administration, Inhalation; Bacterial Infections; Ciprofloxacin; Cross Infection; Disease Outbreaks; | 1989 |
Nosocomial gram-negative bloodstream isolates: a comparison of in vitro antibiotic potency.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactamases; Cefoxitin; Ciprofloxacin; Cross Infect | 1989 |
Use of ciprofloxacin in podiatric medicine.
Topics: Bacterial Infections; Ciprofloxacin; Foot Dermatoses; Humans | 1989 |
Ciprofloxacin: major advances in intravenous and oral quinolone therapy. Proceedings of a symposium. April 28 to 29, 1989, Naples, Florida.
Topics: Administration, Oral; Bacterial Infections; Ciprofloxacin; Humans; Infusions, Intravenous | 1989 |
Safety and efficacy of intravenous ciprofloxacin in the treatment of selected infections.
Topics: Adult; Bacteria; Bacterial Infections; Ciprofloxacin; Humans; Infusions, Intravenous; Male; Middle A | 1989 |
Sequential intravenous/oral therapy with ciprofloxacin in severe infection.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections; Ciprofloxaci | 1989 |
Intravenous ciprofloxacin therapy in severe infections.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections; Ciprofloxacin; Female; Humans; Inf | 1989 |
Intravenous and sequential intravenous and oral ciprofloxacin in the treatment of severe infections.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bacterial Infections; Ciprofloxacin; Drug Admi | 1989 |
Clinical study of intravenous and oral ciprofloxacin in complicated bacterial infections.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bacterial Infections; Ciprofloxacin; Drug Resi | 1989 |
Intravenous and oral ciprofloxacin treatment of 52 infections.
Topics: Administration, Oral; Bacterial Infections; Ciprofloxacin; Female; Humans; Infusions, Intravenous; M | 1989 |
Ciprofloxacin in the treatment of gram-negative bacillary meningitis.
Topics: Adult; Aged; Bacterial Infections; Ciprofloxacin; Female; Gram-Negative Bacteria; Humans; Male; Meni | 1989 |
Intravenous ciprofloxacin for infections in cancer patients.
Topics: Bacterial Infections; Ciprofloxacin; Drug Therapy, Combination; Female; Humans; Infusions, Intraveno | 1989 |
An update on the efficacy of ciprofloxacin in animal models of infection.
Topics: Abscess; Animals; Bacterial Infections; Ciprofloxacin; Disease Models, Animal; Endocarditis, Bacteri | 1989 |
[Prevention of bacterial infections using ciprofloxacin in granulocytopenic patients with cancer].
Topics: Adolescent; Adult; Aged; Agranulocytosis; Antineoplastic Agents; Bacterial Infections; Ciprofloxacin | 1989 |
In vitro and in vivo antibacterial activities of KB-5246, a new tetracyclic quinolone.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Fluoroquinolones; Male; Mice; M | 1989 |
[Ciprofloxacin in bacterial infections].
Topics: Adult; Bacterial Infections; Ciprofloxacin; Dose-Response Relationship, Drug; Drug Evaluation; Drug | 1989 |
Clinical role of the quinolones today and in the future.
Topics: Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Clinical Protocols; Forecasting; Humans; | 1989 |
[Fluoroquinolones--antibacterial activity, pharmacokinetics and indications for a new group of chemotherapeutic drugs].
Topics: Adult; Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Dose-Response Relations | 1989 |
Clinical experience with ciprofloxacin: analysis of a multi-practice study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections; Ciprofloxacin; Female; Humans; Mal | 1989 |
Efficacy of ciprofloxacin in the treatment of various bacterial infections.
Topics: Bacterial Infections; Ciprofloxacin; Humans | 1989 |
Increasing rates of in vitro resistance to ciprofloxacin and norfloxacin in isolates from urine specimens.
Topics: Bacteria; Bacterial Infections; Ciprofloxacin; Drug Resistance, Microbial; Humans; Norfloxacin | 1989 |
Use of oral ciprofloxacin in community-acquired pneumonia.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bacterial Infections; Ciprofloxacin; Drug Admi | 1989 |
[Ciprofloxacin treatment in bacterial skin infections].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bacterial Infections; Ciprofloxacin; Female; H | 1989 |
In vitro activities of amifloxacin and two of its metabolites.
Topics: Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Enterobacteriaceae; Fluoroquin | 1989 |
Use of ciprofloxacin in patients undergoing transurethral prostatic surgery.
Topics: Bacterial Infections; Bacteriuria; Ciprofloxacin; Drug Evaluation; Humans; Male; Postoperative Compl | 1989 |
Effect of ciprofloxacin compared to gentamicin in the treatment of experimental intraabdominal infections in rats.
Topics: Abdomen; Abscess; Animals; Bacterial Infections; Ciprofloxacin; Clindamycin; Drug Combinations; Gent | 1989 |
In vitro and in vivo antibacterial activities of BMY 40062, a new fluoronaphthyridone.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Fluoroquinolones; Mac | 1989 |
[Intra aqueous humor penetration of ciprofloxacin in humans].
Topics: Aged; Aged, 80 and over; Aqueous Humor; Bacterial Infections; Cataract; Cataract Extraction; Ciprofl | 1989 |
In-vitro activity of FCE 22101 and synergy studies with other antimicrobial agents.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; beta-Lactamase Inhibitors; beta-Lactamases; b | 1989 |
Treatment with ciprofloxacin of Aeromonas hydrophila associated colitis in a male with antibodies to the human immunodeficiency virus.
Topics: Adult; Aeromonas; Bacterial Infections; Ciprofloxacin; Colitis; HIV Seropositivity; Humans; Male; Op | 1989 |
In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone.
Topics: Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Enoxacin; Fluoroquino | 1989 |
[Local antibiotic therapy of bacterial ear infections].
Topics: Administration, Topical; Bacterial Infections; Ciprofloxacin; Humans; Lymphadenitis; Mastoiditis; Ot | 1989 |
Comparative in vitro activity of ciprofloxacin against aerobic and anaerobic bacteria from clinical isolates.
Topics: Anti-Bacterial Agents; Bacteria, Aerobic; Bacteria, Anaerobic; Bacterial Infections; Ciprofloxacin; | 1987 |
Ciprofloxacin and norfloxacin--potent oral antiinfectives.
Topics: Administration, Oral; Bacterial Infections; Ciprofloxacin; Humans; Norfloxacin | 1989 |
Open, prospective study of the clinical efficacy of ciprofloxacin.
Topics: Adolescent; Adult; Aged; Arthritis; Bacterial Infections; Ciprofloxacin; Female; Gastrointestinal Di | 1985 |
In vitro activity of ciprofloxacin against pediatric pathogens.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Child; Ciprofloxacin; Drug Resistance, Microb | 1985 |
The comparative in-vitro activity of norfloxacin, ciprofloxacin, enoxacin and nalidixic acid against 423 strains of gram-negative rods and staphylococci isolated from infected hospitalised patients.
Topics: Acinetobacter; Bacteria; Bacterial Infections; Ciprofloxacin; Citrobacter; Drug Resistance, Microbia | 1986 |
[New oral quinolone compounds in chronic bronchitis].
Topics: Administration, Oral; Anti-Bacterial Agents; Bacterial Infections; Bronchitis; Chronic Disease; Cipr | 1986 |
Comprehensive evaluation of ciprofloxacin in combination with beta-lactam antibiotics against Enterobacteriaceae and Pseudomonas aeruginosa.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Ciprofloxacin; Drug Synergism; E | 1986 |
Antibiotic-induced bacterial cell lysis: a therapeutic dilemma.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Bacteriolysis; Ciprofloxacin; Endotoxins; Esch | 1986 |
Activity of ciprofloxacin against resistant clinical isolates.
Topics: Bacteria; Bacterial Infections; Cefotaxime; Ceftazidime; Ciprofloxacin; Drug Resistance, Microbial; | 1986 |
Ciprofloxacin therapy of infections caused by Pseudomonas aeruginosa and other resistant bacteria.
Topics: Administration, Oral; Adult; Aged; Bacterial Infections; Ciprofloxacin; Drug Resistance, Microbial; | 1985 |
Ciprofloxacin: pharmacokinetics and clinical experience.
Topics: Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Humans; Kinetics; Quinolines | 1986 |
Ciprofloxacin in the treatment of acute exacerbations of chronic bronchitis.
Topics: Aged; Anti-Bacterial Agents; Bacterial Infections; Bronchitis; Chronic Disease; Ciprofloxacin; Drug | 1986 |
Ciprofloxacin in the treatment of infections caused by gentamicin-resistant gram-negative bacteria.
Topics: Anti-Bacterial Agents; Bacterial Infections; Bone Diseases; Catheters, Indwelling; Ciprofloxacin; Dr | 1986 |
Clinical evaluation of treatment with ciprofloxacin.
Topics: Abdomen; Abscess; Adolescent; Adult; Aged; Anti-Infective Agents; Bacterial Infections; Bronchitis; | 1986 |
In vitro and in vivo antibacterial activity of AM-833, a new quinolone derivative.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Drug Resistance, Micr | 1986 |
Clinical uses of nalidixic acid analogues: the fluoroquinolones.
Topics: Administration, Oral; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Drug Evaluation; D | 1986 |
[Gyrase inhibitor in the local treatment of the chronically infected middle ear following surgery].
Topics: Administration, Topical; Adult; Aged; Bacterial Infections; Ciprofloxacin; Drug Resistance; Escheric | 1986 |
Treatment of infections in non-neutropenic patients with cancer, AIDS, or renal transplant using ciprofloxacin.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Aged, 80 and over; Bacterial Infections; Ciprofloxa | 1988 |
In-vitro activity of Sch 34343, a new penam, against gram-positive isolates from cancer patients.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Fluoroquinolones; | 1986 |
Evaluation of ciprofloxacin's synergism with other agents by multiple in vitro methods.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Drug Synergism; Enter | 1987 |
[Prevention of gram-negative and gram-positive infections with 3 intravenous immunoglobulin preparations and therapy of experimental polymicrobial burn infection with intravenous Pseudomonas immunoglobulin G and ciprofloxacin in an animal model].
Topics: Animals; Bacterial Infections; Burns; Ciprofloxacin; Combined Modality Therapy; Female; Immunoglobul | 1987 |
[In vitro activity of 3 fluoroquinolones on Branhamella catarrhalis].
Topics: Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Humans; In Vitro Techniques; Microbial S | 1988 |
Ciprofloxacin for selective decontamination of the alimentary tract in patients with acute leukemia during remission induction treatment: the effect on fecal flora.
Topics: Acinetobacter; Acute Disease; Adult; Bacterial Infections; Bacteroides; Ciprofloxacin; Clostridium; | 1985 |
[The effectiveness of ciprofloxacin in bacterial skin infections].
Topics: Administration, Oral; Bacterial Infections; Ciprofloxacin; Drug Administration Schedule; Erysipelas; | 1988 |
[Oral ciprofloxacin therapy in salpingitis].
Topics: Administration, Oral; Adult; Bacterial Infections; Ciprofloxacin; Female; Humans; Salpingitis | 1988 |
[Effectiveness of ciprofloxacin in bacterial infections of the respiratory and gastrointestinal tract].
Topics: Adult; Bacterial Infections; Ciprofloxacin; Female; Gastrointestinal Diseases; Humans; Male; Respira | 1988 |
Chemoprophylaxis of bacterial infections in granulocytopenic patients with ciprofloxacin.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Antineoplastic Agents; Bacterial Infections; Ciprof | 1987 |
Ciprofloxacin: initial evaluation in immunocompromised patients.
Topics: Antineoplastic Agents; Bacterial Infections; Bone Marrow Transplantation; Ciprofloxacin; Humans; Imm | 1987 |
Reduction of oral flora with ciprofloxacin in healthy volunteers.
Topics: Adolescent; Adult; Aged; Bacteria; Bacterial Infections; Ciprofloxacin; Head and Neck Neoplasms; Hum | 1988 |
A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial.
Topics: Adolescent; Adult; Aged; Bacterial Infections; Ciprofloxacin; Female; Humans; Male; Middle Aged; Res | 1988 |
Single and multiple dose pharmacokinetics of oral ciprofloxacin in elderly patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Bacterial Infections; Ciprofloxacin; Female; Humans; | 1988 |
Ciprofloxacin: a new broad-spectrum antibacterial agent.
Topics: Bacterial Infections; Ciprofloxacin; Humans | 1987 |
In vitro activity of ciprofloxacin against aerobic bacteria isolated in a southern European hospital.
Topics: Bacteria, Anaerobic; Bacterial Infections; Ciprofloxacin; Humans; Italy | 1987 |
The use of ciprofloxacin in the treatment of patients with cystic fibrosis.
Topics: Adult; Bacterial Infections; Ciprofloxacin; Cystic Fibrosis; Drug Resistance, Microbial; Haemophilus | 1987 |
Treatment of chronic osteomyelitis with ciprofloxacin.
Topics: Adult; Aged; Bacterial Infections; Chronic Disease; Ciprofloxacin; Female; Humans; Male; Middle Aged | 1987 |
Quinolone antimicrobial agents in acute exacerbations of chronic bronchitis.
Topics: Anti-Infective Agents; Bacterial Infections; Bronchitis; Ciprofloxacin; Enoxacin; Female; Humans; Ma | 1986 |
Preliminary evaluation of ciprofloxacin, a new 4-quinolone antibiotic, in the treatment of febrile neutropenic patients.
Topics: Adult; Aged; Agranulocytosis; Bacterial Infections; Ciprofloxacin; Female; Fever; Half-Life; Humans; | 1986 |
In vitro evaluation of S-25930 and S-25932, two new quinolones, against aerobic gram-negative isolates from cancer patients.
Topics: Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Enoxacin; Fluoroquinolones; Gram-Negativ | 1987 |
Treatment of ciprofloxacin- and ceftizoxime-induced resistant gram-negative bacilli.
Topics: Amikacin; Animals; Azlocillin; Bacterial Infections; Cefotaxime; Ceftizoxime; Ciprofloxacin; Drug Ev | 1987 |
Comparative in vitro activity of ciprofloxacin, ofloxacin and pefloxacin against resistant clinical isolates.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Drug Resistance, Microbial; Hu | 1987 |
[Therapeutic contribution of the new quinolones].
Topics: Anti-Infective Agents; Bacterial Infections; Biotransformation; Chemical Phenomena; Chemistry; Cipro | 1987 |
Oral ciprofloxacin in the treatment of 14 patients with bacterial pneumonia.
Topics: Administration, Oral; Adult; Aged; Bacterial Infections; Ciprofloxacin; Female; Humans; Male; Middle | 1987 |
Treatment of acute exacerbations of chronic bronchitis with ciprofloxacin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections; Bronchitis; Ciprofloxacin; Female; | 1987 |
External otitis in divers: etiology and in vitro activity of ciprofloxacin and local agents.
Topics: Acinetobacter; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Diving; Enterobacteriacea | 1987 |
An assessment of ciprofloxacin per os in treatment of serious infections.
Topics: Administration, Oral; Adult; Aged; Bacteria; Bacterial Infections; Ciprofloxacin; Female; Humans; Ma | 1987 |
In vivo evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.
Topics: Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Enterobacteriaceae In | 1986 |
Pharmacokinetics and pharmacodynamics of intravenous ciprofloxacin. Studies in vivo and in an in vitro dynamic model.
Topics: Bacterial Infections; Ciprofloxacin; Escherichia coli Infections; Humans; In Vitro Techniques; Infus | 1987 |
Ciprofloxacin: a major advance in quinolone chemotherapy.
Topics: Bacteria; Bacterial Infections; Ciprofloxacin; Humans; In Vitro Techniques | 1987 |
Effect of ciprofloxacin on fecal flora of patients with cystic fibrosis and other patients treated with oral ciprofloxacin.
Topics: Administration, Oral; Adolescent; Adult; Aged; Bacterial Infections; Ciprofloxacin; Cystic Fibrosis; | 1987 |
Economic impact of oral ciprofloxacin. A pharmacist's perspective.
Topics: Administration, Oral; Bacterial Infections; Ciprofloxacin; Cost Control; Drug Interactions; Humans; | 1987 |
Ciprofloxacin: an overview and prospective appraisal.
Topics: Administration, Oral; Animals; Bacterial Infections; Ciprofloxacin; Cystic Fibrosis; Disease Models, | 1987 |
Evaluation of ciprofloxacin alone and in combination with other antibiotics in a murine model of thigh muscle infection.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Disease Models, Animal; Drug In | 1987 |
Oral ciprofloxacin in refractory gram-negative bacillary infections.
Topics: Adult; Aged; Aged, 80 and over; Bacterial Infections; Chronic Disease; Ciprofloxacin; Female; Gram-N | 1987 |
Effect of peritoneal dialysis fluid and pH on bactericidal activity of ciprofloxacin.
Topics: Anti-Bacterial Agents; Ascitic Fluid; Bacteria; Bacterial Infections; Ciprofloxacin; Drug Synergism; | 1987 |
Clinical efficacy and levels of ciprofloxacin in tissue in patients with soft tissue infection.
Topics: Adult; Aged; Aged, 80 and over; Bacteria, Anaerobic; Bacterial Infections; Cellulitis; Ciprofloxacin | 1987 |
Overview of preclinical studies with ciprofloxacin.
Topics: Animals; Bacterial Infections; Ciprofloxacin; Drug Evaluation, Preclinical; Female; Gram-Negative Ba | 1987 |
[New specifics registered in Austria].
Topics: Austria; Bacteria; Bacterial Infections; Ciprofloxacin; Humans; Microbial Sensitivity Tests | 1987 |
[Antibacterial effectiveness of ciprofloxacin].
Topics: Bacteria; Bacterial Infections; Ciprofloxacin; Dose-Response Relationship, Drug; Drug Resistance, Mi | 1986 |
Ciprofloxacin: quinolones in practice. Madrid, 30-31 May, 1986.
Topics: Animals; Bacterial Infections; Ciprofloxacin; Humans; Quinolines | 1986 |
Treatment of respiratory tract infections with ciprofloxacin.
Topics: Adult; Aged; Aged, 80 and over; Bacteria; Bacterial Infections; Ciprofloxacin; Female; Humans; Male; | 1986 |
Treatment of skin and soft tissue infections with oral ciprofloxacin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections; Cellulitis; Ciprofloxacin; Female; | 1986 |
Ciprofloxacin for soft tissue infections.
Topics: Adult; Aged; Aged, 80 and over; Bacterial Infections; Cellulitis; Ciprofloxacin; Female; Humans; Mal | 1986 |
Oral ciprofloxacin therapy of infection caused by multiply resistant bacteria other than Pseudomonas aeruginosa.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bacterial Infections; Ciprofloxacin; Drug Resi | 1986 |
Synthesis and structure-activity relationships of novel arylfluoroquinolone antibacterial agents.
Topics: Acinetobacter; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Chemical | 1985 |